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CHAPTER 1. INTRODUCTION
1.1. Motives of the research
1.1.1. Medicinal chemistry lacks diversity in compound collections
Drug discovery is a highly complex and multidisciplinary process. The medicinal
chemistry community has driven tremendous advances in drug discovery programs in last
two decades. The need of screening millions of compounds to develop one lead in the
drug development process led to the development of high throughput screening (HTS).
HTS can efficiently generate millions of data just by screening large libraries in short
periods of time.1 Both the academic and the industrial communities benefit enormously
from HTS in terms of time and cost of identifying preclinical drug candidates (lead
compounds). As a result, HTS originated small molecules dominate the collections of the
US FDA approved new drug candidates implying that HTS is an essential and necessary
frontline tool in drug discovery today.2
As HTS and its latest variant, the fragment-based approach, are in full-swing and
are key methods in drug discovery programs, the compositions of compound libraries will
have a significant impact on the outcomes in pharmaceutical discoveries.1,3 To assure
the quality of the outcomes that can be tractable in clinical phases, medicinal chemists
today follow principles of drug-like or lead-like molecules while generating compound
libraries. These principles use several molecular descriptors in order to filter the
compounds. One of the widely used practices in HTS compound collections is Lipinski’s
rule of five (RO5).4 Alternatively, the fragment based approach follows the Astex rule of
three (RO3).5 Several properties like molecular weight, topological polar surface area,
rotatable bonds, and numbers of hydrogen bond donors and acceptors are considered
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while filtering.4,5 Another approach in identifying drug-like chemical space is exclusion of
undesirable molecular moieties from compound collections.6 Moieties which are known
to generate false positives in screening and are associated with toxicities are
undesirable.6 For example, molecules with heteroatom-heteroatom bonds are excluded
from current compound collections based upon their perceived reactivity and toxicity.6
Although HTS is a successful approach in addressing multiple biological targets,
failures in clinical phases as well as in hitting challenging complex biological targets such
as protein-protein interactions are also common.3 These failures are warnings to
medicinal chemists about the lack of the diversity in their current compound libraries and
are unavoidable. Also, the descriptors used in the commonly applied principles of druglike molecules do not address molecular complexity directly.7 As a result, current HTS
libraries are highly populated by low molecular weight and relatively planar compounds
with high sp2 character and little stereochemical complexity.3,7 Unfortunately, such planar
compounds cover only a very small corner of the chemical space. Furthermore, the
binding sites in biological targets are rarely planar, which undoubtfully can be viewed as
one of the primary reasons of failure in HTS campaigns. In order to overcome the
limitations of planarity, the so-called flatland, and to fulfil the need for complexity, the
strategy of increasing the fraction of saturated carbons (Fsp3) within compounds should
be considered. In 2009, Lovering et al. conducted a survey7 on the collection of
compounds in different phases of drug discovery and development processes and found
that the fractions of sp3 hybridized atoms and the number of stereogenic centers are
higher in those compounds. Therefore, the survey suggested considering the Fsp3 of the
molecules as a descriptor in the compound collections.
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Recognizing the need for complexity and diversity, several creative strategies have
been designed to date in order to generate more diverse libraries. Diversity oriented
synthesis (DOS)8-11 is one of the approaches that generates architecturally diverse
molecules in few steps starting from simple starting materials. These compounds
resemble more natural product or drug-like molecules with high Fsp3 and stereochemical
complexity. Other strategies are centered on the use of natural products as the starting
point to generate the natural product-like molecules.12 Even though these creative ideas
have introduced natural product-like moieties with complexity in terms of Fsp3 and the
presence of stereogenic centers, several problems are still left unaddressed such as the
creation of new complex scaffolds from unexplored parts of chemical space. Furthermore,
the synthesis of compounds with the natural product-like scaffolds is still considered as a
challenging and time-consuming area of the research.
To overcome these shortcomings, the medicinal chemistry community needs a
novel strategy that can open up the new chemical space with new scaffolds. Also, these
scaffolds should have the potential of generating large libraries of compounds with
reduced synthetic difficulty but high structural complexity.
1.1.2. Hydroxylamines and hydrazines as surrogates of sp3 carbons
The Crich lab has identified the hydroxylamine and the hydrazine functionalities as
new scaffolds that have the potential to enrich compound collections by increasing Fsp3
in compounds and to address the necessity of diversity from the new chemical space
without the synthetic complications arising from the presence of additional stereogenic
centers.
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With low basicity (pKa = 5.9 in water)13,14 and a low inversion barrier (~15 kcal.mol1),15-19

hydroxylamines are little protonated under normal physiological conditions and

have the potential of changing configuration by rapid inversion at the nitrogen center.
Therefore, tri-substituted hydroxylamines, in particular, can serve to mimic both
enantiomers of simple stereogenic ethers and alkanes while reducing synthetic and
structural complexity (Figure 1).

Figure 1. Hydroxylamines as convertible mimics of stereogenic centers. a) NAlkoxypiperidines as mimics of axial and equatorial glycosides.18,19 b) Hydroxylamines
as mimics of chirally substituted alkanes and ethers.
Hydrazines share similar properties to hydroxylamines including their low inversion
barriers (~8 kcal.mol-1)20 and weak basicity (pKa = 6.4 in water).21 These properties
establish hydrazines as another interesting functional group in which the two nitrogen
atoms can substitute for two stereogenic centers and reduce synthetic and structural
complexity (Figure 2).

Figure 2. Hydrazines as convertible mimics of two stereogenic centers.
Taking advantage of these unique properties of hydroxylamines and hydrazines,
the Crich lab initiated a program to design molecules in which the nitrogen atoms of
hydroxylamine and hydrazine functionality substitute important stereogenic centers of
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medicinally important molecules, with the goal of reducing synthetic complexity and
developing new compositions of matter. As a proof of concept, the Crich lab has recently
prepared and evaluated a series of mono-, di-, and tri-meric N-alkoxyimino sugars as β(1→3)-glucan mimetics in which the hydroxylamine nitrogen replaces the anomeric
carbon and eliminates the need for diastereoselective glycosidic bond formation (Figure
3).18,19

Figure 3. Hydroxylamine based β-(1→3)-glucan mimetics as hydroxalogs of β-(1→3)glucans.
1.1.3. Aims of the research
Recognizing the inherent potentials of hydrazines and hydroxylamines in medicinal
chemistry, the research presented in this thesis aims to apply the concept of hydrazine
and hydroxylamine analogs beyond the carbohydrates studied initially. However, before
the broader application of hydroxylamines and hydrazines can be investigated, improved
methods for their synthesis are required. Therefore, the work will also focus on developing
an effective methodology that can give easy access to diverse sets of tri-substituted
hydroxylamines and so potentially be applied in generating libraries of compounds.
Characteristic features of the hydroxylamines and hydrazines including their
conformational properties and syntheses, and analog design will be discussed in the
following sections.
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1.2. Hydroxylamines
1.2.1. Introduction
Hydroxylamines or alkoxyamines represent the class of compounds that are
derived from the parent hydroxylamine (H2N-OH). Depending upon the substitution
patterns on the nitrogen and oxygen atoms, they can be classified as mono-substituted,
di-substituted, or tri-substituted (Figure 1).

Figure 4. Structures of substituted hydroxylamines.
The N-O bond is also present in oximes and hydroxamic acids (Figure 5), which
are considered as derivatives of the parent hydroxylamine (NH2OH). However, oximes
have C=N double bonds and hydroxamic acids have N-acyl groups giving properties that
differentiate them from hydroxylamines particularly in the context of their planar sp2
nitrogens.22

Figure 5. Structures of hydroxylamines, oximes, and hydroxamic acids.
A common confusion in the literature revolves around the use of the word
hydroxylamine. Some literature uses it to represent all the derivatives of the parent
hydroxylamine including oximes and hydroxamic acids, whereas others have used it to
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represent only aryl and alkyl-substituted hydroxylamines. In this thesis, the later
representation will be followed.
1.2.2. Conformational properties of hydroxylamines
The presence of an oxygen atom adjacent to nitrogen atom has a substantial effect
on the conformation of hydroxylamines. The repulsive interaction between the lone pairs
of electrons on these atoms should be minimized in the preferred conformation. In
molecular orbital calculations, two energy minima were observed for hydroxylamines
representing two stable conformations 1a and 1b (Figure 6).22,23 The energy differences
between these conformers range from 0.67 kcal.mol-1 to 10.79 kcal.mol-1 depending upon
the substitution patterns.23 Interestingly, conformer 1a is more stable with eclipsing of lone
pairs with bonds, whereas conformer 1b is less stable with staggered lone pairs and
bonds. This property of hydroxylamines can be viewed as an effect of maximization of
separation of the lone pairs on adjacent atoms.23

Figure 6. Conformations of hydroxylamine.
Another interesting phenomenon in hydroxylamines is the fast conformational
inter-conversion. This stereomutation is attributable to either an individual or a
combination of two unique processes; nitrogen inversion (Ninv) and N-O bond rotation (NOrot).17 The energy barriers for nitrogen inversion in hydroxylamines were determined15-18
to be ~ 15 kcal.mol-1, and are higher than their amine analogs (~ 5 kcal.mol-1),24 however,
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they are low enough to permit rapid inversion at the nitrogen center at ambient
temperature. Due to their fast inversion at room temperature, the pyramidal nitrogen
atoms in hydroxylamines are not configurationally stable.
The stereomutation of hydroxylamines can be best illustrated as in Scheme 1.17
Owing to the low barrier to inversion, the more stable conformer 1a converts to the less
stable conformer 1b, which in turn converts to the enantiomer of the more stable
conformer 1a* by rotation of the N-O bond and minimization of the lone pair-lone pair
repulsions. The barrier to rotation in the above conversion (1b → 1a*) is usually small (<
5 kcal.mol-1).17 Similarly, another enantiomeric less stable conformer 1b* is the result of
N-O bond rotation of 1a or nitrogen inversion of 1a* . The barrier to rotation for the
conversion of 1a to 1b* is unusually high (12 - 15 kcal.mol-1), since the former is more
stable than the latter and the high torsional barriers are associated with the process.17
The more stable conformers 1a and 1a* are epimers of each other as are the less stable
conformers 1b and 1b*. As the population of the more stable conformer 1a and 1a* are
identical and interconvertible at room temperature, a single molecule of a hydroxylamine
can represent both epimers of a compound. This is the principle behind the hydroxylamine
analog or hydroxalog concept.
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Scheme 1. Stereomutation in hydroxylamines.
1.2.3. Hydroxylamines in medicinal chemistry
The hydroxylamine moiety is an underrepresented functional group in medicinal
chemistry, though it has potential to enrich compound collections without synthetic
complication from the presence of an additional stereogenic center. Although not
common, the hydroxylamine moiety does exist in a small number of bioactive natural
products. The antitumor antibiotics esperamicin A125,26 and calicheamicins,27,28 and the
selective inhibitor of bacterial tyrosyl tRNA synthase SB-21938329 are some
representative examples containing a hydroxylamine moiety in nature (Figure 7).
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Figure 7. Natural compounds with hydroxylamine moieties.
On the other hand, there are a few examples of the use of hydroxylamines in medicinal
chemistry that aim to exploit its rich potential. Two examples are the hydroxylamine-based β(1→3)-glucan mimetics19 from Crich lab, and a selective inhibitor of human neuraminidase
isoenzymes NEU330 from the Cairo lab (Figure 8).

Figure 8. Synthetic compounds with hydroxylamine moieties for use in medicinal chemistry.

Though hydroxylamines have the potential to enrich compound libraries, they have
been typically excluded as undesirable moieties6,31 based upon the perceived problems
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with the N-O bond, particularly, its supposed weakness and electrophilicity. However,
both DFT6 and experimentally32 determined bond dissociation energies for the N-O bond
range from 55 to 65 kcal.mol-1 depending upon the substitution patterns. Therefore, they
are stable entities and are not thermodynamically liable as perceived. On the other hand,
hydroxylamines, particularly N-arylhydroxylamines, with free -NH or -OH groups, are
intermediates on the metabolic pathway of amines, and are converted to electrophilic
metabolites by acylation or sulfation as exemplified in Scheme 2. 33,34 These metabolites
further bind covalently to DNA and induce mutation. In contrast, with no free -NH and OH groups, tri-substituted hydroxylamines cannot activated to electrophiles in this
manner. Therefore, they are not prone to form adducts with DNA to cause genotoxicity
and also do not bind covalently with proteins to result in the false positives in screening.6
Moreover, heteroatom-heteroatom bonds such as N-O and N-N bonds and other
electrophilic scaffolds are rather common in marketed drugs.31 Therefore, discarding
hydroxylamines from screening collections based upon the perceived false positives and
the weak N-O bond can lead to the loss of quality hits.6,35

12

Scheme 2. A representative pathway of metabolic activation of aromatic amines.
1.2.4. Synthesis of tri-substituted hydroxylamines
Depending upon the strategic disconnection approach and the available synthetic
methods in the literature, three possible ways for tri-substituted hydroxylamines synthesis
can be devised (Scheme 3). An ideal route to the substituted hydroxylamines should
involve N-O bond formation (Scheme 3 route a). This ideal route has a huge potential of
generating large libraries of compounds starting from commercially available amines and
alcohols as starting materials. However, very few examples of tri-substituted
hydroxylamine synthesis were reported to date following this route, which involves the
displacement of a leaving group from a nitrogen atom by an alcohol or from an oxygen
atom by an amine or an amide.36-39 Progress in this line of work has not been promising
due to the combination of low yields and harsh reaction conditions. This approah remains
challenging for synthetic chemists.
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Scheme 3. Possible ways for the synthesis of tri-substituted hydroxylamines.
N-Alkylation (Scheme 3 route b) of N,O-disubstituted hydroxylamines or Oalkylation (Scheme 3 route c) of N,N-disubstituted hydroxylamines

are viewed as

plausible alternative routes. Several synthetic methods for hydroxylamine derivatives
have been developed using direct N-alkylation and O-alkylation routes,40,41 however
methods for the synthesis of tri-substituted hydroxylamines, in particular, are relatively
sparse.
One of the traditional and common approaches for the tri-substituted
hydroxylamines is N-alkylation of N,O-disubstituted hydroxylamines via reductive
amination (Scheme 4a) or SN2 substitution reactions (Scheme 4b).41 Several Nalkoxyiminosugar derivatives have been prepared from O-substituted hydroxylamines as
starting materials by using either double reductive amination (Scheme 4c) or combination
of reductive amination and SN2 substitution reactions (Scheme 4d).18,19,42,43 Various trisubstituted hydroxylamines have also been synthesized from N-methoxyamides in a one
pot reaction that involved partial reduction with DIBAL, followed by Lewis acid catalyzed
in situ generation of N-oxy iminium ions and the nucleophilic addition of carbon
nucleophiles (Scheme 4e).44 Moreover, bicyclic N-oxy amides have also been reduced
to tri-substituted hydroxylamines with in situ generated AlH3 (Scheme 4f).45 However, all
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these methods give access to tri-substituted hydroxylamines with diversity on the nitrogen
only.

Scheme 4. Synthesis of tri-substituted hydroxylamines.
Alternatively, the approach of O-alkylation of N,N-disubstituted hydroxylamine has
the potential to introduce diversity on the O-substituent. However, only alkylation with
simple and activated electrophiles such as allyl and aryl halides was reported by this route
(Scheme 5).41

Scheme 5. O-Alkylation of N,N-disubstituted hydroxylamines.
In conclusion, an efficient method is lacking for the synthesis of tri-substituted
hydroxylamines, which particularly, should have the potential of not only the diversification
of O-substituents but also easy access to these class of compounds, so that the library
of compounds with great diversity can be generated for the medicinal chemistry
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community. Recognizing this need, an efficient method will be developed to address the
existing problem in the synthesis of tri-substituted hydroxylamines.
1.3. Hydrazine
1.3.1. Introduction
Hydrazines represent the class of compounds that are the derivatives of parent
hydrazine (H2N-NH2). Depending upon the substitution patterns on both nitrogen atoms,
they can be classified as mono-substituted, di-substituted, tri-substituted, and tetrasubstituted hydrazines (Figure 9).

Figure 9. Structures of substituted hydrazines.
If one of the substituents is an acyl group, the compounds are classified as
hydrazides, and if one of the nitrogen forms a double bond with sp2 hybridized carbon
atom, the compounds are classified as hydrazones (Figure 10). Since N-N bonds are
present in both the hydrazones and the hydrazides, they are also considered as hydrazine
derivatives, however, they differ significantly from hydrazines in terms of properties. In
this thesis, the use of the term hydrazine does not incorporate hydrazones or hydrazides.

Figure 10. Structures of hydrazines, hydrazones, and hydrazides.
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1.3.2. Conformational properties of hydrazines
Alkyl hydrazines are considered bipyramidal, and two diastereomeric staggered
conformations, gauche (2) and trans (3) (referring to the lone pairs), are possible (Figure
11).46

Figure 11. Possible conformations of hydrazine.
The lone pair-lone pair repulsive interaction is a dominant factor in determining the
conformation and should be minimized in the most stable one. The low energy lone pairbond pair and bond pair-bond pair interactions are neglected accordingly. The trans
conformation (3) at first seems to be the more stable one since it offers minimal interaction
between the lone pairs. However, the quasi-gauche conformation (5) (Figure 11) with 90o
of interorbital angle (Ø) is the most stable conformation according to the spectroscopic
studies and molecular orbital calculations.46 The calculated potential energy function of
hydrazine has two energy maxima and one energy minimum (Figure 12).47,48 One
maximum corresponds to the cis (Ø = 0o) conformation (4) and the other to the trans (Ø
= 180o) conformation (3) (Figure 11). The energy minimum is the quasi-gauche (Ø = 90o)
conformation (5).
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Figure 12. The torsional potential function of H2N-NH2.
Several interpretations have been proposed to explain why the trans conformation
with the least lone pair-lone pair interaction is not adopted by the system.46-54 The most
conceptual and qualitative interpretation46 is the interaction between the lobes of nonbonding orbitals of two nitrogen atoms is minimal at 90o, while it is maximum at 180o
(Figure 13). Therefore, two maxima and one minimum are observed in the torsional
potential function of hydrazine.

Figure 13. Interactions of non-bonding orbitals of nitrogen atoms at Ø = 90o and 180o.
The interconversion of conformations about the N-N bond is a common
phenomenon in hydrazines and is a result of the interplay of internal N-N bond rotations
and/or pyramidal nitrogen inversions. The inversion barrier for the parent hydrazine (H2NNH2) is about 7.5 kcal.mol-1.55 The experimentally calculated barriers for either rotations
or inversions in acyclic tetra-alkyl hydrazines range from 5.1 to 11.2 kcal.mol-1 depending
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upon the nature of alkyl substituents.20 Though the quasi-gauche (Ø = 90o) conformation
is the stable conformation, the staggered gauche (Ø = 60o) conformation will be used to
describe the inversion and rotation processes here after for convenience.
The conformational changes of hydrazine by inversion processes are described in
Scheme 6.20 In hydrazines, two distinct types of N-inversion are recognized,46 which are
named as non-eclipsing inversion (non-passing) and eclipsing inversion (passing
inversion). The non-eclipsing inversion is a fast and low energy process without eclipsing
of substituents. A gauche conformation (6) leads to another gauche conformation (7) via
a non-eclipsing inversion and the barrier to inversion is around 7.5 kcal.mol-1. The
eclipsing inversion, on the other hand, is a high energy process with eclipsing of
substituents. A gauche conformation (6) leads to a trans conformation (8) via eclipsing
inversion process and the barrier to inversion is 10.5 kcal.mol-1 (7.5 kcal.mol-1 for inversion
and 3 kcal.mol-1 for eclipsing interactions of alkyl groups). However, the barrier to
inversion for the reverse process (trans to gauche) is 3 kcal.mol-1 smaller than the forward
process (gauche to trans).
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Scheme 6. Diagram showing two different types of N-inversions.
The conformational changes of hydrazine by rotation are described in Scheme 7.20
In an acyclic hydrazine two distinct rotational processes are recognized.46 The first one is
the low energy rotational process that involves eclipsing of one pair of substituents. The
conversion of gauche (9) to trans (10) conformation is a result of 120o torsional rotation
and is a low energy rotational process with an energy barrier of 6-7 kcal.mol-1. However,
the barrier to the rotation for reverse transformation (trans to gauche) is lower by 3
kcal.mol-1 than for the forward transformation (gauche to trans). The second one is the
high energy rotational process that involves eclipsing of two pairs of substituents and two
lone pairs. This process occurs in only the gauche conformation and leads to another
gauche conformation. The energy barrier for this type of transformation is around 16
kcal.mol-1 (10 kcal.mol-1 for eclipsing lone pairs, and 6 kcal.mol-1 for two eclipsed
interactions of alkyl substituents).
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Scheme 7. Diagram showing two types of N-N bond rotations.
1.3.3. Hydrazines in medicinal chemistry
N-N bond motifs are relatively scarce in natural products.56-58 Nevertheless, a
survey from Sperry and Blair in 201357 showed that over 200 natural products containing
the N-N bond motif are known including hydrazines, hydrazones, hydrazides, and many
other related functionalities. However, only four of them have the simple hydrazine
functionality namely N-amino-D-proline, munroniamide, braznitidumine, and ostrerine A
(Figure 14). Ostrerine A, which was isolated from a mollusk, is the only compound
belonging to the tetra-substituted hydrazine class and biological activity of the molecule
is still unknown.
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Figure 14. Natural products with the hydrazine moiety.
Recently, Zhang and Hertweck have independently isolated dixiamycins A and B
(Figure 15), the atropisomeric indoloterpenoid natural products.59,60 These compounds
are the N-N linked dimers of an antibacterial natural product xiamycin A and were found
to be more potent than xiamycin A itself (Figure 15).59,60

Figure 15. Structures of xiamycin A and dixiamycins A and B.
Hydrazine derivatives are an important class of compounds in medicinal chemistry
as they are present in several clinical therapeutics. Some of the representative examples
are listed in Figure 16. Anti-depressant phenelzine61 and anti-hypertensive agent
hydralazine62 are examples of mono-substituted hydrazines. Di-substituted hydrazine
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procarbazine is used to treat Hodgkin’s disease, melanoma, and bronchogenic carcinoma
as a part of a chemotherapeutic cocktail.61 Anti-depressant isocarboxazid and antituberculosis antibiotic isoniazid belong to hydrazide class of compounds.61 Anti-cancer
compound PAC-1 is a hydrazone that selectively induces apoptosis in cancerous cells.63
However, no therapeutic agents with a tetra-substituted hydrazine moiety have been
reported to date.

Figure 16. Structures of therapeutic hydrazines and hydrazides.
Although the hydrazine moiety is common in therapeutic agents and has several
pharmacological applications in treating pathological diseases, their clinical use is limited
due to their toxicity.34,61 Several hydrazine containing drugs were discontinued in the last
decades based on their toxic side effects like hepatotoxicity, induction of systemic lupus
erythematosus, and cancinogenesis.61 Octamoxin, pheniprazine, phenoxypropazine, and
safrazine are some of the antidepressants which were withdrawn from the market owing
to hepatotoxicity concerns (Figure 17).64 In addition to pharmaceutical agents, toxicity
was also observed with several other hydrazine derivatives.65,66
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Figure 17. Structures of discontinued therapeutic hydrazines.
The toxicity of the hydrazine derivatives is attributable to the alkylation of DNA by
the reactive intermediates like carbocations, carbon-centered radicals, and reactive
oxygen species that are generated during the enzyme catalyzed metabolism
process.34,61,66 The metabolisms of mono-substituted and di-substituted derivatives are
catalyzed by several enzyme systems like cytochrome P450, horseradish peroxidase
(HRP), hepatocytes, microsomes, oxyhemoglobin (HbO2), myeloperoxidase, and
neutrophils (PMNs). Scheme 8 describes the common mechanism for the formation of
the reactive species from N,N-disubstituted hydrazines. The carbocations and the alkyl
radicals are formed from two distinct pathways (path a and b respectively) after oxidation
of hydrazine-derived azo compounds. The so-formed reactive intermediates induce
carcinogenesis by alkylating DNA bases.
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Scheme 8. Metabolic transformation of di-substituted hydrazines.
In case of mono-arylhydrazines, several possible metabolic pathways have been
reported.66 The arenediazonium ion is the reactive intermediate that is supposed to react
directly with DNA bases, such as adenine, to generate aryl triazenes (Scheme 9).67 This
ion can also react with the DNA backbone to cleave the strand.66 Alternatively, the
diazonium ion can reduce to an alkyl radical which in turn may react with purines (Scheme
9) or cleave the DNA strand.66,68-73
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Scheme 9. Metabolic transformation in mono-aryl hydrazines.
Because of these observed toxicities together with the observance of false
positives from hydrazine derivatives in the screening process, medicinal chemists have
classified hydrazines as undesirable moieties, and they are currently excluded from
compound collections.6,31 However, the exclusion of the whole hydrazine class of
compounds based upon the negative results of some compounds is arbitrary. In fact,
several therapeutic agents in the market still contain hydrazine moieties and are nontoxic. More importantly, the toxicities are reported only for the mono-substituted, and the
di-substituted hydrazines and the key intermediates for the formation of the reactive
species are azo-compounds or diazonium ions. However, the formation of these key
intermediates is not possible from tetra-substituted hydrazines, which might be one of the
reasons why toxicity reports for the tetra-substituted hydrazines are not available. In
addition, the false positives in the screening process result from the attack of proteins on
electrophilic hydrazine derivatives like hydrazides and N-sulfonamides. In contrast, tetrasubstituted hydrazines are not electrophilic like their lower congeners. Therefore,
exclusion of a whole class of compounds, more importantly, tetra-substituted hydrazines,
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from compound collection based on the few toxicity and false positive reports, is reducing
the chance of finding quality hits in the drug discovery process. Tetra-substituted
hydrazines, in particular, have the potential to enrich compound collections without
additional synthetic and stereogenic complexity because of their low basicity and low
inversion barriers.
1.3.4. Synthesis of tetra-substituted hydrazines
The development of synthetic routes for substituted hydrazines is an attractive
area in synthetic organic chemistry due to their importance in pharmaceutical,
agrochemical, polymer, and dye industries and as precursors for organic synthesis.74 An
ideal route for the synthesis of all kinds of substituted hydrazines is the reaction between
two amines forming an N-N bond (Scheme 10). Since thousands of amines are available
commercially, this route would have a huge potential for generating a large library of
compounds with diversity. In the flip side, success by this route is considered challenging
since forming a heteroatom-heteroatom bond itself remains a challenging goal in the
synthetic organic chemistry. Despite the challenge of forming an N-N bond, a few
aminations of amines with aminating reagents like chloroamines and sulfonate derivatives
of hydroxylamines are documented and are used in laboratory and industrial
preparations.75,76 However, the scope of those methods is narrow due to the limited
substrate scope and poor yields. An alternative route is the alkylation or reductive
amination of parent hydrazines. However, multiple steps are required to access tri and
tetra-substituted hydrazines by this route. Since the synthesis of mono, di, and trisubstituted hydrazines are required as a prelude to the synthesis of tetra-substituted
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hydrazines, the available methods for all classes of substituted hydrazines will be
discussed briefly including aminations of amines.

Scheme 10. Ideal route for the synthesis of hydrazines.
1.3.4.1. From hydrazines and their derivaties
Several synthetic methods have been reported aiming at mono-substituted
hydrazines.77 The direct mono-alkylation approach of a free hydrazine, although seems
practical, is difficult to control and delivers a mixture of mono-substituted product, overalkylation, and starting material.76,77 Therefore, alkylation of N-protected hydrazines,
followed by deprotection, became the method of choice to access mono-subsituted
hydrazines (Scheme 11a).75 Alternatively, reduction of hydrazones and hydrazides with
suitable reducing agents like NaBH4, NaCNBH3, and LiAlH4 was also found to be practical
and efficient methods (Scheme 11b and 11c).75-78

Scheme 11. Synthesis of mono-substituted hydrazines.
The di-substituted hydrazines can be classified into two distinct types namely N,Ndisubstituted hydrazines (also known as 1,1-disubstituted or unsym-disubstituted
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hydrazines) and N,N’-disubstituted hydrazines (also known as 1,2-disubstituted or symdisubstituted hydrazines).76,77 Direct alkylation of mono-substituted hydrazines was
generally used to afford N,N-disubstituted hydrazines (Scheme 12a), whereas strategic
protection of the mono-substituted precursor before alkylation and deprotection after
alkylation are necessary to generate the N,N’-disubstituted hydrazines (Scheme
12b).75,77 Furthermore, the N,N’-disubstituted hydrazines were also accessed from
reduction of hydrazones (Scheme 12c) and N,N’-diacylhydrazines (hydrazides) (Scheme
12c) under similar reduction conditions to those used in reduction approaches for the
mono-substituted hydrazines.75,77,78

Scheme 12. Synthesis of di-substituted hydrazines.
Similarly, tri and tetra-substituted hydrazines were also prepared from the direct
alkylation of di-substituted hydrazines, mostly with activated alkyl halides and alkenes
(Michael addition).77 A recent approach of controlled alkylations of di-anions of N,N’disubstituted hydrazines to generate tri and tetra-substituted hydrazines is a noteworthy
example of this kind (Scheme 13a and 13b).74,79,80 The tri-substituted hydrazines also
result from the transformation of N,N-disubstituted hydrazines to hydrazone or hydrazide
derivatives, followed by reduction (Scheme 13c and 13d).77 Some of tetra-
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alkylhydrazines were also prepared by the sequence of hydrazone formation from N,Ndisubstituted hydrazines and reduction by NaCNBH3 in the presence of formaldehyde
(Scheme 13c).75,77 Reduction of tetra-substituted hydrazides with powerful reducing
agents like diborane or LiAlH4 is a common method used in the preparation of simple to
complex tetra-substituted hydrazines.75-77,81

Scheme 13. Synthesis of tri and tetra-substituted hydrazines.
1.3.4.2. From direct amination of amines
Several N-N linked dimers of carbazole derivatives have been generated by
electrochemical oxidation via nitrogen centered radical intermediates (Scheme 14a).82
However, this method is limited to symmetric hydrazines only. The reactions of primary
and secondary amines with chloroamine83-85 or hydroxylamine-O-sulfonic acid76,86,87 are
useful methods for preparing mono-substituted and N,N-disubstituted hydrazines
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(Scheme 14b). For example, the reaction of dimethylamine with chloroamine is an
industrial preparation of N,N-dimethylhydrazine (rocket fuel).75 The N,N’-disubstituted
hydrazines were prepared from the reaction of N-chloro derivatives of primary amines
with azomethines followed by the hydrolysis (Scheme 14c).75,77 Moreover, a series of
aminating agents based on N-protected oxaziridines with various substituents on their
carbons has been developed for electrophilic amination of amines (Scheme 14d).75,88
This method was found to be efficient for the synthesis of N,N-disubstituted hydrazines
only. Several other aminating agents based on hydroxylamine sulfonates can be
accessed commercially or synthetically89 and have the potential to form hydrazines
directly from amines.

Scheme 14. Synthesis of substituted hydrazines by direct aminations.
In conclusion, N-alkylations of protected hydrazines, reductions of hydrazones and
hydrazides, and aminations of amines with aminating reagents are some of the important
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and widely used methods in the synthesis of substituted hydrazines. 77 Several other
methods including transition metal catalyzed reactions are also reported, 90-93 however,
short and efficient entries to substituted hydrazines are always in demand.
1.4. Designing hydroxylamine and hydrazine analogs of kalkitoxin
1.4.1. Discovery of kalkitoxin and its biological activitites
Kalkitoxin (13) is a natural stretch-peptide that was discovered by Gerwick, Shioiri,
and co-workers as a secondary metabolite of Lyngbya majuscule, a marine
cyanobacterium.94,95 It was isolated from an extract of L. majuscule by the brine shrimp
and gold fish toxicity assay guided fractionation process and was disclosed as
ichthyotoxic against common gold fish (Carassius auratus, LC50 700 nM) and potently
toxic against brine shrimp (Artemia salina, LC50 170 nm).95 The potencies of kalkitoxin
were also observed in the inhibition of the cell division process in a fertilized sea urchin
embryo assay (IC50 ~50 nM), in suppression of inflammation as measured in an
inflammatory disease model that measures IL-1β-induced sPLA2 secretion from HepG2
cells (IC50 27 nM), and in blockage of voltage sensitive Na+ channel in mouse neuro-2a
cells (EC50 1 nM).95-98 In addition, an exceptional concentration-dependent neurotoxicity
(LC50 3.86 nM) was observed with kalkitoxin when tested in a primary cell culture of rat
cerebral granule neurons whose the effects were prevented with non-competitive Nmethyl-D-aspartate (NMDA) receptor antagonists.94 Furthermore, The potent anti-cancer
property of kalkitoxin was revealed by its excellent cytotoxicity (IC50 1 nM) measured
against the human colorectal cancer cell line (HCT-116).99 In a recent mechanistic study
by Nagle, Zhou, and co-workers,100 kalkitoxin was found to inhibit hypoxia-induced
activation of HIF-1 in T47D breast tumor cells (IC50 5.6 nM) selectively by suppressing
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mitochondrial oxygen consumption at electron transport chain (ETC) complex I (NADHubiquinone oxidoreductase). Further, kalkitoxin was also found to inhibit angiogenesis by
blocking the induction of angiogenic factors like vascular endothelial growth factors
(VEGF) in tumor cells.

Figure 18. Structure of kalkitoxin.
The structure of kalkitoxin is as interesting as its biology. Gerwick, Shioiri and coworkers carried out the total synthesis of natural kalkitoxin and its possible stereoisomers
in order to determine the configuration.95,101 After comparing their NMR spectra and on
the basis of the asymmetric synthesis, the absolute configuration of natural (+)-kalkitoxin
was assigned as (3R,7R,8S,10S,2’R). The structure of kalkitoxin includes a 2,4disubstituted thiazoline with one substituent being an unsaturated side chain and the
other a stretch-peptide side chain. The arrangement of the three methyl substituents in
the 1,2,4-anti,anti fashion is the most significant and structurally attractive feature of the
stretch-peptide side chain.
1.4.2. Total syntheses of kalkitoxin
With its exceptional biological activities and three methyl substituents in 1,2,4anti,anti fashion in its stretch-peptide side chain, kalkitoxin became an attractive target
for the synthetic chemists. As a result, five total syntheses have been published to date.
Gerwick, Shioiri, and co-workers reported a first total synthesis of kalkitoxin in 2000
(Scheme 15), while determining its absolute configuration.95 The synthesis commenced
with deoxygenation of a known compound 14,102 after which the resulting alkene was
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subjected to hydroboration, followed by azide 15 formation. The azide 15 was then
reduced to an amine, coupled with (R)-methylbutyric acid (16), and methylated to provide
amide 17. The subsequent O-desilylation and oxidation resulted in an aldehyde, which
was further subjected to the Horner-Emmons reaction with 18 in order to afford the
precursor to asymmetric conjugate addition. Hruby’s method103 of conjugate addition
resulted in the adduct 19 with the required 1,2,4-anti,anti methyl sequence as a single
isomer. Conversion of the chiral auxiliary to the acid functionality and coupling with (R)amino

alcohol

20 delivered

di-amide 21.

Finally, Wipf’s oxazoline-thiazoline

interconversion reaction sequence104 was utilized in order to get kalkitoxin (13). In this
process the amide 21 was first cyclized to a 2-oxazoline in the presence of DAST, then
treatment with hydrogen sulfide afforded the thioamide. DAST was again used for the
second cyclization to deliver the targeted kalkitoxin (13). In conclusion, the synthesis of
kalkitoxin was accomplished in 17 linear steps, starting from a known compound 14 in
9% of overall yield. The 1,2,4-anti,anti sequence was achieved by 1,4-conjugate addition
with the aid of a chiral auxiliary and the thiazoline ring was introduced by Wipf’s oxazolinethiazoline interconversion protocol.
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Scheme 15. Total synthesis of kalkitoxin by Gerwick, Shioiri, and co-workers. a) n-BuLi,
pTsCl. b) LiAlH4. c) 9-BBN, ultrasound; NaOH, H2O2. d) MsCl, Et3N, DMAP. e) NaN3, 55
oC.

f) H2 (1 atm) 5% Pd-C. g) 16, DEPC, Et3N. h) n-BuLi, MeI. i) TBAF. j) Py.SO3, Et3N,

DMSO. k) 18, NaHMDS. l) MeMgBr, CuBr.DMS, -30 oC. m) LiOH, H2O2. n) 20, EDCI,
DIPEA, DMAP. o) DAST, -20 oC. p) H2S, Et3N. q) DAST, -20 oC.
The second total synthesis was executed by the White group in 2003 (Scheme
16).99,105 A one pot entry to the 1,2,4-anti,anti methyl sequence via asymmetric conjugate
addition, followed by in situ enolate alkylation, and a TiCl4 induced thiazoline ring
formation were the two key steps of the synthesis. The synthesis started with a three-step
reaction sequence involving asymmetric alkylation, reduction, and Appel reaction to
generate alkyl bromide 23 from literature molecule 22106 as a starting material. After
transformation of 23 to an organocopper species, it was treated with (S)-N-(transcrotonyl)-4-phenyloxazolidin-2-one (24) and the so-obtained anti-1,3-dimethyl enolate
was trapped in situ with methyl iodide to deliver a mixture of 25 (with the desired 1,2,4-
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anti,anti configuration) and 26 favoring 25 (3.6:1). After hydrogenation of 25, the resulting
alcohol side chain was extended to amide 27 by Swern oxidation, reductive amination,
and coupling with (R)-methylbutyric acid (16). The chiral auxiliary was removed by
reduction and the resulting alcohol was subjected to Swern oxidation, followed by
homologation, to give a mixture of alkenes (E/Z) 28 via the Wittig reaction. The mixture
28 was then hydrolyzed to an aldehyde and oxidized to an acid 29. Next, amine 32, the
coupling partner of the acid 29, was synthesized from L-cysteine (30) in 5 steps. First, the
free thiol and amine groups of 30 were protected as a benzyl thioether and a carbamate,
respectively, and the remaining free acid function was transformed to Weinreb amide 31.
Then reduction, Wittig reaction, and selective amine deprotection delivered amine 32.
The resulting amine 32 was coupled with acid 29 and the so-formed thioamide 33 was
subjected to Birch reduction conditions to get thioamide 34 with a free thiol group. Finally,
the TiCl4-mediated cyclization of 34 delivered the targeted kalkitoxin. In summary,
kalkitoxin was synthesized in 16 linear steps starting from a literature amide 22 in 3%
overall yield.
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Scheme 16. Total synthesis of kalkitoxin by White et al. a) LDA, LiCl, 2-iodoethyl benzyl
ether, 0 oC, 98%. b) LDA, BH3.NH3, 0 oC, 90%. c) Ph3P, NBS, 74%. d) Mg; CuBr.SMe2;
24; MeI, 64%. e) H2 (1 atm), 15% Pd-C, 100%. f) (COCl)2, DMSO, Et3N, 85%. g)
MeNH2.HCl, NaCNBH3, 81%. h) 16, EDCI, HOAt, 84%. i) LiBH4, 80%. j) (COCl)2, DMSO,
Et3N. k) Ph3PCH2OMeCl, n-BuLi, 52% (2 steps) l) HCl, MeCN. m) NaClO2, NaH2PO4, 2methyl-2-butene, 96% (2 steps). n) BnBr, NaOH, EtOH, 94%. o) Boc2O, Et3N, 99%. p)
MeNHOMe.HCl, EDCI, HOBt, 84%. q) LiAlH4, 91%. r) Ph3PCH3Br, n-BuLi, 55%. s) TFA,
no purification. t) HATU, DIPEA, 32, 93% u) Na, NH3, 87%. v) TiCl4, 67%.
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The next total synthesis was reported by the Shioiri group in 2004,101 and was
similar to their first total synthesis except for the installation sequence of some of the
building blocks in the developing stretch-peptide chain. In 2012, Matsuda and co-workers
also reported a total synthesis,107 in which the stretch-peptide chain was synthesized
following the route of the Gerwick and Shioiri synthesis, and the thiazoline ring was
installed following White’s protocol.
More recently, Aggarwal and co-workers have reported the shortest route to date
for kalkitoxin using an iterative synthesis approach (Scheme 17).108 The most attractive
feature of this synthesis was the stereoselective achievement of amide 41 from boronic
ester 35 in a few steps with a single purification process. First, the boronic ester 35 was
converted to a core aliphatic chain 38 by a reaction sequence of two consecutive
homologations with (S)-36, a methylene insertion with 37, another homologation with (R)36, and two methylene insertions. The-so obtained boronic ester 38 was treated with
lithiated methoxyamide (39) and the resulting amine 40 was coupled with (R)methylbutyric acid (16) to furnish amide 41. After methylation of amide 41, the resulting
amide intermediate was converted to acid 29 in the presence of RuCl3 and NaIO4. Unlike
the White synthesis, the coupling partner of acid 29 (i.e., 32) was prepared from butadiene
monoepoxide (43) as a starting material. An allylic imide 45 was prepared from the
reaction of phthalimide and butadiene monoepoxide under Trost’s dynamic kinetic
asymmetric transformation conditions. The free hydroxyl group was next converted to a
thioether via mesylation and subsequent displacement by benzylmercaptan and the
resulting thioether was subjected to aminolysis to produce amine 32. With acid 29 and
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amine 32 in hand, the synthesis of kalkitoxin was completed following White’s protocol.
The total steps for kalkitoxin synthesis were cut down to thirteen in 12% overall yield.

Scheme 17. Total synthesis of kalkitoxin by Aggarwal and co-workers.
1.4.3. SAR studies of kalkitoxin
Several kalkitoxin analogs have been synthesized and screened for their
bioactivities in order to understand the role of structural and configurational motifs of
kalkitoxin in its observed bioactivity. The structures of these kalkitoxin analogs and their
activities against brine shrimp bioassay (LC50 data) or against human colon cancer cell
line HCT-116 (IC50 data) are tabulated in Table 1.

39
Table 1. Biological activities of kalkitoxin and its analogs.
Kalkitoxin and its isomers

Brine shrimp

HCT-116

Ref.

assay, LC50 (nM) IC50 (nM)
1

170-180

1

95,99,101,107

2

15000

-

107

3

3600

-

107

4

1700

-

107

5

620

-

107

6

550

-

101

7

1800

-

107

8

Inactive

-

107

9

9300

-

101
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10

Inactive

-

101

11

Inactive

-

101

12

1700

-

101

13

1100

-

101

14

-

400

99

15

-

190

99

From these results it is clear that the configuration of the stereogenic center C-3
of kalkitoxin is very important for the activity since the 3S-isomer (46) of kalkitoxin was
found to be ~80 fold less active than kalkitoxin (Table 1, entry 2). The activities of 7Sisomer (47) and 8R-isomer (48) (Table 2, entries 3 and 4) were found to be 20 and 10
fold less than that of kalkitoxin suggesting that the configurations of stereogenic centers
C-7 and C-8 in kalkitoxin are also important for the activity. However, the configurations
of stereogenic centers C-10 and C-2’ in kalkitoxin are comparatively less important for the
activity as both the10R isomer (49) and 2’S-isomer (50) (Table 1, entries 5 and 6) were
found to be only about 3 fold less active than kalkitoxin. The isomers 54 and 55 (Table 1,
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entry 10 and 11) were found to be almost inactive and the enantiomer (53) of kalkitoxin
(Table 1, entry 9) was found to be 50 fold less active than kalkitoxin. Moreover, isomers
56 and 57 (Table 1, entry 12 and 13) were also found to be less potent than kalkitoxin.
The LC50 values for 10-nor-kalkitoxin (51) and 16-nor-kalkitoxin (52) suggest that the
methyl groups CH3-15 and CH3-16 are very important for the activity. White et al. have
screened the synthetic precursors of kalkitoxin (33 and 34) against human colon cancer
cell line (HCT-116) in addition to kalkitoxin (Table 1, entries 1, 14, and 15). The precursors
33 and 34 were found to be 400 and 190 fold less potent, respectively than kalkitoxin.
Therefore, the thiozoline ring is a very important part of the molecule for the activity. In
conclusion, the configurations of all stereogenic centers, methyl groups CH3-15 and CH316, and thiazoline ring are important for the potency of the kalkitoxin.
1.4.4. Design of hydroxylamine and hydrazine analogs
In order to test the concepts of hydroxylamine and hydrazine analogs, kalkitoxin
was chosen as a potential candidate for three reasons. First, kalkitoxin has potent
bioactivity as described in section 1.5.1. Second, the configurations of stereogenic
centers in kalkitoxin are important for the activity as discussed in section 1.5.3. And third,
kalkitoxin has the potential to serve as a common candidate to test both the
hydroxylamine and hydrazine analog concepts since it has two adjacent stereogenic
centers.
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Figure 19. Kalkitoxin and its hydroxalogs and hydrazine analog.
Two hydroxalogs of kalkitoxin were designed, namely, 6-oxa-7-azakalkitoxin (58)
and 9-oxa-10-azakalkitoxin (59). The former was designed by substituting the C-6 with
an oxygen atom and the stereogenic center C-7 with a nitrogen atom and the latter was
designed by substituting the C-9 with an oxygen atom and the stereogenic center C-10
with a nitrogen atom. The hydrazine analog of kalkitoxin, 7,8-diazakalkitoxin (60), was
designed by substituting the stereogenic centers C-7 and C-8 with two nitrogen atoms
thereby introducing the hydrazine moiety. These modifications are intended to reduce the
synthetic as well as the stereogenic complexities due to the rapid inversions at the
nitrogen centers. The synthesis of all three analogs will be executed and the compounds
will be screened against several cancer cell lines in the Valeriote lab at the Henry Ford
Hospital Cancer Center in Detroit.

43
CHAPTER 2. SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES
2.1. Design and development of the method
As is described in section 1.2.4 of Chapter 1 (Scheme 3), an ideal route for the
synthesis of tri-substituted hydroxylamies is the N-O bond formation in which commercial
amines and alcohols can be utilized to generate a library of compounds. However, owing
to the challenges associated with this line of work, chemists have shifted their interest to
alternative routes such as N-derivatization of N,O-disubstituted hydroxylamines and Oderivatization of N,N-disubstituted hydroxylamines. Several methods for N-alkylation
have been devised for tri-substituted hydroxylamine synthesis.18,19,41-43 However,
methods for O-alkylation of N,N-disubstituted hydroxylamine are limited with the
exception of O-alkylation with simple and activated electrophiles like allyl and aryl
halides.41 In addition to the observed limitation of the substrate scope, the available
method for O-alkylation also lacks the potential to introduce diversity on the O-substituent.
To introduce diversity on O-substituent, an efficient method for O-alkylation of N,Ndisubstituted hydroxylamines is needed to provide easy access to libraries of trisubstituted hydroxylamines with great diversity.
To solve the existing problem in O-alkylation, indirect O-alkylation of N,Ndisubstituted hydroxylamine was designed. Since acylation is much easier than alkylation,
O-alkylation of N,N-disubstituted hydroxylamines was considered analogous to the
synthesis of ethers from alcohols by reductive etherification, for which a number of
attractive ideas were formulated recently.109,110 Therefore, by adapting Rychnovsky
reductive etherification,109

acylation of N,N-disubstituted hydroxylamines to N-

acyloxyamines, followed by a two-step method, was considered for the synthesis of tri-
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substituted hydroxylamines based upon the stepwise reduction of N-acyloxyamines
(Scheme 18). The N-acyloxyamines was first reduced with diisobutylaluminum hydride
(DIBAL) at lower temperature and then was treated with acetic anhydride in the presence
of

pyridine

and

4-(dimethylamino)pyridine

(DMAP).

The

resulting

O-(α-

acetoxyalkyl)hydroxylamine was further reduced with triethylsilane in the presence of
Lewis acid such as BF3.OEt2 to provide tri-substituted hydroxylamine.

Scheme 18. a) Rychnovsky reductive etherification. b) Synthesis of tri-substituted
hydroxylamines from N-acyloxyamines.
A possible mechanism for this two-step method is proposed in Scheme 19.
Scheme 19a is the mechanism for the first reduction step, and Scheme 19b is the
mechanism for the second reduction step. Partial reduction of the N-acyloxyamine with
DIBAL generates a chelation-stablized tetrahedral intermediate similar to Colby’s
aluminium complex of hydroxylamine111 at −78 oC. This tetrahedral intermediate is
trapped in situ with acetic anhydride in the presence of DMAP generating a more stable
O-(α-acetoxyalkyl)hydroxylamine. In the second reduction step, an acetoxy anion is
released from the O-(α-acetoxyalkyl)hydroxylamine with an aid of a Lewis acid and forms
an aminoxocarbenium ion intermediate in situ. Donation of hydride from triethylsilane to
this intermediate ion generates the tri-substituted hydroxylamine.
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Scheme 19. Proposed mechanism for 2-step reaction in Scheme 18.
2.1.1. Synthesis of N,N-disubstituted hydroxylamines
A simple protocol to prepare N,N-disubstituted hydroxylamines from N(benzoyloxy)amines derived from the reaction of amines with dibenzoyl peroxide was
executed (Table 2). N-(Benzoyloxy)amines (62a-62e) were prepared from benzoyl
peroxide and commercial secondary amines by adaptation of the Ganem protocol 112 in
good yields. On exposure to 2.5 equivalents of DIBAL in ice cold conditions, these N(benzoyloxy)amines were reduced to N,N-disubstituted hydroxylamines (63a-63e).
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Table 2. Synthesis of N,N-disubstituted hydroxylamines.

Entry

Amine, 61

N-Benzoyloxyamine 62, Hydroxylamine 63,
% yield[a]

% yield[b]

1

61a, R1 = R2 = Bn

62a, 81%

63a, 90%

2

61b, R1 =Me, R2 = Bn

62b, 82%

63b, 93%

3

61c, piperidine

62c, 86%

63c, 63%

4

61d, 4-methylpiperidine

62d, 82%

63d, 84%

5

61e, 4-chloropiperidine

62e, 81%

63e, 85%

[a]

Stirring with (BzO)2 (1.1 equiv) and K2HPO4 (1.5 equiv) in DMF, at rt for 1-22 h. [b]

Stirring with DIBAL (2.5 equiv) in CH2Cl2 at 0 oC for 15 min.

Scheme 20. An alternative synthesis of N-acyloxy amines exemplified for N-(4phenylbutyroyl)pyrrolidine.
Alternatively, N,N-disubstituted hydroxylamine 63f was effectively generated from
aza-Michael addition of a secondary amine to acrylonitrile, followed by N-oxide formation
and Cope elimination (Scheme 20).113

Subsequent treatment of crude 63f with 4-

47
phenylbutyric acid in the presence of dicyclohexylcarbodiimide (DCC) and DMAP
afforded N-acyloxyamine 62f.
2.1.2. Synthesis of N-acyloxyamines
N-acyloxyamines

(62g-62o)

were

prepared

from

N,N-disubstituted

hydroxylamines (63a-63f) and the corresponding carboxylic acids with DCC and DMAP
as activating reagents (Table 3).114
Table 3. Synthesis of N-acyloxyamines.

Entry

R1

R2

R3

N-Acylhydroxylamine, 62,
%yield

1

Bn

Bn

Ph(CH2)3

62g, 98%

2

Bn

Bn

C10H15

62h, 72%

3

Bn

Bn

tBuCH2

62i, 63%

4

Bn

Me

Ph(CH2)4

62j, 93%

5

-(CH2)5-

Ph(CH2)3

62k, 93%

6

-(CH2)2CHMe(CH2)2-

Ph(CH2)3

62l, 91%

7

-(CH2)2CHCl (CH2)2-

Ph(CH2)3

62m, 80%

8

Bn

Bn

2-C10H7OCH2

62n, 89%

9

Bn

Bn

3-C5H4N

62o, 97%

[a]

R3CO2H (1.25-2.5 equiv), DCC (1.25-2.5 equiv), DMAP (0.2 equiv), CH2Cl2,

RT, 0.5-30 h.
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2.1.3. Synthesis of N,N,O-trisubstituted hydroxylamines
With a series of N-acyloxyamines in hand, the efficiency of the two-step by method
for the synthesis of tri-substituted hydroxylamines (Table 4) was investigated adapting
Rychnovsky’s protocol109 for the synthesis of ethers from esters. The N-acyloxyamines
were reduced with DIBAL at −78 °C, and the tetrahedral intermediates were trapped in
situ as O-(α-acetoxyalkyl)hydroxylamines with acetic anhydride in the presence of
pyridine and DMAP, followed by warming to 0 °C. A diverse range of O-(αacetoxyalkyl)hydroxylamines 65 were obtained in good to excellent yields. The reaction
is quite general, as exemplified through a diverse set of substrates with alkyl and aryl
groups in both nitrogen and oxygen substituents. In addition, substrates with branching
at the α- and β-positions of the acyl groups (62h and 62i) were also compatible with the
reaction conditions.
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Table 4. Synthesis of trisubstituted hydroxylamines.

[a]

i) DIBAL (1.25-2 equiv), CH2Cl2, -78 oC, time; ii) Ac2O (6 equiv), Py (3 equiv), DMAP

(2 equiv), CH2Cl2, -78

o

CH2Cl2, -78 o to RT.

Not isolated. [d] Yield over two steps.

[c]

to 0 oC.

[b]

Et3SiH (2.5-5 equiv), BF3OEt2 (2.5-6.25 equiv),

The so-obtained O-(α-acetoxyalkyl)hydroxylamines were then treated with
triethylsilane in the presence of boron trifluoride etherate at −78 °C, and the reaction was
warmed to 0 °C to give the desired N,N,O-trisubstituted hydroxylamines in good yields
(Table 4). As some O-(α-acetoxyalkyl)-N,N-dialkyl hydroxylamines intermediates (65a,
65b, and 65o) were found to be quite unstable and decomposed during the purification
process, they were transformed to their corresponding tri-substituted hydroxylamines
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(66a, 66b, and 66o) directly without further purification in overall good yield for the twostep process.
On careful monitoring of the reactions, the actual temperature of the Lewis acidmediated reduction of the O-(α-acetoxyalkyl)hydroxylamines by triethylsilane was
observed to be substrate dependent, reflecting the stability of the presumed intermediate
aminoxocarbenium ions. The β-(2-naphthyloxy)-ethyl system 65n is an extreme example
of the effect of substituent on reduction as it required multiple equivalents of triethylsilane
and BF3.OEt2 at room temperature, and took 7 days in order to afford a 38% isolated
yield of hydroxylamine 66n. The relative slowness of this particular reduction reflects the
destabilizing influence of alkoxy groups on oxocarbenium ion like intermediates such as
is widely appreciated in carbohydrate chemistry.115-117
To understand the effect of electron withdrawing groups in the reduction further
and to support the existence of assumed aminoxocarbenium ion intermediate, reductions
of a series of three O-(β,γ, and δ-azido-1-acetoxyalkyl) hydroxylamines were executed
(Scheme 21).

Scheme 21. Synthesis of azidoalkylhydroxylamines.
The synthesis of three O-(β,γ, and δ-azido-1-acetoxyalkyl) hydroxylamines were
achieved by a similar protocol to the one described previously. As anticipated, the
subsequent

Lewis

acid-mediated

reduction

by

triethylsilane

to

give

the

O-
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(azidoalkyl)hydroxylamines was strongly affected by the proximity of the azido group to
the center of reaction. Thus, while the 1-acetoxy-4-azidobutyl system 65r was reduced
to the hydroxylamine 66r in 54% yield under the standard conditions of treatment with
BF3.OEt2 and triethylsilane at −78 oC in dichloromethane followed by warming to 0 oC and
workup, a more modest 48% yield of the lower homolog 66q was obtained from the 1acetoxy-3-azidopropyl precursor 65q only when the reaction was warmed to room
temperature and stirred for 24 h. Reduction of next lower homolog 65p was significantly
slower, such that 66p was obtained only in 17% yield after stirring for four days at room
temperature. The presence of an electron-withdrawing group vicinal to the reaction
center therefore, very strongly retards reduction of the O-(1-acetoxyalkyl)hydroxylamines,
but the effect falls off rapidly with the insertion of successive methylene groups. The
strongly retarding effect of the electron-withdrawing group thus observed in the reduction
of both 65n and 65p supports the intermediacy of an aminoxocarbenium ion intermediate
(Scheme 22) in these reactions.

Scheme 22. Intermediate aminoxocarbenium ion destabilized by the electronwithdrawing group X.
2.1.4. Synthesis of tri-substituted hydroxylamines with C-C bond formation
The isolation of the O-(α-acetoxyalkyl)hydroxylamines also provided an
opportunity to introduce nucleophiles adjacent to the oxygen and increase the molecular
complexity of the product hydroxylamines. Therefore, adapting literature methods for the
reductive allylation of α-acetoxy ethers,118,119 various carbon nucleophiles such as
allylstannanes, enolethers, and 2-methylfuran were used in this boron-trifluoride etherate-
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promoted substitution to afford a number of novel hydroxylamines (Table 5) in modest to
excellent yields.
Table 5. Synthesis of trisubstituted hydroxylamines with concomitant C-C bond formation.

Entry

Ester

O-(α-Acyloxy)hydroxyl

Reagent, conditions

-amine, 65[a]
1

62a

65a, -[b]

Hydroxylamine,
70, %yield

Bu3SnCH2CH=CH2 (2.5 equiv),

70a, 82%[c]

BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC
2

62b

65b, -[b]

Bu3SnCH2CH=CH2 (2.5 equiv),

70b, 54%[c]

BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC
3

-

65h

Bu3SnCH2CH=CH2 (2.5 equiv),

70c, 79%

BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC
4

62a

65a, -[b]

CH2=C(OTMS)CMe3, (2.5 equiv),

70d, 66%[c]

BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC
5

62a

65a, -[b]

2-methylfuran (2.5 equiv),

70e, 51%[c]

BF3OEt2 (2.5 equiv), CH2Cl2, -78 oC
6

-

65g

2-methylfuran (2.5 equiv),

70f, 20%

BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC
[a]

i) DIBAL (2 equiv), CH2Cl2, -78 oC; ii) Py (3 equiv), DMAP (2 equiv), Ac2O (6 equiv), CH2Cl2, -78 to 0 oC.

[b]

Not isolated.

[c]

Two steps.
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2.1.5. Study of stereoselectivity of addition of nucleophiles
As the carbon nucleophile addition on aminoxocarbenium ion intermediate in Lewis
acid-mediated reaction creats a new stereogenic center in the molecule, the
stereoselectivity of the reaction was investigated by applying the standard conditions in
the substrates with pre-existing stereocenters (Scheme 23). Intermediate 73 was
prepared from Evan’s alkylated product 71.120 Reaction of hydrogen peroxide and lithium
hydroxide with 71 afforded the corresponding acid. The resulting acid was then used for
acylation of N,N-dibenzylhydroxylamine in the presence of N-(3-dimethylaminopropyl)-N′ethylcarbodiimide (EDCI) and Hunig’s base, and O-acyl hydroxylamine 72 was
generated. Upon reduction with DIBAL at −78 oC followed by treatment with acetic
anhydride and warming to 0 oC, 72 was converted to O-(α-acetoxyalkyl)-N,N-dialkyl
hydroxylamine 73.

Scheme 23. Study of stereoselectivity of the Lewis acid-mediated reaction.
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With the intermediate 73 in hand, the stereoselectivity of the nucleophilic addition
was studied. In a reaction of 73 with allyltributylstannane as a nucleophile in the presence
of BF3.OEt2, a mixture of two inseparable diastereomers (74a and 74b) was isolated in
87% yield with poor selectivity (1:1.2). The product 74b (conformation D) and product 74a
(conformation A) were identified as the major and minor products, respectively from the
NOE experiments and 3JH1,H2 values (Figure 20). Under similar reaction conditions, an
unassigned mixture of inseparable diastereomers (75a and 75b) was obtained in a ratio
of 1:1 when using dimethylzinc as a nucleophile. Owing to the observed poor selectivity
of these reactions, further investigation towards diastereoselective reaction was aborted.

Figure 20. NOE correlation of 74a and 74b.
2.1.6. Considering an analogy between tetra-substituted hydrazines and trisubstituted hydroxylamines
The synthesis of tetra-substituted hydrazines was considered analogously to the
synthesis of tri-substituted hydroxylamines. Therefore, a two-step reaction method was
designed for tetra-substituted hydrazine synthesis based upon stepwise reduction of a

55
hydrazide, which itself can be accessed from N-acylation of a tri-substituted hydrazine
(Scheme 24.).

Scheme 24. Synthesis of tetra-substituted hydrazines.
To test the idea, hydrazide 79 was prepared from 1-Boc-1-methylhydrazine 76121
(Scheme 25). Benzylation of 76 with excess benzyl bromide afforded 1-Boc-1-methyl2,2-dibenzylhydrazine

(77),

which

was

then

deprotected

to

1,1-dibenzyl-2-

mehylhydrazine (78) by treatment with trifluoroacetic acid. Treatment of 78 with 4phenylbutyric acid in the presence of DCC and DMAP afforded the hydrazide 79 in
excellent yield.

Scheme 25. Synthesis of hydrazide 79.
Reduction of hydrazide 79 to N-(α-acetoxyalkyl)hydrazine 80 was tested by
treating with 1.5 equivalents of DIBAL at −78 oC, followed by addition of acetic anhydride,
pyridine, and DMAP, and warming to 0

oC.

Surprisingly, the anticipated N-(α-

acetoxyalkyl)hydrazine 80 was not observed, but the tetra-substituted hydrazine 81 and
hydrazide 82 were isolated in 33% and 30% yields, respectively. When 79 was treated
only with 3 equivalents of DIBAL at lower temperature, the tetra-substituted hydrazine 81
was isolated in 65% yield, and 14% of starting material was recovered. When the reaction
was exposed to allyltributylstannane after treatment with 1.25 equivalent of DIBAL at −78
oC

followed by warming to room temperature, compound 83 was isolated in 31% yield.
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Scheme 26. Results from the reductions of hydrazide 79.
Consistent with the reduction of 79, hydrazide 84, which was prepared from trisubstituted hydrazine 78 and benzoic acid, also resulted in the formation of tetrasubstituted hydrazine 85 in 61% yield when reduced with 3 equivalents of DIBAL at −78
oC.

Similarly, precursor 86, which was prepared from sym-dimethylhydrazine and an

excess of 4-phenylbutyric acid, also afforded tetra-substituted hydrazine 87 in 46% yield
with 6 equivalents of DIBAL.

Scheme 27. Synthesis of tetra-substituted hydrazines 85 and 87.
The failure to observe N-(α-acetoxyalkyl)hydrazine 80 from hydrazide 79 in the
presence of DIBAL and acetic anhydride, and complete reduction of hydrazides 79, 84,
and 86 to tetra-substituted hydrazine with DIBAL only, suggests that these reactions
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proceeds via azaiminium ion intermediate (Figure 21). As azaiminium ion is more stable
than aminoxocarbenium ion, at low temperature, the formation of azaiminium ion
intermediate was facile and unavoidable in the DIBAL reduction of hydrazide, whereas
the formation of aminoxocarbenium ion in the reduction of O-acylhydroxylamine was not
observed .

Figure 21. Structures of azaiminium ion and aminoxocarbenium ion intermediates.
2.2. Conclusion
A straightforward two-step synthesis of N,N,O-trisubstituted hydroxylamines has
been developed based upon the stepwise reduction of O-acylhydroxylamines. The Oacylhydroxylamines were easily accessed from acylation of

N,N-disubstituted

hydroxylamines, which themselves were achieved from the benzoylation of commercial
amines followed by deacylation. The reductive deacetoxylation of an intermediate O-(αacetoxyalkyl)hydroxylamine

is

proposed

to

proceed

via

intermediacy

of

an

aminoxocarbenium ion. This hypothesis is supported by the diminished reactivity of O-(αacetoxyalkyl)hydroxylamine with electron withdrawing substituents in an alkyl side chain.
The replacement of triethylsilane with various carbon nucleophiles in the reductive
deacetoxylation step enabled the introduction of substitutions on the α-position of the Osubstituents. Poor stereoselectivities were observed when the reductive deacetoxylation
was conducted on substrates with the pre-existing stereocenters adjacent to the acetoxy
group regardless of the nature of carbon nucleophiles used. Overall, the method has
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extended the availability of a range of fully substituted hydroxylamines permitting wider
application of this under-utilized functionality in medicinal chemistry.
2.3. Future directions
The scope of the hydroxylamine-forming process can be further expanded by
manipulating final reduction steps in several ways. Some of the possible manipulations
are presented in Scheme 28. A well-designed intramolecular cyclization in reductive
deacetoxylation of O-(α-acetoxyalkyl)hydroxylamine has a potential to form a series of
compounds with carbocycles on O-substituents (Scheme 28a). Also, aminoxysugar
derivatives are possible if the intramolecular nucleophile is an oxygen atom (Scheme
28b). Alternatively, endocyclic hydroxylamines can be achieved if the intramolecular
nucleophile is appended to the N-substituent (Scheme 28c). Overall, the method has the
potential to generate diverse sets of tri-substituted hydroxylamines to enrich compound
libraries for medicinal chemistry.

Scheme 28. Some possible future applications for the hydroxylamine-forming method.
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CHAPTER 3. CONFORMATIONAL DYNAMICS OF N-ALKOXYPIPERIDINES AND
PYRROLIDINES
To minimize repulsive interactions between the lone pairs of electrons on nitrogen
and oxygen atoms, hydroxylamines adopt two stable conformers (Figure 22) with lone
pairs of one atom eclipsing bonds of the next atom. The inter-conversion of these
conformers at ambient temperature is a rapid process that is attributable to the low
inversion barrier at the nitrogen and the low rotation barrier around the N-O bond.
Understanding the degree of contributions and the relative energetics of these two
processes in the stereomutation of hydroxylamines has been an area of interest for
chemists. As a result, extensive studies, both computational and spectroscopic, have
been conducted and described in a series of reviews.17,122-124

Figure 22. Stereomutation of acyclic hydroxylamine.
The situation is more complex for cyclic hydroxylamines in which the N-O bond is
a part of the ring system, and understanding the conformational changes of such systems
is rather more complicated due to ring inversion. This complication in stereomutation can
be attributable to the individual processes of nitrogen inversion, N-O bond rotation, and
ring flip or the interplay of a combination of all three processes. Several studies discussing
about this problem have been reported for the endocyclic systems like oxazines in which
the N-O bond is a part of the ring system.17,122-124 However, the studies for the exocyclic
hydroxylamines such as N-alkoxypiperidines are rare. To shed light on conformational
preferences in the N-alkoxypiperidine system, variable temperature NMR (VT-NMR)
studies

of

4-substituted

N-hydroxypiperieines,

N-alkoxypiperidines,

and

N-
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alkoxypyrrolidines (Figure 23) were conducted, and the data were analyzed together with
the literature data of analogous comparators.

Figure 23. N-hydroxypiperidines, N-alkoxypiperidines, and N-alkoxypyrrolidine studied
by variable temperature NMR.

Figure 24. Cyclic hydroxylamines with exocylic N-O bond. a) Six-membered and b) fivemembered.
According to the existing literature on saturated six membered hydroxylamines
with an exocyclic N-O bond, the nitrogen atoms are predominantly pyramidal as revealed
by their X-ray crystal structures,17,122-124 and the rings adopt chair conformations with the
nitrogen substituents in equatorial positions (Figure 24a).45,125-128 The nitrogen atom is
also pyramidal in similarly substituted five-membered nitrogen heterocycles as observed
in their X-ray crystal structures (Figure 24b).129-133 Consistent with the acyclic and
endocyclic hydroxylamines,17,122-124 these exocyclic hydrxoylamines also prefer
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conformations in which the lone pair on nitrogen eclipses with the substituent on oxygen,
whether it is a simple alkyl group,45,125,128,133 a vinyl group,131 a trifluoromethyl group,127
an acyl group,132 or a 1-hydroxyalkyl group.126 Therefore, N-alkoxypiperidines and
pyrrolidines are expected to exist in solution as a mixture of two equivalent conformers,
and nitrogen inversion, ring inversion, and rotation about the N-O bond is involved in the
interconversion of these conformers (Figure 25).

Figure 25. Stereomutation of the N-alkoxypiperidines (n = 2) and pyrrolidines (n = 1).
In 1985, Jenkins et al. conducted VT-NMR studies in a series of 2-alkoxy-1,1,3,3tetramethylisoindolines 95 (Figure 26) and measured the energy barriers to
stereomutation. Based upon the increasing barriers with increasing steric bulk of alkoxy
group and decreasing barriers with increasing solvent polarity, the authors inferred that
the two processes, the nitrogen inversion and the N-O bond rotation, on these molecules
take place at the same time.134 Later in a VT-NMR study of a series of 1-alkoxy-2,2,6,6tetramethylpiperidines 96 (Figure 26), Anderson et al. also observed similar changes in
energy barriers with the steric bulk of the alkoxy groups, although not in a linear fashion. 125
Anderson and coworkers further considered that, as each of the three individual
processes of N-O bond rotation, ring inversion, and nitrogen inversion have substantial
individual barriers, stepwise processes are more likely than composite ones. Finally, they
concluded that the main component of the observed barrier in 96 is the barrier to N-O
bond rotation.125 Although VT-NMR studies were performed in a series of N-hydroxy and
N-acyloxy 2,2,6,6-tetramethylpiperidines with the substituents at 4-position in order to
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determine the energy barriers,135 no such studies are reported for 4-substituted Nalkoxypiperidines.

Figure 26. General structures of literature comparators.
To understand the stereomutation process in 4-substituted N-alkoxypiperidines
and N-hydroxylpiperidines in the absence of extreme steric buttressing like in 95 and 96,
VT-NMR studies were performed in N-hydroxypiperidines 88-90, N-alkoxypiperidines 9193, and N-alkoxypyrrolidine 94. These exocyclic hydroxylamines were previously
synthesized

during

the

methodology

development

program

for

trisubstituted

hydroxylamine (Chapter 2) and are re-numbered in this section for the sake of
convenience.
After comparing the 1H NMR spectra of N-hydroxypiperidines 88-90 at ambient
temperature in CDCl3, the effect of substituent at the 4-position on the conformational and
configurational equilibria of these systems was clearly noted (Figure 27).

The

unsubstituted N-hydroxypiperidine system 88 predominantly adopts a chair-like
conformation with a distinct axial and equatorial protons at the 2- and 6-postions, since
two sets of two non-equivalent hydrogens germinal to the ring nitrogen are observed in
the 1H NMR spectrum. However, the spectrum of 4-chloro-N-hydroxypiperidine 89 reveals
two isomers, 89a and 89b, in a 1:1 ratio. The spectrum of 89a is similar to that of 88 with
the chloride group in an equatorial position of the chair conformation. In contrast, the
spectrum of 89b, has only three signals. One for H4, a second one for all four germinal
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protons at the 2- and 6-positions which are merged into a single resonance, and a third
one for the combined protons at 3- and 5-postions mixed together.
As in 89, the spectrum of 4-methyl-N-hydroxypiperidine 90 also represents two
species 90a and 90b, but in a nearly 8.5:1 ratio. The major isomer 90a adopts a chairlike conformation in which the methyl group is in an equatorial positions. Otherwise, the
spectrum is consistent with the unsubstituted system 88 and the isomer 89a of the 4chloro system. The spectrum of the minor isomer 90b, however, is similar to that of the
isomer 89b of the 4-chloro system as all methylene protons at the 2- and 6-positions are
aggregated as a single resonance as are other protons at the 3- and 5-positions.

Figure 27. Partial 1H-NMR spectra of the N-hydroxypiperidines 88 (a), 89 (b), and 90 (c).
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When the unsubstituted system 88 was heated above 90 oC (coalescence
temperature), the signals for the geminal protons at the 2- and 6-positions merged
together as they became equivalent. This phenomenon clearly signifies that out of three
processes, N-O bond rotation, ring inversion, and nitrogen inversion, at least one of them
is slow at room temperature on the NMR time scale. When the system is substituted at
the 4-position as in 89 and 90, the nitrogen inversion process is slow on the NMR
timescale and two diastereomers, namely cis and trans, are observed. However, the ratio
of these diastereomers depends upon the size of the substituents present. When the
substituent is smaller like a chlorine atom (steric A value = 0.53 – 0.64 kcal.mol-1),136 the
ratio is about 1:1 and when the substituent is larger like a methyl group (steric A value =
1.74 kcal.mol-1),136 the trans isomer is favored. In general, Figure 28 represents the
overall conformational equilibria of a series of N-hydroxypiperidines.

Figure 28. Conformational dynamics of the N-hydroxypiperidines (R = H) and Nalkoxypiperidines (R = alkyl).
Therefore, unsubstituted N-hydroxypiperidine 88, isomer 89a of 4-chloro-Nhydroxypiperidine, and major isomer 90a of 4-methyl-N-hydroxypiperidine adopt
predominantly chair conformations in which both the substituents are in equatorial
positions (Figure 28, trans-manifold). In case of other isomer 89b of 4-chloro-N-
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hydroxypiperidine and minor isomer 90b of 4-methyl-N-hydroxypiperidine, a mixture of
several rapidly interconverting conformers including twist boats (Figure 28, cis-manifold)
is possible, which results in the aggregation of the four protons geminal to nitrogen atom
into a single resonance. Likewise, the four vicinal protons to nitrogen coalesce into a
single peak in the minor cis isomers. A similar conclusion can be drawn from the 1H NMR
spectra of a series of N-alkoxypiperidines 91-93 recorded at room temperature in CDCl3
(Figure 29).

Figure 29. Partial 1H-NMR spectra of the N-alkoxypiperidines 91 (a), 92 (b), and 93 (c),
and the N-alkoxypyrrolidine 94 (d).
After inspection of 1H-NMR spectra of these N-alkoxy systems, three crucial pieces
of information are instantly discerned. First, all alkoxy groups are fully conformationally
equilibrated on the NMR time scale at room temperature, since sharp signals are

66
observed for all the 4-phenylbutyl protons in each molecule. Second, the cis and trans
isomers are still present in the N-alkoxy systems 92 and 93, with broader line shapes for
the piperidine moiety than in the corresponding N-hydroxy systems. Similar broadening
was also observed for the unsubstituted system 91. These broader resonances of the
piperidine moiety imply that the N-alkoxy series is closer to the coalescence temperature
for interconversion between the cis and trans configurations than the N-hydroxy series,
and the nitrogen inversion barrier is lower for the former than for the latter. This result is
in line with the inversion process occurring through a low energy planar transition state
due to relief from steric interactions in the case of N-alkoxy series. Third, the entire set of
NMR signals for the protons in N-alkoxypyrrolidine 94 at room temperature were sharp
suggesting complete conformational equilibration on the NMR time scale. In order to
scrutinize further, VT-NMR studies were conducted in N-hydroxypiperidine 88 and Nalkoxy systems 91-94 in toluene and DMF as NMR solvents, and the energy barriers to
stereomutation were determined. These energy barriers are listed in Table 6 in increasing
order of barrier, together with the barriers for a number of literature comparators.

67
Table 6. Barriers to stereomutation in 91-94, 88, and literature18,137,138 comparators as
determined by VT 1H-NMR.
Entry
1

Hydroxylamine

Inversion barrier (∆GC≠), kcalmol-1

Reference

13.3 (toluene-d8)

-[a]

12.3 (DMF-d7)
2

15.3 (toluene d8)

-[a]

15.4 (DMF-d7)
3

15.9 (toluene d8)

-[a]

15.9 (DMF-d7)
4

-[b]

-[a]

5

16.4 (toluene d8)

-[a]

16.4 (DMF-d7)
6

15.3 (DMF-d7)

18

7

14.6 (DMF-d7)

18

8

14.5 (DMF-d7)

18

9

11.5 (THF-d8)

137

68
10

17.0 (CCl4)

137

11

12.0 (DMF-d7)

138

: this work. [b]: no coalescence below 120 oC.

[a]

The inversion barriers for the series of N-alkoxypiperidines 91-93 and 97-99 (Table
6, entries 2-4 and 6-8) are significantly higher than for the N-alkoxypyrrolidine 94 (Table
6, entry 1). This result is consistent with the fact that i) the six-membered ring inversion
is a more difficult process than the pseudorotation of the five-membered ring, and ii) the
accommodation of an sp2-hybridized atom is much easier for a five-membered than for
six-membered ring. Failure to achieve a coalescence temperature for 4-methyl-Nalkoxypiperidine 93 (Table 6, entry 4) below 120 oC led to a conclusion that the inversion
barrier is significantly higher for the 4-methyl system than for the unsubstituted system
91, 4-chloro system 92, and other literature comparators (Table 6, entries 6-8). Based on
the observations of increasing barrier with increasing steric at 4-postision in the piperidine
system and the lower barrier for the pyrrolidine system over the piperidine system, the
barrier in the piperidine system can be primarily attributed to the ring flip. The
comparatively higher barrier to stereomutation of the literature molecule N-methoxy2,2,6,6-tetramethylpiperidine 101 (Table 6, entry 10) than the barriers of the Nalkoxypiperidines 91 and 92 (Table 6, entries 2 and 3) and the other literature
comparators (Table 6, entries 6-8) indicates that the main component of the barrier has
switched to N-O bond rotation from ring flip due to steric buttressing in 101 as described
by Anderson et al.125 A similar conclusion can be drawn for the inversion barriers in the
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N-hydroxypiperidine series. The barrier to stereomutation of N-alkoxypiperidine 91 (Table
6, entry 3) is slightly smaller than that of the corresponding N-hydroxy system 88 (Table
6, entry 5), implying that the oxygen substituent has minimal effect on stereomutation
process. However, the barrier of N-methoxy-2,2,6,6-tetramethylpiperidine (Table 6, entry
10) is considerably higher than that of its N-hydroxy analog (Table 6, entry 9), which can
be attributed to steric buttressing on N-O bond rotation. The observed lower barrier to
stereomutation in the tetra-alkyl system 100 (Table 6, entry 9) in comparison to its
sterically less hindered N-hydroxy and alkoxy analogs 88 and 91 (Table 6, entries 3 and
5) is, however, not surprising, since a similar pattern is observed in N-alkyl piperidine
systems139-141 and N-diazenyl piperidine systems142,143 (Figure 30). The barrier is lower
for 2,2,6,6-tetramethyl system 104 than for its unsubstituted congener 103. A similar trend
is also observed for 2,2,6,6-tetramethyl system 106 and its unsubstituted analog 105.
These phenomena reflect the situation in cyclohexane and 1,1,3,3-tetramethyl
cyclohexane systems wherein the chair/twist boat energy gap is reduced on tetrasubstituted systems in comparison to unsubstituted systems, as in the former case the
chair conformation is destabilized by the repulsive syn 1,3-diaxial interaction between the
alkyl groups.144

Figure 30. Unsubstituted and 2,2,6,6-tetramethyl substituted systems of N-alkyl
piperidine and N-diazenyl piperidine.
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3.1. Conclusion
In order to explore the remained uncertainty in the N-alkoxypiperidine system,
variable temperature NMR studies of a series of 4-substituted N-hydroxypiperidines, Nalkoxypiperidines, and N-alkoxypyrrolidines were conducted. The observed strong
dependence of VT NMR phenomena on the substituent at the 4-position together with
other evidence from literature comparators led to the conclusion that the rate-determining
step in the stereomutation of such piperidines is the ring flip and not the nitrogen inversion
or the N-O bond rotation. When the system is sterically crowded like in N-alkoxy-2,2,6,6tetramethylpiperidines, the barrier to N-O bond rotation becomes the major component of
the barrier to stereomutation.
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CHAPTER 4. SYNTHESES OF HYDROXYLAMINE AND HYDRAZINE ANALOGS OF
KALKITOXIN
As described in Chapter 1, hydrazines and hydroxylamines have the potential to
enrich compound collections in medicinal chemistry as they can be used to increase the
sp3 fraction of molecule as well as molecular complexity and diversity. As weak bases,
hydroxylamines and hydrazines are little protonated under normal physiological
conditions. Their low inversion barriers allow them to invert rapidly at nitrogen at ambient
temperature, thereby reducing the stereogenic complexity of the molecule. Owing to
these unique properties, hydroxylamine and hydrazine moieties can be considered as the
surrogates of sp3 carbons in the carbon frameworks (Figure 31), offering new
compositions of matter to new libraries representing unexplored areas of chemical space.
Taking advantage of these unique properties of the hydroxylamine and hydrazine
functionalities, a broad program was initiated where hydroxylamine and hydrazine serve
as convertible mimics for stereogenic centers in the carbon framework .

Figure 31. Hydroxylamine and hydrazine as surrogates of sp3 carbons.
To test the concept of hydrazine and hydroxylamine analogs, kalkitoxin, a natural
anticancer compound, was chosen as an initial substrate, because of the combination of
its potent bioactivity and the presence of stereogenic centers that are crucial for activity.
Two hydroxalogs and a hydrazine analog of kalkitoxin were designed, as shown in Figure
32. The hydroxalog 6-oxa-7-azakalkitoxin (108) was designed by substituting an oxygen
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atom for C-6 and replacing the stereocenter C-7 with a nitrogen atom. The second
hydroxalog, 9-oxa-10-azakalkitoxin (109), was designed by replacing C-9 with an oxygen
atom and the stereogenic center C-10 with a nitrogen atom. The hydrazine analog 7,8diazakalkitoxin (110) was designed by substituting the stereogenic centers C-7 and C-8
with two nitrogen atoms. These hydrazine and hydroxylamine analogs are intended to
reduce the synthetic and stereogenic complexity of the target owing to the rapid
inversions at nitrogen centers, and to test their influence on biological activity.

Figure 32. Kalkitoxin and the proposed hydroxylamine and hydrazine analogs.
The program commenced with the synthesis of these analogs. The parent
compound, kalkitoxin, was also synthesized for the comparative study. The syntheses of
kalkitoxin and its analogs and their biological assessments are described in the following
sections.
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4.1. Synthesis of kalkitoxin (107)

Scheme 29. Retrosynthesis of kalkitoxin.
Kalkitoxin was synthesized by partially adapting previous methods as shown in the
retrosynthetic analysis (Scheme 29).95,105 Wipf’s oxazoline-thiazoline ring conversion
sequence104 (Scheme 30), utilized by Gerwick’s synthesis,95 was selected to construct
thiazoline ring. The stretched-peptide chain 111 was, however, was prepared from alkyl
bromide 113 by following the reaction conditions from White’s kalkitoxin synthesis, 105
relying on their short and efficient pathway to assemble the 1,2,4-anti,anti-methyl
sequence. γ-Butyrolactone (114) was chosen as a starting substrate to synthesize alkyl
bromide 113.

Scheme 30. Wipf’s oxazoline-thiazoline conversion strategy.
The synthesis of kalkitoxin (107) commenced with hydrolysis of γ-butyrolactone
(114), followed by benzylation of the resulting alcohol (Scheme 31).145 Acylation of
Lithiated (R)-4-benzyl-2-oxazolidinone (120) with acid 119 delivered N-acyloxazolidinone
121. Enolization of N-acyloxazolidinone, followed by alkylation with methyl iodide, gave
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122 stereoselectively. Lithium borohydride-mediated reduction afforded next alcohol 123,
which was transformed to bromide 113 upon subjection to Appel’s reaction conditions.

Scheme 31. Synthesis of alkyl bromide 113.
Alkyl bromide 113 was then used to synthesize the stretch-peptide 111 by White’s
procedure (Schemes 32 and 33). After transformation of alkyl bromide 113 to an
organocopper species 124, it was treated with (S)-N-(trans-crotonyl)-4-phenyloxazolidin2-one (125). The so-obtained product (126) with the 1,3-anti dimethyl configuration (79%
yield) was enolized and further alkylated to deliver 127 (with the desired 1,2,4-anti,anti
configuration) and 128 (with 1,2,4-syn,anti configuration) in 62% and 20% yields,
respectively. The stereochemistry of compounds 126, 127, and 128 were confirmed by
comparing their NMR spectra and specific rotation data with the literature data of these
compounds synthesized from similar reaction conditions.99
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Scheme 32. Construction of the 1,2,4-anti,anti methyl sequence.
After hydrogenation of the major diastereomer 127, Swern oxidation of the
resulting alcohol 129 generated corresponding aldehyde 130 (Scheme 33). This
aldehyde was then extended to amide 133 by reductive amination followed by coupling
with (R)-methylbutyric acid (132). The chiral auxiliary was removed by lithium
borohydride-mediated reduction to obtain alcohol (134). Subjection of this alcohol to
Swern oxidation, followed by homologation by a Wittig reaction, gave a mixture of alkenes
(E/Z) 135. The mixture 135 was converted to acid 111 by hydrolyzing to the aldehyde,
followed by Pinnick oxidation.
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Scheme 33. Synthesis of acid 111.
Further development of acid 111 to kalkitoxin was achieved by Gerwick’s protocol
(Scheme 34).95 Acid 111 was coupled with amine 112 to access amido alcohol 136, the
precursor for Wipf’s oxazoline-thiazoline reaction sequence.

A DAST-mediated

cyclization of 136 to 2-oxazoline derivative 137 and subsequent treatment with hydrogen
sulfide resulted in thioamide 138. DAST was again used for the second cyclization to
deliver the targeted kalkitoxin (107) as a colorless oil. As expected, a mixture of rotamers
was observed in its NMR spectra due to amide functionality.
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Scheme 34. Synthesis of kalkitoxin from acid 111.
In summary, kalkitoxin, a stretch-peptide, was synthesized in 21 linear steps from
γ-butyrolactone to provide 94 mg of the natural product. The unique 1,2,4-anti,anti
configuration in the alkyl chain was obtained by the protocol used in White’s kalkitoxin
synthesis. However, the thiazoline ring was constructed efficiently adapting the procedure
from the Gerwick’s kalkitoxin synthesis. The so-obtained kalkitoxin (107) and its oxazoline
congener (137) were then submitted for biological assessment in the Valeriote lab at the
Henry Ford Hospital in Detroit.
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4.2. Synthesis of 6-oxa-7-azakalkitoxin (108)

Figure 33. Structure of kalkitoxin and its proposed hydroxalog 6-oxa-7-azakalkitoxin.
The intended modification of kalkitoxin 107 to hydroxalog 108 introduces a novel
and unexplored functional moiety, the 2-aminoxy thiazoline, in the molecule. Hence,
before undertaking the total synthesis of 108, it was necessary to find a route to introduce
such moiety with the aid of a simple model. Therefore, the model compound 141 was
targeted for synthesis (Scheme 35). Treatment of ethyl (R)-2-oxothiazolidine-4carboxylate (139),146 an L-cysteine-derived thiazolidinone, with triflic anhydride in the
presence of Hunig’s base afforded triflate 140. Owing to its unstable nature, triflate 140
was subsequently treated with the sodium alkoxide of N,N-dibenzylhydroxylamine without
purification. The targeted compound 141 was observed in the crude reaction mixture by
mass spectrometry but decomposed during the workup, leading to the conclusion that the
targeted functionality is unstable and difficult to handle. Based on the observed instability
of the model compound 141, the plan to synthesize 108 was halted.

Scheme 35. Synthesis of a model 2-aminoxy thiazoline.
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4.3. Synthesis of 9-oxa-10-azakalkitoxin (109)

Figure 34. Structure of kalkitoxin and its hydroxalog 9-oxa-10-azakalkitoxin.
The retrosynthetic analysis for hydroxalog 109 was performed relying partially on
Gerwick’s kalkitoxin synthesis95 (Scheme 36). The synthesis of the target was proposed
from three fragments, 112, 142, and 132. As in Gerwick’s kalkitoxin synthesis,95 thiazoline
ring was envisaged by adaptation of Wipf’s oxazoline-thiazoline conversion strategy104
(Scheme 30). Fragment 112 is a known compound, which was derived from L-serine in
literature,147 whereas fragment 132 is a commercial species. Fragment 142, with a 1,2trans dimethyl moiety, was proposed to access from acid 143 and hydroxylamine 144
using an indirect alkylation approach of N,N-dialkylhydroxylamine (Chapter 2), developed
previously for tri-substituted hydroxylamines (Scheme 37). The pre-existing methyl
substituent in the substrate was predicted to direct the reaction to achieve the required
diastereoselectivity. Acid 143 is an accessible species from a stereoselective reaction
involving a chiral auxiliary system, and sym-dimethylethylenediamine 145 was intended
to serve as a precursor to N,N-disubstituted hydroxylamine 144.
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Scheme 36. Retrosynthetic analysis of 9-oxa-10-azakalkitoxin.

Scheme 37. Indirect alkylation of N,N-disubstituted hydroxylamine.
Before approaching the synthesis of hydroxalog 109, suitable protecting groups
for one of the secondary amines in sym-dimethylethylenediamine 145 and for the alcohol
in fragment 143 were required, and their compatibility under the standard reaction
conditions for tri-substituted hydroxylamine synthesis was examined. For the secondary
amine, the triazene moiety was considered as a possible protecting group whereas a tertbutyldimethylsilyl ether was chosen for the alcohol protection. First, the compatibility was
tested for triazene protecting group by targeting tri-substituted hydroxylamine 149 as a
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model

(Scheme

38). To begin

the

synthesis, one

amino

group

of

sym-

dimethylethylenediamine 145 was protected as a triazene, after which the other was
oxidized with benzoyl peroxide to deliver 146. Upon reduction with DIBAL, compound 146
was converted to a N,N-diakylhydroxylamine, which was further acylated in situ to give
N-acyloxyamine 147. Adapting the protocol for the tri-substituted hydroxylamine
synthesis, 147 was then reduced with DIBAL at -78 oC, and the resulting tetrahedral
intermediate was trapped with acetic anhydride as O-(α-acyloxyalkyl)hydroxylamine 148
in good yield. However, the Lewis acid-mediated conversion of 148 to the tri-substituted
hydroxylamine 149 was unsuccessful in the presence of dimethylzinc, as deprotection of
the triazene functionality was observed after addition of BF3.OEt2, suggesting that the
triazene protecting group is incompatible with the reaction conditions for the tri-substituted
hydroxylamine synthesis.

Scheme 38. Compatibility test for triazene group.
Next, the carboxybenzyl (Cbz) protecting group was chosen for the secondary
amine functionality (Scheme 39), considering its tolerance to a wide range of reaction
conditions. Intermediate 150 was prepared from sym-dimethylethylenediamine, wherein
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one amino group was protected as the benzyl carbamate and the other was
benzoyloxylated. Debenzoylation of 150 with DIBAL, however, afforded N,N-dialkyl
hydroxylamine 151 in only 52% yield, as partial deprotection of the carbamate group was
observed. Alternatively, debenzoylation was best achieved by a transesterification
reaction in an excellent yield.

Scheme 39. Compatibility test for carbamate and silyl ether.
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Following a known protocol,148 acid 153 was prepared from the hydrolysis of
compound 152.148 After purification, the acid 153 was isolated as a colorless oil with [α]20D
–13.21 (c 8.25, EtOH). However, the specific rotation of the acid 153 was recorded with
opposite sign in literature [lit148 [α]20D +13.51 (c 1.8, EtOH)]. The so-obtained acid 153
was then used for the acylation of di-substituted hydroxylamine 151 in the presence of
EDCI and hydroxylbenzotriazole (HOBt). The resulting N-acyloxyamine 154 was reduced
with DIBAL at -78 oC followed by treatment with acetic anhydride, DMAP, and pyridine
and warmed to 0 oC in order to provide O-(α-acyloxyalkyl)hydroxylamine 155. When 155
was subjected to Lewis acid-mediated deacetoxylation followed by the reaction with
dimethylzinc, two products, 156 and 157, were isolated in 27% and 50% yields,
respectively. From the NMR spectra, 156 was analyzed as a mixture of two diastereomers
of the desired product in a ratio of 5:3, and 157 was characterized as a mixture of two
anomers of a cyclic derivative in a 4:1 ratio. The individual isomers in both of the mixtures
were not characterized due to the presence of rotamers in the NMR spectra. The aminoxy
sugar derivatives in 157 are the cyclized products resulting from nucleophilic attack of the
silyl ether oxygen on the two faces of aminoxocarbenium ion intermediate. After observing
the cyclized products as the major outcome, the need for an alternative alcohol protecting
group was recognized. However, the carbamate protection for the secondary amine was
compatible with the reaction conditions.
To overcome the problem of cyclization, acid 153 was replaced with acid 160,149
which carries an olefinic bond, instead of the silyl ether, and which can be converted to
the desired alcohol functionality whenever needed (Scheme 40). Acid 160 was prepared
by stereoselective alkylation of enolate of (S)-4-benzyl-3-propionyloxazolidin-2-one
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(158)150 with cinnamyl bromide, followed by lithium peroxide-mediated hydrolysis. The soobtained acid 160 was then used for acylation of N,N-dialkylhydroxylamine 151 to isolate
N-acyloxyamine 161. Upon reduction with DIBAL at a low temperature, followed by the
treatment with acetic anhydride, pyridine, and DMAP, 161 was transformed to O-(αacyloxyalkyl) hydroxylamine 162. The subsequent subjection of 162 to a Lewis acid
promoted deacetoxylation, followed by the treatment with dimethylzinc, gave only the
desired product 163 in 62% yield as a 4:3 diastereomeric ratio, proving the compatibility
of the olefinic double bond to the reaction conditions. However, the poor selectivity,
coupled with difficulties in separation and characterization for each diastereomer,
necessitated an alternative route for the hydroxalog 109.

Scheme 40. Synthesis of tri-substituted hydroxylamine 163.
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In a view of the difficulty in installing the hydroxylamine moiety stereoselectively,
an alternative retrosynthesis (Scheme 41) was proposed for hydroxalog 109. The
strategy for the thiazoline ring construction remained the same as depicted in the previous
synthetic plan. Nevertheless, disconnection of acid 164 was proposed such that it could
be obtained from N,O-disubstituted hydroxylamine 165 and aldehyde 166, exploiting a
classical reductive amination-like reaction. The enantiomerically pure acid 132 was
chosen as a precursor to aldehyde 166. The synthesis of hydroxylamine 165 was planned
to begin from a literature compound 167,151 wherein the two methyl groups in 1,2-antifashion will be incorporated directly from 167, and the hydroxylamine moiety will be
introduced by amination of terminal benzylated hydroxyl group after hydrogenolysis.

Scheme 41. An alternative retrosynthesis for hydroxalog 109.
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To start the synthesis, literature compound 167 was synthesized on a gram scale
in 8 steps following the literature protocol151 from (+)-L-arabinose in 33% overall yield
(Scheme 42). Conversion of 167 to imidazolyl thioether 169 was achieved in excellent
yield by stirring with thiocarbonyldiimidazole (TCDI) at 50 oC. Upon subjection to Barton’s
radical deoxygenation, followed by hydrogenolysis, thioether 169 was converted to
alcohol 170.

Scheme 42. Synthesis of alcohol 170.
In order to introduce the hydroxylamine moiety to alcohol 170, direct amination of
the hydroxyl functionality was conceived. However, methods for hydroxylamine synthesis
via the construction of the N-O bond are extremely rare in the current toolbox due to
several unsolved challenges as described in Chapter 1. Although not common, the Boger
lab was successful in forming an N-O bond during the syntheses of the prodrugs of
duocarmycin via amination of aryl alcohol with carbamate tosylates and Nhydroxyphthalimide as aminating agents (Scheme 43).152
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Scheme 43. Examples of amination of aryl alcohols from the Boger lab.
Before attempting amination on 170, the feasibility of the reaction was studied on
1-phenyl-2-propanol as a model (Scheme 44). A series of aminating reagents, NH2Cl,
H2N-OTs, CbzHN-OTs, and PhthN-OTs, were synthesized153-155 and were tested for the
substitution reactions with 1-phenyl-2-propanol in basic media. Unfortunately, all attempts
at amination of this alcohol were unsuccessful.

Scheme 44. Test reactions for the amination of alcohol.
As the direct N-O bond formation was unsuccessful in a model substrate, the
hydroxylamine functionality was installed by utilizing the Mitsunobu reaction, a classical
approach for hydroxylamine synthesis (Scheme 45). First, the configuration of the alcohol
was inverted by a Mitsunobu reaction with nitrobenzoic acid, followed by
transesterification to access alcohol 172. A second Mitsunobu reaction with Nhydroxyphthalimide resulted in hydroxylamine 173 with overall retention of the
configuration.
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Scheme 45. Installation of the N-O bond by Mitsunobu reaction.
Before moving forward with the hydroxylamine intermediate 173, aldehyde 166
was synthesized from acid 132 in two steps (Scheme 46). Acid 132 was first coupled with
N-allylmethylamine in the presence of HOBt and EDCI and the resulting amide 174 was
then subjected to reductive ozonolysis to access crude aldehyde 166.

Scheme 46. Synthesis of aldehyde 166.
After the synthesis of aldehyde 166, the hydroxylamine intermediate 173 was
extended to hydroxalog 109 (Scheme 47). Deprotection of the hydrazine functionality in
173 with hydrazine hydrate, followed by the treatment with paraformaldehyde, delivered
oxime 175 in an excellent overall yield over 2 steps. Further reduction of this oxime was
carried out by using sodium cyanoborohydride as a reductant in an acidic medium, and
the resulting N,O-disubstituted hydroxylamine intermediate was subjected to reductive
amination conditions with crude aldehyde 166 in order to generate tri-substituted
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hydroxylamine 176. Compound 176 was then converted to acid 164 via a three-step
reaction sequence of tetrabutylammonium fluoride (TBAF)-mediated deprotection of 1,2diol, oxidative cleavage to aldehyde, and Pinnick oxidation. Transformation of the soobtained acid 164 to amide 177 was accomplished by amidation with amino alcohol 112
with the aid of EDCI and DMAP. The conversion of amide 177 to 2-oxazoline 178 was
best achieved by diethylaminosulfur trifluoride (DAST)-mediated cyclization at -78 oC.
Finally, Wipf’s oxazoline-thiazoline conversion sequence was utilized to convert oxazoline
derivate 178 to hydroxalog 109, wherein the oxazoline ring was first opened to the
thioamide by stirring with hydrogen sulfide-saturated methanolic triethylamine and then
cyclized to the thiazoline ring in the presence of DAST at -78 oC. The hydroxalog 109
was isolated as a colorless oil and as a single stereoisomer. Like in kalkitoxin, a mixture
of rotamers is observed in the NMR spectra of 109 due to amide functionality.
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Scheme 47. Synthesis of the hydroxalog 109 from the hydroxylamine intermediate 173.
In summary, a total synthesis of the novel hydroxalog 109 of natural kalkitoxin was
accomplished in 25 linear steps, starting from a commercially available (+)-L-arabinose in
3% overall yield. The hydroxylamine moiety in the molecule was installed by utilizing the
Mitsunobu reaction, and reductive amination was applied to generate the tri-substituted
hydroxylamine intermediate 176 from its N,O-disubstituted precursor. The thiazoline ring
in the molecule was constructed by adapting Wipf’s oxazoline-thiazoline conversion
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strategy from oxazoline derivative 178, which itself was synthesized via DAST-mediated
cyclization of amido alcohol intermediate 177.
4.4. Synthesis of 7,8-diazakalkitoxin (110)

Figure 35. Structure of kalkitoxin and its hydrazine analog.
The retrosynthetic analysis for the hydrazine analog 110 is presented in Scheme
48. The synthesis of analog 110 was proposed from fragments 180, 181, and 132. A
Lewis acid-mediated cyclization was chosen to construct the thiazoline ring, by adapting
protocol from White’s kalkitoxin synthesis.105 Compound 180, with a suitable protecting
group for the thiol functionality, was designed to synthesized from L-cysteine. Reductive
amination was planned to deliver tetra-substituted hydrazine core 181 from tri-substituted
hydrazine 183 and known aldehyde 184,156 whereas 183 itself was proposed to generate
from sym-dimethylhydrazine 185, and cinnamyl bromide 186 was chosen as an initial
precursor to aldehyde 184.
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Scheme 48. Retrosynthetic analysis of 7,8-diazakalkitoxin (110).
The synthesis of hydrazine analog 110 commenced with the synthesis of
enantiomeric aldehyde 184156 as described in Scheme 49. Alcohol 187157 was obtained
from reduction of 159, a cinnamyl bromide-derived oxazoline derivative (Scheme 40),
with LiBH4 as a reductant. Dess-Martin periodinane (DMP)-mediated oxidation of the
resulting alcohol 187 gave the desired aldehyde 184.

Scheme 49. Synthesis of an aldehyde 184.
The tri-substituted hydrazine 183, a product resulting from the controlled monoalkylation of sym-dimethylhydrazine 185 with benzyl bromoacetate,158 was subjected to
NaCNBH3-assisted reductive amination with aldehyde 184 to obtain 188 (Scheme 50).
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Upjohn dihydroxylation159 of the resulting tetra-substituted hydrazine backbone 188,
followed by the NaIO4-mediated oxidative cleavage, gave aldehyde 189 in 52% overall
yield over two steps. Conversion of this aldehyde 189 to amine 190 was best achieved
via a reductive amination reaction. After acylation of the secondary amine 190 with
commercial acid 132 in the presence of HOBt and EDCI, amide 191 was furnished in 67%
yield.

Scheme 50. Synthesis of tetra-substituted hydrazine core 191.
Before advancing to the next stage, synthesis of vicinal amino thiol 180 (Scheme
48) with a suitable protecting group on the thiol functionality was necessary. Earlier, White
and co-workers synthesized the benzyl thioether derivative of amino thiol 180 for the
synthesis of kalkitoxin.105 However, application of the harsh reaction conditions for the
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benzyl thioether deprotection were predicted to be impractical in the presence of the
hydrazine moiety. Therefore, a protecting group with a comparatively milder deprotection
conditions was required. The replacement of the benzyl thioether with the
trimethoxybenzyl (Tmob) thioether protecting group was considered, as milder reaction
conditions (e.g., stirring with a mixture of trifluoroacetic acid and triethylsilane) can be
applied for deprotection of such functionality.160 Therefore, amino trimethoxybenzyl
thioether 196 was synthesized (Scheme 51) starting from

L-cysteine

by slight

modifications of the protocol of benzyl analog synthesis reported by White and coworkers.105

Scheme 51. Synthesis of amino trimethoxybenzyl thioether 196.
The thiol group of L-cysteine was masked as the trimethoxybenzyl thioether and
was isolated as its trifluoroacetate salt 192.160 The amino group was protected as the tertbutylcarbamate, and the acid functionality was converted to a Weinreb amide. The
resulting amide 193 was reduced to aldehyde 194, which was then homologated to alkene
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195 via a Wittig reaction. Subsequent deprotection of the amine functionality with
trifluoroacetic acid offered amine 196.
After unmasking the acid functionality of amide 191 by hydrogenolysis (Scheme
52), it was coupled with amine 196 in the presence of hexafluorophosphate
azabenzotriazole tetramethyl uranium (HATU) to afford intermediate 197. Unmasking of
the thiol functionality was best achieved by stirring with trifluoroacetic acid in the presence
of triethylsilane as a cation scavenger. The resulting amido thiol 198 was exposed to
titanium tetrachloride to induce cyclization to obtain targeted analog 110, by adapting the
protocol from White’s kalkitoxin synthesis.105 Unfortunately, no cyclization was detected
and only precipitation was observed in the reaction mixture, leading to the conclusion that
the hydrazine moiety of the precursor complexed with the titanium salts. Several other
reaction conditions (e.g., using TMSOTf as Lewis acid or adding Tf2O in basic condition)
were tested, however, no thiazoline ring formation was observed under these conditions.

Scheme 52. An unsuccessful attempt at the hydrazine analog synthesis.
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The failure of the Lewis acid-mediated cyclization to thiazoline ring necessitated
an alternative route. Wipf's oxazoline-thiazoline conversion reaction sequence,104 which
was previously applied in the synthesis of the hydroxalog and a kalkitoxin itself, was
chosen as a promising path to deliver the target. However, before using this approach in
the target molecule, it was considered prudent to test it in a model substrate with similar
functionalities. Therefore, compound 201 (Scheme 53) was synthesized as a model from
the tri-substituted hydrazine 78 (Chapter 2, Scheme 25) in a three-step reaction
sequence; i) substitution reaction of 78 with benzyl bromoacetate to provide tetrasubstituted hydrazine 199, ii) saponification of ester 199 to afford acid 200, and iii)
amidation of acid 200 to obtain amino alcohol 201.

Scheme 53. Synthesis of a model thiazoline derivative.
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With substrate 201 in hand, Wipf’s oxazoline-thiazoline conversion reaction
sequence was tested. On treatment of amide 201 with DAST at -78 oC, cyclization was
completed within 5 minutes, but, the cyclized product 202 was isolated in only 32% yield,
together with the recovery of 40% of starting material 201 after purification. After careful
observation, derivative 202 was found to be unstable due to facile reversion to its
precursor alcohol 201. When product 202 was stirred with hydrogen sulfide saturated
methanolic triethylamine without purification, thioamide 203 was isolated in 66% overall
yield in two steps, together with traces of alcohol 201. Upon subsequent DAST-mediated
cyclization reaction, thiazoline derivative 204 was isolated in 77% yield. The thiazoline
moiety in 204 was found to be more stable than that of the oxazoline moiety in 202, since
ring-opening was not observed during the synthesis. The observed facile ring opening
process of the oxazoline derivative can be viewed as the manifestation of the electron
withdrawing effect of the hydrazine moiety, which is responsible for high electrophilicity
of the sp2 carbon of oxazoline ring. The stability of the thiazoline derivative compared to
the oxazoline derivative is attributable to the difference in electronegativity of sulfur and
oxygen atom in the ring.
After a successful cyclization sequence on the model substrate, the reaction
conditions were employed for the synthesis of hydrazine analog 110 (Scheme 54). Amido
alcohol 206 was obtained in 70% yield from the intermediate 191 by hydrogenolysis,
followed by coupling the intermediate acid with amine 112. In DAST-mediated cyclization,
oxazoline derivative 207 was isolated in 30% yield, together with the recovery of 35%
yield of starting material 206, since the ring opening phenomenon similar to 202 was
observed. Direct conversion to thioamide 208 without purification of 207 was achieved in
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52% isolated overall yield over 2 steps. Eventually, the targeted hydrazine analog 110
was isolated in 89% yield from the thioamide 208 upon treatment with DAST. Here the
thiazoline derivative 110 was also more stable than of its oxazoline counterpart 207. The
hydrazine analog 110 was isolated as a colorless oil and as a single stereoisomer. Like
in kalkitoxin, a mixture of rotamers was observed in the NMR spectra of 110 due to the
amide functionality.

Scheme 54. Synthesis of hydrazine analog 110 of kalkitoxin.
To summarize, the hydrazine analog 110 was synthesized in 11 linear steps
starting from commercially available sym-dimethylhydrazine in 4% overall yield. As
expected, the modification of natural kalkitoxin to the hydrazine analog considerably
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simplified the synthesis by reducing the number of steps from 21 to 11. A classical S N2
substitution reaction was utilized to convert a di-substituted hydrazine to a tri-substituted
hydrazine (185 to 183), and reductive amination delivered a tetra-substituted hydrazine
backbone 188. Wipf’s oxazoline-thiazoline ring conversion strategy was used to construct
thiazoline ring. The oxazoline ring was found to be labile to ring opening due to the
perceived electron withdrawing effect of the hydrazine moiety, whereas, the thiazoline
ring was found to be relatively stable.
4.5. Biological assessments
After completing the syntheses of kalkitoxin (107) and its hydroxylamine and
hydrazine analogs (109 and 110), they were submitted for cytotoxicity assays against
various cell lines in the Valeriote laboratory at Henry Ford Hospital in Detroit. The
oxazoline analogs (137, 178, 207) were also submitted to study the importance of the
thiazoline ring on the biological activity. All compounds were subjected to in vitro disk
diffusion assay to quantify differential cell killing against the eleven human cell lines; one
leukemia (CCRF-CEM), one normal (CFU-GM), and nine solid tumors. The human solid
tumor cell lines were Lung (H125), Ovarian-(OVCAR-5), pancreatic (PANC-1), Liver
(HepG2), Brain (U251N), prostate (LNCaP), colon (H-116), and breast (MCF-7 and MDA).
The in vitro disk diffusion assay was designed to identify the solid tumor selective
compounds by collaborative effort of the Valeriote laboratory at Henry Ford Hospital in
Detroit and the Crews laboratory at the University of California in Santa Cruz.161 Human
lymphocytic leukemia cells, CCRF-CEM, were used as a reference tumor for the assay.
The second reference cell line chosen was a normal cell (CFU-GM). However, before
running assays on expensive human cell lines, the selectivities of the compounds against
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murine colon cancer cell (Colon38) in relation to murine leukemia (L1210) and murine
normal cell (CFU-GM) were conducted. These murine cell lines were selected as they
closely resemble human cell lines. There are four positive results from these assays; i) a
compound is selective to the murine solid tumor over leukemia, ii) a compound is selective
to the murine solid tumor over normal cells, iii) a compound is selective to the human solid
tumor over leukemia, and iv) a compound is selective to the human solid tumor over
normal cells. This unique and effective zone assay guides the discovery of novel
molecular structures with solid tumor selective anticancer properties.
In in vitro disk diffusion assay, samples were solubilized in 0.5 mL DMSO; 15 L of
each sample was applied to a 6.5 mm filter disk, which was allowed to dry overnight and
then placed close to the edge of the petri dish. Depending upon the cell type, the plates
were incubated for 7-10 days and the zones of inhibition were examined by measuring
from the edge of the filter disk to the beginning of normal-sized colony formation. The
diameter of the filter disk was arbitrarily taken as 200 units. A sample is selective if the
zone difference between solid tumor cells and either normal or leukemia cell is greater
than 250 units and is expressed as, for example,

H-125CEM

= 400, which indicates that

there is a 400 unit zone differential between human colon H-125 and leukemia CCRFCEM. If the compound is excessively toxic at the first dosage, the sample solution was
diluted (at 1:4 decrements) and retested against the same tumors. At some dilution,
quantifiable cytotoxicity was invariably obtained.
As the assay is under progress in the Valeriote lab, complete data are not available
currently. Table 7 presents the available data from in vitro disk diffusion assay. Since the
zone inhibition data for kalkitoxin 107 and its analogs 137, 109, and 178 against reference
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cells (normal cells and leukemia) are not available currently, the quantifications of
selectivity of these compounds are not possible. However, kalkitoxin was found to be
highly cytotoxic against most of the cancer cell lines as expected. The toxicity of the
kalkitoxin decreased slightly when the thiazoline ring was changed to oxazoline.
Interestingly, the 9-oxa-10-azakalkitoxin (109) was found equally cytotoxic as parent
kalkitoxin. The potency of its oxazoline analog (178) was reduced against most of the cell
line except against hepato carcinoma cell (HepG2).
In contrast, cytotoxicity of hydrazine analogs 110 and 207 were found to be
comparatively poor against all cancer cell lines except murine colon tumor cell line (colon
38), against which the potencies were average. The observed weak cytotoxicity of these
analogs could be attributable to their less stable thiazoline or oxazoline rings. As the zone
inhibition data for hydrazine analogs 110 and 207 against reference cells except human
normal cells are available, quantifications of their selectivity are possible. Both the
hydrazine analogs 110 and 207 show differential cytotoxicity for murine colon 38 versus
normal cell (38CFU = 550 for 110 and 350 for 207). In addition to murine colon 38,
hydrazine analog 110 also shows differential cytotoxicity for murine colon 38 versus
leukemia (38L1210 = 450) and for human brain tumor cell (U251N) versus leukemia
(U251NCEM = 300).
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Table 7. In vitro disk diffusion assay report for kalkitoxin and its analogs.

HepG2

550

800

500

850

600

>1000

1/16

800

700

300

750

650

>1000

1/64

550

500

600

900

mg/ml

107

6

800

>1000

1/4

500

450

1/16

250

300

6

>1000

>1000

1/4

800

900

1/16

650

600

600

1000

mg/ml
137

600
50

800

550

600

500

>1000

mg/ml

109

1/64

178

900
50

300

6

800

750

250

400

750

1000

>1000

1000

800

>1000

1000

900

500

950

800

700

300

750

650

800

800

1000

500

200

600

mg/ml
1/4

110

10

350

800

250

200

200

100

250

100

500

400

100

300

200

400

600

250

100

100

50

200

50

100

250

0

100

200

mg/ml

207

6
mg/ml

CFU-GM

PANC-1

1/4

MDA

>1000

U251N

LNCaP

600

OVC-5

MCF-7

950

H-125

600

H-116

1000

L1210

700

10

CEM

Human

CFU-GM

Colon 38

Dilution

Compound

Murine
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IC50 values were determined for kalkitoxin 107, hydroxylamine analog 109, and
oxazoline analogs 137 and 178 against liver cancer cell line (HepG2) and the results are
presented in Table 8. Comparison of data indicates that 9-oxa-10-azakalkitoxin 109 and
kalkitoxin are equally potent, which proves the concept of hydroxylamines as convertible
mimics of stereogenic centers. Analog 137 is 50 fold less potent than kalkitoxin and
analog 178 is 500 fold less potent than 9-oxa-10-azakalkitoxin 109. These data together
with the zone inhibition data demonstrate that the thiazoline moiety of the kalkitoxin and
9-oxa-10-azakalkitoxin are needed for the potency of the compounds.
Table 8. IC50 values for kalkitoxin and its analogs against human liver cancer cell line
(HepG2).
Compound

HepG2 (IC50, ng.mL-1)

107

3.2

137

1.6 x 102

109

2.4

178

1.5 x 103

4.6. Conclusion
Kalkitoxin was chosen as a candidate to test the idea of hydroxylamine and
hydrazine analogs. Analogs 108 and 109 were designed as hydroxylamine analogs and
analog 110 was designed as a hydrazine analog. As a model 2-aminoxy thiazoline with
similar functionality like in hydroxalog 108 was found unstable, further work on this analog
was discontinued. Hydroxalog 109 was synthesized from (+)-L-arabinose, in which the
hydroxylamine moiety was introduced by Mitsunobu reaction, and tri-substituted
hydroxylamine intermediate was achieved by utilizing a classical reductive amination
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condition in di-substituted hydroxylamine. Hydrazine analog 110 was synthesized from
sym-dimethylhydrazine, and here too reductive amination condition was best applied to
construct tetra-substituted backbone. Wipf’s oxazoline-thiazoline interconversion strategy
was found to be efficient for the thiazoline ring formation for both the analogs, 109 and
110. For the comparative study of the biological activities, kalkitoxin was synthesized by
partially following previously reported syntheses. The stretched-peptide chain of
kalkitoxin was best achieved by following White’s synthesis whereas, the thiazoline ring
was constructed adapting Gerwick’s synthesis.
Currently, anti-cancer assays of kalkitoxin and its analogs including oxazoline
derivatives are under progress in the Valeriote laboratory at Henry Ford Hospital in
Detroit. The hydroxalog 9-oxa-10-azakalkitoxin (IC50 = 2.4 nm) was found to be as active
as kalktoxin (IC50 = 3.2 nm) against the liver cancer cell line, providing the evidence for
the hydroxylamine analog concept. However, when the thiazoline ring of both kalkitoxin
and hydroxalog were replaced with the oxazoline ring, a remarkable decrease in activity
was observed, revealing the importance of the thiazoline ring for the activity.
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CHAPTER 5. CONCLUSION
An efficient method for the synthesis of tri-substituted hydroxylamines was
developed, adapting Rychnovsky’s reductive etherification protocol. In this method N,Ndialkylhydroxylamines were first acylated to O-acylhydroxylamines, which were then
reduced with DIBAL and the intermediate hemiacetals were trapped in situ with acetic
anhydride as O-(α-acyloxyalkyl)hydroxylamines. In a subsequent Lewis acid-mediated
deacetoxylation reaction, the O-(α-acyloxyalkyl)hydroxylamine was converted to several
novel tri-substituted hydroxylamines by conducting the reaction in the presence of
triethylsilane as a nucleophile. Various highly substituted tri-substituted hydroxylamine
derivatives, with branching to the oxygen substituent, were also isolated when the
triethylsilane was replaced with carbon nucleophiles.
In order to understand the relative energetics and contributions of N-inversion, NO bond rotation, and ring inversion on the stereomutation process, variable temperature
(VT) NMR studies were conducted on several 4-substituted N-hydroxypiperidines, Nalkoxypiperidines, and N-alkoxypyrrolidines. As the VT-NMR phenomena were found to
be strongly dependent on the substituents at the 4-position, the ring flip process was
concluded to be the rate determining step in the stereomutation process of such Nalkoxypiperidine systems.
Kalkitoxin, an anti-cancer agent, was chosen to test the concept of hydrazine and
hydroxylamine analogs. Hydroxylamine analog 9-oxa-10-azakalkitoxin and hydrazine
analog 7,8-diazakalkitoxin were designed by replacing one stereogenic center (C10) and
two stereogenic centers (C7 and C8) of kalkitoxin, respectively with nitrogen. Syntheses
of kalkitoxin and both analogs were executed successfully on a scale of several
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milligrams. Currently, the anti-cancer assays of all these compounds are under progress
in the Valeriote laboratory at the Henry Ford Hospital in Detroit. From the available IC50
values against hepato-carcinoma cells (HepG2), hydroxalog 9-oxa-10-azakalkitoxin
retains bioactivity comparable to kalkitoxin, supporting the concept of hydroxylamines as
surrogates of sp3 carbon centers.
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CHAPTER 6. EXPERIMENTAL SECTION
All reactions were conducted in oven dried glasswares under an argon
atmosphere. All commercial solvents and reagents were used as purchased without
further purification unless otherwise specified. All purifications were performed in flash
column chromatography on silica gel (230-400 mesh) or neutral alumina (32-63 μm) as
stationary phase unless otherwise noted. Reactions were analyzed by thin layer
chromatography technique using pre-coated glass backed plates (w/UV 254), whcih were
visualized by UV irradiation (254 nm) or by charring in cerium-ammonium-molybdate
(CAM) or ninhydrin solution. 400 MHz, 500 MHz, or 600 MHz instruments were used to
record 1H and

13C

NMR spectra of all compounds. High-resolution mass spectra were

recorded under electrospray conditions with a time of flight (TOF) mass analyzer. Melting
points of compounds were determined by using electrothermal melting point apparatus
whenever needed.
Experimental section for chapter 2
General procedure (A) for O-benzoyl hydroxylamines synthesis.
O-Benzoyl hydroxylamines were synthesized by adapting Ganem protocol.112 To
a stirred suspension of K2HPO4 (1.5 mmol), benzoyl peroxide (50% w/w blended with
dicyclohexyl phthalate, 1.1 mmol), and dry DMF (2.5 mL) was added secondary amine (1
mmol) at room temperature. The stirring was continued until the completion of the
reaction, and water (10 mL) was added followed by stirring vigorously for 1 h. The reaction
mixture was extracted with EtOAc, and the resulting EtOAc extract was washed with
saturated aq. NaHCO3, water, and brine followed by drying over anhydrous Na2SO4 and
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concentration. The so-obtained crude was purified by flash column chromatography on
silica gel to give the desired O- benzoyl hydroxylamine.
O-Benzoyl-N,N-dibenzylhydroxylamine (62a).
Following the general procedure A, N,N-dibenzylamine (0.5 mL, 2.60 mmol) was
converted to compound 62a162 (0.67 g, 81%) after stirring for 10 h, which was isolated as
a white solid (eluent: 0 – 5% of acetone in hexane). M.p. 97 – 98 oC; lit162 m.p. 96 – 98
oC; 1H

NMR (400 MHz, CDCl3) δ 7.86 – 7.80 (m, 2H), 7.50 (t, J = 7.3 Hz, 1H), 7.46 – 7.44

(m, 4H), 7.39 – 7.22 (m, 8H), 4.21 (s, 4H);

13C

NMR (100 MHz, CDCl3) δ 164.9, 135.9,

132.8, 129.4, 129.3, 128.3, 128.3, 127.6, 62.1.
O-Benzoyl-N-benzyl-N-methylhydroxylamine (62b).
Following the general procedure A, N-benzyl-N-methylamine (0.5 mL, 3.88 mmol)
was converted to compound 62b (0.77 g, 82%) after stirring for 10 h, which was isolated
as a colorless oil (eluent: 0 – 5% of EtOAc in toluene). 1H NMR (400 MHz, CDCl3) δ 7.93
– 7.88 (m, 2H), 7.52 (t, J = 7.3 Hz, 1H), 7.45 – 7.36 (m, 4H), 7.34 – 7.22 (m, 3H), 4.16 (s,
2H), 2.93 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 164.9, 135.6, 132.9, 129.4, 129.3, 128.4,
128.3, 127.7, 65.1, 46.1; ESIHRMS calculated for C15H15NO2Na [M+Na]+, 264.1000;
found, 264.1006.
1-Piperidinyloxy benzoate (62c).
Following the general procedure A, piperidine (1.0 mL, 10.12 mmol) was converted
to compound 62c162 (1.80 g, 86%) after stirring for 1.5 h, which was isolated as a white
solid (eluent: 0 – 5% of EtOAc in toluene). M.p. 58 – 60 oC; lit162 m.p. 55 – 59 oC; 1H NMR
(400 MHz, CDCl3) δ 8.02 – 7.96 (m, 2H), 7.53 (t, J = 7.3 Hz, 1H), 7.41 (t, J = 7.8 Hz, 2H),
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3.48 (br s, 2H), 2.76 (d, J = 5.9 Hz, 2H), 1.86 – 1.76 (m, 4H), 1.64 (br s, 1H), 1.36 – 1.18
(m, 1H); 13C NMR (100 MHz, CDCl3) δ 164.7, 132.9, 129.6, 129.4, 128.3, 57.5, 25.0, 23.3.
4-Methylpiperidin-1-yl benzoate (62d).
Following the general procedure A, 4-methylpiperidine (2.5 mL, 20.57 mmol) was
converted to compound 62d163 (3.71 g, 82%) after stirring for 1 h. It was isolate as a white
solid (eluent: 0 – 10% of EtOAc in toluene). M.p. 91 – 92 oC; 1H NMR (400 MHz, CDCl3)
δ 7.99 (d, J = 7.3 Hz, 2H), 7.53 (t, J = 7.3 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 3.51 (d, J =
8.8 Hz, 2H), 2.72 (t, J = 10.5 Hz, 2H), 1.75 (d, J = 13.2 Hz, 2H), 1.65 – 1.52 (m, 2H), 1.52
– 1.40 (m, 1H), 0.93 (d, J = 5.9 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 164.8, 132.9,

129.6, 129.4, 128.3, 57.2, 33.5, 30.1, 21.2.
4-Chloropiperidin-1-oxyl Benzoate (62e).
Following the general procedure A, 4-chloropiperidine (1.79 g, 15.0 mmol) was
converted to compound 62e (2.92 g, 81%) after stirring for 1.5 h. It was isolated as a white
solid (eluent: 0 – 10% of EtOAc in toluene). M.p. 63 – 65 oC; IR (neat, cm-1) √ 1738; 1H
NMR (400 MHz, CDCl3) δ 8.00 (d, J = 6.6 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.43 (t, J =
7.7 Hz, 2H), 4.35 (br s, 0.6H), 4.07 (br s, 0.4H), 3.58 (br s, 0.8H), 3.34 (s, 2.4H), 2.97 (br
s, 0.8H), 2.37 – 2.24 (m, 2H), 2.20 – 2.02 (m, 2H);

13C

NMR (100 MHz, CDCl3) δ 164.6,

133.1, 129.4, 129.2, 128.4, 55.1, 54.4, 52.8, 51.7, 33.0; ESIHRMS calculated for
C12H14NO2ClNa [M+Na]+, 262.0611; found, 262.0613.
General procedure (B) for the synthesis of N,N-disubstituted hydroxylamines
To an ice-cold (<5 oC) solution of O-benzoyl hydroxylamine (1 mmol) in dry
dichloromethane (6 mL) was added DIBAL (1 M solution in hexane, 2.5 mmol) carefully.
The resultant mixture was stirred for 15 min in an ice-bath, and the reaction was quenched
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by adding saturated aq. NH4Cl (10 mL) and saturated aq. sodium potassium tartrate (8
mL). The mixture was stirred vigorously at room temperature for 1 h and was extracted
with dichloromethane. The resulting organic extract was washed with brine, dried over
anhydrous Na2SO4, and concentrated. Purification was performed by flash column
chromatography on silica gel to deliver the desired hydroxylamine.
N,N-Dibenzylhydroxylamine (63a).
The title compound 63a164 (60 mg, 90%) was obtained from compound 62a (100
mg, 0.32 mmol) following the general procedure B. It was isolated as a white solid (eluent:
5 – 15% of EtOAc in hexane). M.p. 119 – 121 oC; lit164 m.p. 118 – 119 oC; 1H NMR (400
MHz, CDCl3) δ 7.37 – 7.24 (m, 10H), 6.90 (br s, 1H), 3.69 (s, 4H);

13C

NMR (100 MHz,

CDCl3) δ 137.1, 129.8, 128.3, 127.5, 63.7.
N-Benzyl-N-methylhydroxylamine (63b).
The title compound 63b16 (265 mg, 93%) was obtained from compound 62b (500
mg, 2.07 mmol) following the general procedure B. It was isolated as a colorless oil
(eluent :10 – 30% of EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.24 (m,
5H), 3.70 (s, 2H), 2.51 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 136.9, 129.9, 128.3, 127.5,
66.4, 47.5.
Piperidin-1-ol (63c).
The title compound 63c165 (313 mg, 63%) was obtained from compound 62c (1 g,
4.87 mmol) following the general procedure B. It was isolated as a colorless oil (eluent:
ether). 1H NMR (400 MHz, CDCl3) δ 8.09 (br s, 1H), 3.22 (d, J = 9.8 Hz, 2H), 2.41 (t, J =
11.0 Hz, 2H), 1.70 (d, J = 13.2 Hz, 2H), 1.60 – 1.42 (m, 3H), 1.18 – 1.02 (m, 1H);
NMR (100 MHz, CDCl3) δ 59.0, 25.4, 23.0.

13C

111
4-Methylpiperidin-1-ol (63d).
The title compound 63d166 (443 mg, 84%) was obtained from compound 62d (1 g,
4.56 mmol) following the general procedure B. It was isolated as a colorless oil (eluent:
ether). The NMR data suggest a mixture of two stereo-isomers in 8.4:1 ratio. Major
isomer; 1H NMR (400 MHz, CDCl3) δ 8.60 (br s, 1H) 3.22 (d, J = 10.8 Hz, 2H), 2.44 (t, J
= 11.7 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.42 – 1.30 (m, 1H), 1.30 – 1.17 (m, 2H), 0.86 (d, J
= 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 58.7, 34.0, 29.8, 21.3. The minor isomer was
identified by 1H NMR (400 MHz, CDCl3) δ 3.00 – 2.83 (m, 4H), 1.61 – 1.46 (m, 4H), 0.94
(d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 54.6, 29.4, 20.0.
4-Chloropiperidin-1-ol (63e).
The title compound 63e (1.29 g, 85%) was obtained from compound 62e (2.68 g,
11.2 mmol) following the general procedure B. It was isolated as a mixture of two
stereoisomers (63e-1 and 63e-2) in 1:1 ratio in the form of a white solid (eluent: diethyl
ether). M.p. 97 – 99 oC; NMR of isomer 63e-1: 1H NMR (400 MHz, CDCl3) δ 8.07 (br s,
1H), 3.91 (s, 1H), 3.32 – 3.22 (m, 2H), 2.62 (t, J = 10.7 Hz, 2H), 2.24 (d, J = 12.8 Hz, 2H),
1.93 – 1.80 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 56.5, 55.5, 34.4; NMR of isomer 63e2: 1H NMR (400 MHz, CDCl3) δ 8.07 (br s, 1H), 4.26 (s, 1H), 3.09 – 2.98 (m, 4H), 2.11 –
1.97 (m, 4H);

13C

NMR (100 MHz, CDCl3) δ 54.9, 53.0, 33.0; ESIHRMS calculated for

C5H11NOCl [M+H]+, 136.0529; found, 136.0534.
3-(1-Pyrrolidinyl)propanenitrile (64).
To a stirred solution of acrylonitrile (4.0 mL, 60.88 mmol) and Amberlyst-15 (1 g,
30% w/w) was added pyrrolidine (4.0 mL, 48.70 mmol) in an ice-bath. The ice-bath was
removed, and the reaction mixture was stirred for 0.5 h. The mixture was then diluted with

112
dichloromethane and filtered, and the filtrate was concentrated to yield 64167 (5.57 g, 92%)
as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 2.71 (t, J = 7.2 Hz, 2H), 2.53 – 2.44 (m,
6H), 1.79 – 1.68 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 118.9, 53.8, 51.2, 23.5, 17.6.
1-Pyrrolidinyloxy 4-phenylbutanoate (62f).
To a chilled solution of 64 (0.50 g, 4.03 mmol) in dry CH2Cl2 (40 mL) was added
m-CPBA (0.95 g 77% m-CPBA, 6.05 mmol) and K2CO3 (1.11 g, 8.06 mmol) at –78 oC.
After stirring for 3 h at –78 oC, the mixture was warmed slowly to ambient temperature,
stirred for an additional 12 h, and filtered. 4-phenylbutyric acid (0.99 g, 6.05 mmol), DMAP
(0.10 g, 0.81 mmol), and N,N'-dicyclohexylcarbodiimide (1.25 g, 6.05 mmol) were added
to the resulting filtrate. The resultant mixture was stirred for the next 2 h at room
temperature, filtered through a pad of Celite®, and was washed with saturated aq.
NaHCO3, brine, dried over anhydrous Na2SO4. The resultant solution was concentrated
and purified by flash column chromatography on silica gel (10 – 30% of EtOAc in hexane)
to afford 62f (0.49 g, 52%) as a light red oil. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.23 (m,
2H), 7.22 – 7.13 (m, 3H), 3.14 (s, 4H), 2.64 (t, J = 7.5 Hz, 2H), 2.25 (t, J = 7.5 Hz, 2H),
2.00 – 1.90 (m, 2H), 1.85 (s, 4H);

13C

NMR (100 MHz, CDCl3) δ 172.0, 141.2, 128.5,

128.4, 128.3, 126.0, 57.4, 35.1, 32.4, 26.6, 22.0; ESIHRMS calculated for C14H19NO2Na
[M+Na]+, 256.1313; found, 256.1319.
General procedure (C) for the synthesis of O-acyl hydroxylamines
A solution of N,N'-dicyclohexylcarbodiimide (1.25 – 2.5 mmol) in dry
dichloromethane (1 mL) was added to a mixture of carboxylic acid (1.25 – 2.5 mmol),
N,N-disubstituted hydroxylamine (1 mmol), DMAP (0.2 mmol), and dry dichloromethane
(10 mL) at ambient temperature. The stirring was continued until completion of the
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reaction, and the reaction mixture was filtered through a pad of Celite ®. The resultant
filtrate was washed with saturated aq. NaHCO3 and brine, dried over anhydrous Na2SO4,
and concentrated. After purification by flash column chromatography on silica gel, the
desired O-acyl hydroxylamine was obtained.
N,N-Dibenzyl-O-(4-phenylbutanoyl)hydroxylamine (62g).
Following the general procedure C, the title compound 62g was isolated (1.67 g,
98%) as a colorless oil by stirring 63a (1 g, 4.69 mmol), N,N'-dicyclohexylcarbodiimide
(1.22 g, 5.86 mmol), and 4-phenylbutyric acid (0.96 g, 5.86 mmol) for 40 mins. Eluent: 0
– 5% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.41 (m, 4H), 7.34 – 7.23
(m, 8H), 7.19 – 7.16 (m, 1H), 7.02 (d, J = 6.9 Hz, 2H), 4.07 (s, 4H), 2.37 (t, J = 7.6 Hz,
2H), 2.06 (t, J = 7.3 Hz, 2H), 1.75 – 1.62 (m, 2H);

13C

NMR (100 MHz, CDCl3) δ 171.8,

141.3, 136.1, 129.4, 128.4, 128.3, 128.3, 127.7, 125.8, 62.5, 34.7, 31.9, 26.2; ESIHRMS
calculated for C24H25NO2Na [M+Na]+, 382.1783; found, 382.1779.
O-(1-Adamantanecarbonyl)-N,N-dibenzylhydroxylamine (62h).
Following the general procedure C, the title compound 62h was isolated (1.27 g,
72%) as a white solid by stirring 63a (1 g, 4.69 mmol), N,N'-dicyclohexylcarbodiimide
(1.94 g, 9.38 mmol), and 1-adamantanecarboxylic acid (1.69 g, 9.38 mmol) for 28 h.
Eluent: 0 – 5% of EtOAc in hexane. M.p. 110 – 111 o C; 1H NMR (400 MHz, CDCl3) δ
7.40 (d, J = 7.3 Hz, 4H), 7.34 – 7.23 (m, 6H), 4.05 (s, 4H), 1.89 (s, 3H), 1.69 – 1.53 (m,
12H);

13C

NMR (100 MHz, CDCl3) δ 175.2, 136.1, 129.4, 128.1, 127.5, 62.1, 40.4, 38.5,

36.4, 27.8; ESIHRMS calculated for C25H29NO2Na [M+Na]+, 398.2096; found, 398.2103.
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N,N-Dibenzyl-O-(3,3-dimethylbutanoyl)hydroxylamine (62i).
Following the general procedure C, the title compound 62i was isolated (0.91 g,
63%) as a white solid by stirring 63a (1 g, 4.69 mmol), 3,3-dimethylbutanoic acid (0.75
mL, 5.86 mmol), and N,N'-dicyclohexylcarbodiimide (1.22 g, 5.86 mmol) for 1.5 h. Eluent:
0 – 5% of EtOAc in hexane). M.p. 53 – 54 oC; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J =
6.9 Hz, 4H), 7.34 – 7.22 (m, 6H), 4.05 (s, 4H), 1.95 (s, 2H), 0.77 (s, 9H);

13C

NMR (100

MHz, CDCl3) δ 170.2, 136.3, 129.3, 128.3, 127.5, 62.2, 46.2, 30.5, 29.3; ESIHRMS
calculated for C20H25NO2Na [M+Na]+, 334.1783; found, 334.1782.
N-Benzyl-N-methyl-O-(5-phenylpentanoyl)hydroxylamine (62j).
Following the general procedure C, the title compound 62j was isolated (396 mg,
87%) as a colorless oil by stirring 63b (210 mg, 1.53 mmol), 5-phenylvaleric acid (341
mg, 1.91 mmol) and N,N'-dicyclohexylcarbodiimide (394 mg, 1.91 mmol) for 0.5 h. Eluent:
5 – 20% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.33 (m, 2H), 7.33 –
7.22 (m, 5H), 7.21 – 7.16 (m, 1H), 7.13 (d, J = 7.3 Hz, 2H), 3.99 (s, 2H), 2.81 (s, 3H), 2.54
(t, J = 7.0 Hz, 2H), 2.17 (t, J = 7.0 Hz, 2H), 1.58 – 1.45 (m, 4H);

13C

NMR (100 MHz,

CDCl3) δ 171.8, 142.0, 135.9, 129.3, 128.4, 128.3, 128.3, 127.7, 125.8, 65.0, 46.2, 35.4,
32.7, 30.6, 24.5; ESIHRMS calculated for C19H23NO2Na [M+Na]+, 320.1626; found,
320.1625.
1-Piperidinyloxy 4-phenylbutanoate (62k).
Following the general procedure C, the title compound 62k was isolated (387 mg,
93%) as a colorless oil by stirring 63c (170 mg, 1.68 mmol), 4-phenylbutyric acid (355
mg, 2.10 mmol,) and N,N'-dicyclohexylcarbodiimide (433 mg, 2.10 mmol) for 0.5 h.
Eluent: 5 – 20% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H),
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7.21 – 7.14 (m, 3H), 3.35 (br s, 2H), 2.70 – 2.51 (m, 4H), 2.28 (t, J = 7.3 Hz, 2H), 2.01 –
1.90 (m, 2H), 1.82 – 1.69 (m, 4H), 1.61 (br s, 1H), 1.34 – 1.10 (m, 1H);

13C

NMR (100

MHz, CDCl3) δ 171.5, 141.3, 128.5, 128.4, 126.0, 57.4, 35.1, 32.4, 26.7, 25.0, 23.2;
ESIHRMS calculated for C15H21NO2Na [M+Na]+, 270.1470; found, 270.1465.
4-Methyl-1-piperidinyloxy 4-phenylbutanoate (62l).
Following the general procedure C, the title compound 62l was isolated (740 mg,
91%) as a colorless oil by stirring 63d (360 mg, 3.13 mmol), 4-phenylbutyric acid (642
mg, 3.91 mmol), and N,N'-dicyclohexylcarbodiimide (807 mg, 3.91 mmol) for 0.5 h.
Eluent: 10 – 20% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H),
7.21 – 7.14 (m, 3H), 3.36 (d, J = 8.8 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 10.5 Hz,
2H), 2.27 (t, J = 7.6 Hz, 2H), 2.02 – 1.90 (m, 2H), 1.70 (d, J = 12.7 Hz, 2H), 1.57 – 1.34
(m, 3H), 0.91 (d, J = 5.9 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 171.6, 141.3, 128.5,

128.4, 126.0, 57.1, 35.1, 33.4, 32.4, 30.0, 26.7, 21.2; ESIHRMS calculated for
C16H23NO2Na [M+Na]+, 284.1626; found, 284.1630.

4-Chloro-1-piperidinyloxy 4-Phenylbutanoate (62m).
Following the general procedure C, the title compound 62m was isolated (827 mg,
80%)

as

a

colorless

oil

by

stirring

63e

(500

mg,

3.69

mmol),

N,N'-

dicyclohexylcarbodiimide (951 mg, 4.61 mmol), and 4-phenylbutanoic acid (757 mg, 4.61
mmol) for 1 h. Eluent: 10 – 30% of EtOAc in hexane. IR (neat, cm-1) √ 1757; 1H NMR (400
MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.23 – 7.14 (m, 3H), 4.30 (s, 0.6H), 3.97 (br s, 0.4H),
3.42 (br s 0.8H), 3.18 (s, 2.4H), 2.77 (br s, 0.8H), 2.66 (t, J = 7.6 Hz, 2H), 2.35 – 2.18 (m,
4H), 2.11 – 1.91 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 171.4, 141.2, 128.5, 128.4, 126.1,
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55.0, 51.5, 35.0, 32.9, 32.3, 26.6; ESIHRMS calculated for C15H20NO2ClNa [M+Na]+,
304.1080; found, 304.1077.
N,N-Dibenzyl-O-(2-(2-naphthalenyloxy)acetyl)hydroxylamine (62n).
Following the general procedure C, the title compound 62n was isolated (1.67 g,
89%) as a white solid by stirring 63a (1 g, 4.69 mmol), 2-(naphthalen-2-yloxy)acetic acid
(1.19 g, 5.86 mmol), and N,N'-dicyclohexylcarbodiimide (1.22 g, 5.86 mmol) for 0.5 h.
Eluent: 10 – 45% of EtOAc in hexane. M.p. 87 – 89 oC; 1H NMR (400 MHz, CDCl3) δ
7.76 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.47 – 7.28 (m,
12H), 6.99 (dd, J = 8.8, 2.5 Hz, 1H), 6.66 (d, J = 2.5 Hz, 1H), 4.44 (s, 2H), 4.13 (s, 4H);
13C

NMR (100 MHz, CDCl3) δ 168.4, 155.6, 135.5, 134.2, 129.6, 129.5, 129.3, 128.6,

128.1, 127.6, 127.0, 126.3, 124.0, 118.2, 107.1, 64.6, 63.1; ESIHRMS calculated for
C26H23NO3Na [M+Na]+, 420.1576; found, 420.1575.
N,N-Dibenzyl-O-nicotinoylhydroxylamine (62o).
Following the general procedure C, the title compound 62o was isolated (1.45 g,
97%) as a white solid by stirring 63a (1 g, 4.69 mmol), nicotinic acid (0.72 g, 5.86 mmol),
and N,N'-dicyclohexylcarbodiimide (1.22 g, 5.86 mmol) for 1 h. Eluent: 10 – 45% of
EtOAc in hexane. M.p. 117 – 118 oC; 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 1.5 Hz,
1H), 8.70 (dd, J = 4.9, 2.0 Hz, 1H), 8.05 (td, J = 7.9, 2.0 Hz, 1H), 7.44 (d, J = 6.7 Hz, 4H),
7.34 – 7.22 (m, 7H), 4.22 (s, 4H);

13C

NMR (100 MHz, CDCl3) δ 163.6, 153.3, 150.3,

136.8, 135.7, 129.4, 128.4, 127.8, 125.3, 123.3, 62.4; ESIHRMS calculated for
C20H18N2O2Na [M+Na]+, 341.1266; found, 341.1261.
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General procedure (D) for the synthesis of O-(α-acetoxy) hydroxylamines.
A solution of O-acyl hydroxylamines (0.5 mmol) in dry dichloromethane (3 mL) was
chilled at –78 oC. A 1 M DIBAL solution in hexane (0.63 – 1 mmol) was added dropwise
followed by the sequential addition of pyridine (1.5 mmol), a solution of DMAP (1 mmol)
in dry dichloromethane (1.5 mL), and Ac2O (3 mmol). After stirring for 12 h (overnight) at
–78 oC, the reaction mixture was warmed slowly to 0 oC followed by addition of saturated
aq. NH4Cl (5 mL) and saturated aq. sodium potassium tartrate (4 mL). The mixture was
stirred vigorously at room temperature for 1 h and was extracted with dichloromethane.
The organic extract was washed with brine and dried over anhydrous Na2SO4. The
resultant solution was concentrated and purified by column chromatography on silica gel
unless otherwise specified.
4-Phenyl-1-(1-pyrrolidinyloxy)butyl acetate (65f).
The title compound 65f (75 mg, 63%) was isolated as a colorless oil from 62f (100
mg, 0.43 mmol) and DIBAL (0.64 mL, 1 M in hexane, 0.64 mmol) by following the general
procedure D. Eluent: 10 – 20% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 –
7.24 (m, 2H), 7.21 – 7.14 (m, 3H), 6.13 – 6.08 (m, 1H), 3.00 (s, 4H), 2.67 – 2.59 (m, 2H),
2.09 (s, 3H), 1.76 (s, 4H), 1.71 – 1.64 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 170.4, 142.0,
128.4, 128.3, 125.8, 100.2, 57.4, 35.5, 32.5, 26.1, 21.9, 21.5; ESIHRMS calculated for
C16H23NO3Na [M+Na]+, 300.1576; found, 300.1582.
O-(1-Acetoxy-4-phenylbutyl-N,N-dibenzylhydroxylamine (65g).
The title compound 65g (102 mg, 88%) was isolated as a colorless oil from 62g
(100 mg, 0.28 mmol) and DIBAL (0.56 mL, 1 M in hexane, 0.56 mmol) by following general
procedure D. Eluent: 0 – 5% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.40 –
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7.21 (m, 12H), 7.19 – 7.16 (m, 1H), 7.07 (d, J = 7.3 Hz, 2H), 5.88 (t, J = 5.4 Hz, 1H), 4.01
(br s, 2H), 3.78 (d, J = 12.7 Hz, 2H), 2.41 (t, J = 7.3 Hz, 2H), 1.85 (s, 3H), 1.51 – 1.22 (m,
4H); 13C NMR (100 MHz, CDCl3) δ 170.2, 141.9, 137.1, 129.5, 128.4, 128.3, 128.2, 127.4,
125.7, 100.4, 62.9, 35.3, 32.4, 25.4, 21.2; ESIHRMS calculated for C 26H29NO3Na
[M+Na]+, 426.2045; found, 426.2048.
O-(1-Acetoxy-1-adamantanylmethyl)-N,N-dibenzylhydroxylamine (65h).
The title compound 65h (217 mg, 65%) was isolated as a colorless oil from 62h
(300 mg, 0.80 mmol) and DIBAL (1 mL, 1 M in hexane, 1 mmol) by following the general
procedure D. Eluent: 0 – 8% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.36 –
7.28 (m, 8H), 7.28 – 7.22 (m, 2H), 5.58 (s, 1H), 3.91 (d, J = 13.2 Hz, 2H), 3.82 (d, J =
13.2 Hz, 2H), 1.89 (s, 3H), 1.82 (s, 3H), 1.65 (d, J = 11.7 Hz, 3H), 1.58 (d, J = 11.7 Hz,
3H), 1.49 (d, J = 12.2 Hz, 3H), 1.33 (d, J = 12.2 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ

170.6, 137.2, 129.6, 128.1, 127.2, 103.1, 62.2, 37.0, 36.7, 36.5, 27.9, 21.1; ESIHRMS
calculated for C27H33NO3Na [M+Na]+, 442.2358; found, 442.2367.
O-(1-Acetoxy-3,3-dimethylbutyl)-N,N-dibenzylhydroxylamine (65i).
The title compound 65i (85 mg, 75%) was isolated as a colorless oil from 62i (100
mg, 0.32 mmol) and DIBAL (0.48 mL, 1 M in hexane, 0.48 mmol) by following the general
procedure D. Eluent: 0 – 5% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.39 –
7.29 (m, 8H), 7.28 – 7.22 (m, 2H), 6.00 (t, J = 5.4 Hz, 1H), 4.00 (br s, 2H), 3.77 (d, J =
13.2 Hz, 2H), 1.88 (s, 3H), 1.40 (dd, J = 14.2, 5.9 Hz, 1H), 1.34 (dd, J = 14.2, 4.9 Hz,
1H), 0.68 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.1, 137.3, 129.4, 128.3, 127.3, 98.5,
62.8, 46.1, 29.6, 29.1, 21.5; ESIHRMS calculated for C22H29NO3Na [M+Na]+, 378.2045;
found, 378.2046.
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O-(1-Acetoxy-5-phenylpentyl)-N-benzyl-N-methylhydroxylamine (65j).
The title compound 65j (51 mg, 89%) was isolated as a colorless oil from 62j (50
mg, 0.17 mmol) and DIBAL (0.30 mL, 1 M in hexane, 0.30 mmol) by following the general
procedure D. Eluent: 5 – 10% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.35 –
7.23 (m, 7H), 7.20 – 7.11 (m, 3H), 5.91 (br s, 1H), 3.88 (br s, 1H), 3.76 (d, J = 12.7 Hz,
1H), 2.64 (s, 3H), 2.53 (t, J = 7.6 Hz, 2H), 1.99 (s, 3H), 1.52 (s, 4H), 1.22 (br s, 2H);

13C

NMR (100 MHz, CDCl3) δ 170.3, 142.4, 136.9, 129.6, 128.4, 128.2, 128.2, 127.4, 125.6,
100.3, 65.4, 46.5, 35.7, 32.7, 31.0, 23.6, 21.3; ESIHRMS calculated for C 21H27NO3Na
[M+Na]+, 364.1889; found, 364.1885.
4-Phenyl-1-(1-piperidinyloxy)butyl acetate (65k).
The title compound 65k (64 mg, 55%) was isolated as a colorless oil from 62k (100
mg, 0.40 mmol) and DIBAL (0.6 mL, 1 M in hexane, 0.60 mmol) by following the general
procedure D. Flash column chromatography on neutral alumina (0 – 8% of EtOAc in
hexane). 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.25 (m, 2H), 7.21 – 7.15 (m, 3H), 6.07 (t,
J = 4.6 Hz, 1H), 3.24 (br s, 2H), 2.63 (t, J = 6.9 Hz, 2H), 2.54 – 2.36 (m, 2H), 2.06 (s, 3H),
1.79 – 1.62 (m, 6H), 1.55 (br s, 3H), 1.14 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 170.3,
142.0, 128.4, 128.3, 125.8, 99.8, 58.2, 57.0, 35.5, 32.6, 26.1, 25.3, 23.4, 21.4; ESIHRMS
calculated for C17H25NO3Na [M+Na]+, 314.1732; found, 314.1739.
1-(4-Methyl-1-piperidinyloxy)-4-phenylbutyl acetate (65l).
The title compound 65l (98 mg, 84%) was isolated as a colorless oil from 62l (100
mg, 0.38 mmol) and DIBAL (0.57 mL, 1 M in hexane, 0.57 mmol) by following the general
procedure D. Eluent: 5 – 10% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 –
7.25 (m, 2H), 7.21 – 7.14 (m, 3H), 6.06 (t, J = 4.8 Hz, 1H), 3.32 – 3.17 (m, 2H), 2.63 (t, J
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= 6.9 Hz, 2H), 2.53 – 2.36 (m, 2H), 2.06 (s, 3H), 1.77 – 1.58 (m, 6H), 1.40 – 1.19 (m, 3H),
0.88 (d, J = 5.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.4, 142.0, 128.4, 128.3, 125.8,
99.9, 57.8, 56.7, 35.5, 34.0, 33.9, 32.6, 30.1, 26.1, 21.4, 21.3; ESIHRMS calculated for
C18H27NO3Na [M+Na]+, 328.1889; found, 328.1888.
1-(4-Chloro-1-piperidinyloxy)-4-phenylbutyl acetate (65m).
The title compound 65m (98 mg, 85%) was isolated as a colorless oil from 62m
(100 mg, 0.35 mmol) and DIBAL (0.62 mL 1 M in hexane, 0.62 mmol) by following the
general procedure D. Eluent: 0 – 20% of EtOAc in hexane. IR (neat, cm -1) √ 1738; 1H
NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.23 – 7.13 (m, 3H), 6.05 (s, 1H), 4.21 (br
s, 0.5H), 3.92 (s, 0.5H), 3.28 (br s, 1H), 3.05 (br s, 2H), 2.63 (s, 3H), 2.26 – 1.78 (m, 7H),
1.69 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 170.3, 141.9, 128.4, 128.4, 125.9, 99.6, 55.9,
55.5, 52.4, 51.3, 35.5, 34.1, 33.0, 32.5, 26.0, 21.4; ESIHRMS calculated for
C17H24NO3ClNa [M+Na]+, 348.1342; found, 348.1346.
O-(1-Acetoxy-2-(naphthalen-2-yloxy)ethyl)-N,N-dibenzylhydroxylamine (65n).
The title compound 65n (100 mg, 90%) was isolated as a colorless oil from 62n
(100 mg, 0.25 mmol) and DIBAL (0.38 mL, 1 M in hexane, 0.38 mmol) by following the
general procedure D. Eluent: 0 – 10% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ
7.76 (d, J = 8.3 Hz, 1H), 7.73 – 7.67 (m, 2H), 7.44 (t, J = 7.1 Hz, 1H), 7.41 – 7.30 (m, 9H),
7.30 – 7.23 (m, 2H), 7.04 (dd, J = 8.8, 2.5 Hz, 1H), 6.95 (d, J = 2.0 Hz, 1H), 6.26 (t, J =
5.4 Hz, 1H), 4.04 (d, J = 13.2 Hz, 2H), 3.97 – 3.87 (m, 3H), 3.84 (dd, J = 10.3, 5.4 Hz,
1H) 1.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.9, 156.1, 136.9, 134.4, 129.7, 129.3,
129.1, 128.3, 127.6, 127.5, 126.8, 126.3, 123.8, 118.7, 106.9, 96.7, 66.6, 62.8, 21.0;
ESIHRMS calculated for C28H27NO4Na [M+Na]+, 464.1838; found, 464.1826.
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General

procedure

(E)

for

the

direct

synthesis

of

N,N,O-trisubstituted

hydroxylamines from O-acyl hydroxylamines.
A 1 M DIBAL solution in hexane (1 mmol) was added dropwise to a chilled solution
of O-acyl hydroxylamine (0.5 mmol) in dry dichloromethane (3 mL) at –78 oC. To this
solution were added sequentially, dropwise, pyridine (1.5 mmol), a solution of DMAP (1
mmol) in dry CH2Cl2 (1.5 mL), and Ac2O (3 mmol). The reaction mixture was stirred for
12 h at –78 oC, warmed slowly to 0 oC, and added saturated aq. NH4Cl (5 mL) and
saturated aq. sodium potassium tartrate (4 mL). The resultant mixture was vigorously
stirred at room temperature for 1 h. Then the mixture was extracted with dichloromethane,
and the resultant organic extract was washed with brine, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The so-obtained intermediate residue was
dissolved in dry dichloromethane (10 mL) and cooled to –78 oC. Et3SiH (1.25 mmol) and
BF3.OEt2 (1.25 mmol) were added one after the other, and the reaction mixture was
warmed slowly to 0 oC followed by the addition of saturated aq. NaHCO 3. The mixture
was then extracted with pentane, and the resulting organic extract was dried over
anhydrous Na2SO4. Subsequent concentration followed by the purification of the resultant
residue by flash column chromatography on silica gel (0 – 5% of EtOAc in hexane) gave
the desired hydroxylamines.
N,N,O-Tribenzylhydroxylamine (66a).
According to general procedure E, compound 66a168 (143 mg, 50%) was isolated
as a colorless oil from 62a (300 mg, 0.95 mmol). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.42
(m, 4H), 7.39 – 7.27 (m, 6H), 7.25 – 7.20 (m, 3H), 6.98 – 6.96 (m, 2H), 4.19 (s, 2H), 3.90
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(s, 4H);

13C

NMR (100 MHz, CDCl3) δ 137.8, 137.0, 129.8, 129.1, 128.1, 127.7, 127.3,

76.1, 62.9.
N,O-Dibenzyl-N-methylhydroxylamine (66b).
According to general procedure E, compound 66b (34 mg, 53%) was isolated as
a colorless oil from 62b (68 mg, 0.28 mmol). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m,
8H), 7.24 – 7.19 (m, 2H), 4.51 (s, 2H), 3.83 (s, 2H), 2.65 (s, 3H);

13C

NMR (100 MHz,

CDCl3) δ 137.5, 129.7, 128.8, 128.2, 128.2, 127.7, 127.3, 74.9, 65.2, 45.6; ESIHRMS
calculated for C15H18NO [M+H]+, 228.1388; found, 228.1385.
General procedure (F) for the synthesis of N,N,O-trisubstituted hydroxylamines
from O-(α-acetoxy)hydroxylamines.
To a chilled solution of O-(α-acetoxy)hydroxylamine (0.25 mmol) in dry
dichloromethane (5 mL) were added Et3SiH (0.63 mmol) and BF3.OEt2 (0.63 mmol)
dropwise at –78 oC. The reaction mixture was warmed slowly to 0 oC or room temperature
in 2.5 h and stirring was continued until completion. The reaction was quenched by
saturated aq. NaHCO3 and was extracted with pentane. The so-obtained organic extract
was dried over anhydrous Na2SO4, concentrated, and purified by flash column
chromatography on silica gel to afford the trisubstituted hydroxylamines.
1-(4-Phenylbutoxy)pyrrolidine (66f).
Compound 66f (30 mg, 77%) was prepared according to general procedure F
using 65f (50 mg, 0.18 mmol) with warming to room temperature and stirring for an
additional 3 h. It was isolated as a colorless oil (0 – 10% EtOAc in hexane). 1H NMR (400
MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 7.21 – 7.15 (m, 3H), 3.71 (t, J = 6.4 Hz, 2H), 3.01 –
2.92 (m, 4H), 2.63 (t, J = 7.6 Hz, 2H), 1.77 (br s, 4H), 1.71 – 1.55 (m, 4H); 13C NMR (100
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MHz, CDCl3) δ 142.5, 128.4, 128.2, 125.7, 72.1, 56.6, 35.8, 28.6, 28.1, 21.9; ESIHRMS
calculated for C14H22NO [M+H]+, 220.1701; found, 220.1702.
N,N-Dibenzyl-O-(4-phenylbutyl)hydroxylamine (66g).
Compound 66g (33 mg, 83%) was prepared according to general procedure F
using 65g (47 mg, 0.12 mmol) with warming to 0 oC. It was isolated as a colorless oil (0
– 5% EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 6.9 Hz, 4H), 7.34 –
7.24 (m, 8H), 7.22 – 7.14 (m, 1H), 7.09 (d, J = 6.9 Hz, 2H), 3.86 (s, 4H), 3.34 (t, J = 6.4
Hz, 2H), 2.42 (t, J = 7.6 Hz, 2H), 1.44 – 1.37 (m, 2H), 1.34 – 1.27 (m, 2H); 13C NMR (100
MHz, CDCl3) δ 142.5, 137.9, 129.6, 128.4, 128.1, 128.1, 127.2, 125.5, 72.9, 62.6, 35.5,
28.1, 27.8; ESIHRMS calculated for C24H28NO [M+H]+, 346.2171; found, 346.2177.
O-(1-Adamantanylmethyl)-N,N-dibenzylhydroxylamine (66h).
Compound 66h (39 mg, 89%) was prepared according to general procedure F
using 65h (50 mg, 0.12 mmol) with warming 0 oC. It was isolated as a white solid (0 – 5%
EtOAc in hexane). M.p. 48 – 49 oC; 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 6.9 Hz, 4H),
7.34 – 7.22 (m, 6H), 3.83 (s, 4H), 2.91 (s, 2H), 1.85 (s, 3H), 1.64 (d, J = 12.2 Hz, 3H),
1.56 (d, J = 11.3 Hz, 3H), 1.30 (d, J = 2.0 Hz, 6H);

13C

NMR (100 MHz, CDCl3) δ 137.9,

129.8, 128.0, 127.0, 83.5, 62.5, 39.6, 37.2, 33.4, 28.2; ESIHRMS calculated for C25H32NO
[M+H]+, 362.2484; found, 362.2498.
N,N-Dibenzyl-O-(3,3-dimethylbutyl)hydroxylamine (66i).
Compound 66i (50 mg, 81%) was prepared according to general procedure F
using 65i (75 mg, 0.21 mmol) with warming to 0 oC and stirring for an additional 0.5 h. It
was isolated as a colorless oil (0 – 5% EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ
7.40 (d, J = 7.3 Hz, 4H), 7.36 – 7.23 (m, 6H), 3.85 (s, 4H), 3.32 (t, J = 7.6 Hz, 2H), 1.17
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(t, J = 7.6 Hz, 2H), 0.69 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 137.9, 129.7, 128.1, 127.1,
70.5, 62.7, 41.5, 29.5, 29.3; ESIHRMS calculated for C20H28NO [M+H]+, 298.2171; found,
298.2175.
N-Benzyl-N-methyl-O-(5-phenylpentyl)hydroxylamine (66j).
Compound 66j (35 mg, 85%) was prepared according to general procedure F
using 65j (50 mg, 0.15 mmol) with warming to 0 oC and stirring for an additional 45 min
at 0 oC. It was isolated as a colorless oil (0 – 5% EtOAc in hexane). 1H NMR (400 MHz,
CDCl3) δ 7.39 – 7.25 (m, 7H), 7.21 – 7.14 (m, 3H), 3.79 (s, 2H), 3.52 (t, J = 6.4 Hz, 2H),
2.62 (s, 3H), 2.57 (t, J = 7.8 Hz, 2H), 1.60 – 1.51 (m, 2H), 1.51 – 1.42 (m, 2H), 1.32 –
1.21 (m, 2H);

13C

NMR (100 MHz, CDCl3) δ 142.7, 137.6, 129.7, 128.4, 128.2, 128.1,

127.2, 125.6, 72.1, 65.1, 45.5, 35.9, 31.3, 28.6, 25.8; ESIHRMS calculated for C19H26NO
[M+H]+, 284.2014; found, 284.2016.
1-(4-Phenylbutoxy)piperidine (66k).
Compound 66k (37 mg, 75%) was prepared according to general procedure F
using 65k (61 mg, 0.21 mmol) with warming to 0 oC and stirring for an additional 2 h. It
was isolated as a colorless oil (0 – 10% EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ
7.31 – 7.24 (m, 2H), 7.21 – 7.13 (m, 3H), 3.71 (t, J = 6.4 Hz, 2H), 3.26 (br s, 2H), 2.63 (t,
J = 7.6 Hz, 2H), 2.34 (br s, 2H), 1.80 – 1.45 (m, 9H), 1.14 (br s, 1H); 13C NMR (100 MHz,
CDCl3) δ 142.5, 128.4, 128.2, 125.6, 71.2, 56.9, 35.8, 28.6, 28.2, 25.5, 23.5; ESIHRMS
calculated for C15H24NO [M+H]+, 234.1858; found, 234.1863.
4-Methyl-1-(4-phenylbutoxy)piperidine (66l).
Compound 66l (60 mg, 76%) was prepared according to general procedure F
using 65l (98 mg, 0.32 mmol) with warming to 0 oC and stirring for an additional 2 h. It
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was isolated as a colorless oil (0 – 5% EtOAc in hexane). 1H NMR (500 MHz, toluene-d8,
T = 363 K) δ 7.14 – 6.95 (m, 5H), 3.66 (t, J = 6.2 Hz, 2H), 3.17 (d, J = 10.4 Hz, 2H), 2.50
(t, J = 7.5 Hz, 2H), 2.39 (t, J = 9.6 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.59 – 1.52 (m, 2H), 1.43
(d, J = 13.1 Hz, 2H), 1.30 – 1.13 (m, 3H), 0.76 (d, J = 6.1 Hz, 3H);

13C

NMR (125 MHz,

toluene-d8) δ 143.2, 129.1, 128.9, 126.3, 71.7, 57.3, 36.6, 34.9, 31.1, 29.5, 29.1, 22.0;
ESIHRMS calculated for C16H26NO [M+H]+, 248.2014; found, 248.2009.
4-Chloro-1-(4-phenylbutoxy)piperidine (66m).
Compound 66m (52 mg, 74%) was prepared according to general procedure F
using 65m (85 mg, 0.26 mmol) with warming to room temperature and stirring for an
additional 2 h. It was isolated as a colorless oil (eluent: 0 – 10% of EtOAc in hexane). 1H
NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.22 – 7.15 (m, 3H), 4.25 (br s, 0.45H),
3.89 (br s, 0.55H), 3.69 (t, J = 6.3 Hz, 2H), 3.26 (br s, 1H), 3.01 (br s, 1.8H), 2.63 (t, J =
7.5 Hz, 2H), 2.51 (br s, 1H), 2.27 – 1.80 (m, 4H), 1.76 – 1.54 (m, 4H); 13C NMR (100 MHz,
CDCl3) δ 142.4, 128.4, 128.3, 125.7, 71.5, 56.1, 55.8, 54.4, 51.0, 35.8, 34.7, 33.1, 28.5,
28.1; ESIHRMS calculated for C15H23NOCl [M+H]+, 268.1468; found, 268.1470.
N,N-Dibenzyl-O-(2-(2-naphthalenyloxy)ethyl)hydroxylamine (66n).
To an ice-cold solution of 65n (160 mg, 0.36 mmol) in dry dichloromethane (7.2
mL) were added Et3SiH (290 μL, 1.80 mmol) and BF3.OEt2 (230 μL, 1.80 mmol). The icebath was removed and the reaction mixture was stirred for 7 days. After quenching the
reaction with saturated aq. NaHCO3, the mixture was extracted with pentane. The
resulting organic extract was dried over anhydrous Na2SO4, concentrated, and purified
by flash column chromatography on silica gel (0 – 5% EtOAc in hexane) to give 66n (52
mg, 38%) as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 1H), 7.71
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– 7.65 (m, 2H), 7.46 – 7.38 (m, 5H), 7.36 – 7.28 (m, 5H), 7.28 – 7.22 (m, 2H), 7.06 (dd, J
= 8.8, 2.5 Hz, 1H), 6.87 (d, J = 2.5 Hz, 1H), 3.93 (s, 4H), 3.78 (t, J = 4.9 Hz, 2H), 3.71 (t,
J = 4.9 Hz, 2H);

13C

NMR (100 MHz, CDCl3) δ 156.6, 137.4, 134.5, 129.8, 129.1, 128.9,

128.2, 127.6, 127.4, 126.6, 126.2, 123.5, 119.0, 106.5, 71.3, 65.8, 62.7; ESIHRMS
calculated for C26H25NO2Na [M+Na]+, 406.1783; found, 406.1778.
N,N-Dibenzyl-O-(pyridin-3-ylmethyl)hydroxylamine (66o).
A 1M solution of DIBAL in hexane (0.63 mL, 0.63 mmol) was added dropwise to a
stirred solution of 62o (100 mg, 0.31 mmol) in dry dichloromethane (1.9 mL) at –78 oC.
Subsequently, pyridine (76 μL, 0.94 mmol), a solution of DMAP (77 mg, 0.63 mmol) in
dry dichloromethane (0.9 mL), and Ac2O (178 μL, 1.88 mmol) were added dropwise and
sequentially. The reaction mixture was then allowed to stir for 12 h at –78 oC, and it was
warmed slowly to 0 oC in 2.5 h followed by the additions of saturated aq. NH4Cl (3.2 mL)
and saturated aq. sodium potassium tartrate (2.4 mL). The resultant mixture was
vigorously stirred at room temperature for 1 h before the extraction with dichloromethane.
The resulting organic extract was washed with brine, dried over anhydrous Na 2SO4, and
concentrated. The so-obtained crude residue 65o was dissolved in dry dichloromethane
(6.3 mL) and again cooled to –78 oC. Et3SiH (252 μL, 1.58 mmol) and BF3.OEt2 (200 μL,
1.58 mmol) were added dropwise and sequentially to this chilled solution, and the
resulting solution was warmed to room temperature and stirring was continued for an
additional 36 h. After quenching with saturated aqueous NaHCO3, the reaction mixture
was extracted with pentane. The organic extract was then dried over anhydrous Na 2SO4,
concentrated, and purified by column chromatography on neutral alumina (5 – 20% of
EtOAc in hexane) to deliver product 66o (40 mg, 42%) as a colorless oil. 1H NMR (400
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MHz, CDCl3) δ 8.45 (s, 1H), 8.16 (s, 1H), 7.41 – 7.24 (m, 10H), 7.20 – 7.15 (m, 1H), 7.13
– 7.07 (m, 1H), 4.12 (s, 2H), 3.88 (s, 4H);

13C

NMR (100 MHz, CDCl3) δ 150.3, 149.0,

137.5, 136.7, 132.4, 129.8, 128.2, 127.4, 123.2, 73.3, 63.1; ESIHRMS calculated for
C20H21N2O [M+H]+, 305.1654; found, 305.1657.
N,N-Dibenzyl-O-(2-azidoacetyl)hydroxylamine (62p).
Following the general procedure C, the title compound 62p was isolated (1.38 g,
65%) as a yellow oil by stirring 63a (1.53 g, 7.17 mmol), 2-azidoacetic acid 67 (1.45 g,
14.35 mmol), and N,N’-dicyclohexylcarbodiimide (2.97 g, 14.35 mmol) for 2 h. Eluent: 0
– 5% of EtOAc in hexane. IR (neat, cm-1) √ 2108, 1765; 1H NMR (400 MHz, CDCl3) δ
7.47 – 7.22 (m, 10H), 4.10 (s, 4H), 3.47 (s, 2H);

13C

NMR (100 MHz, CDCl3) δ 167.6,

135.3, 129.5, 128.5, 128.1, 63.0, 49.5; ESIHRMS calculated for C16H16N4O2Na [M+Na]+,
319.1171; found 319.1169.
N,N-Dibenzyl-O-(3-azidopropionyl)hydroxylamine (62q).
Following the general procedure C, the title compound 62q was isolated (1.30 g,
52%) as a yellow oil by stirring 63a (1.74 g, 8.15 mmol), 3-azidopropionic acid 68 (1.41
g, 12.23 mmol), and N,N’-dicyclohexylcarbodiimide (2.52 g, 12.23 mmol) for 2 h. Eluent:
0 – 10% EtOAc in hexane. IR (neat, cm-1) √ 2098, 1756; 1H NMR (400 MHz, CDCl3) δ
7.40 (d, J = 6.8 Hz, 4H), 7.37 – 7.25 (m, 6H), 4.08 (s, 4H), 3.26 (t, J = 6.7 Hz, 2H), 2.26
(t, J = 6.7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 169.6, 135.7, 129.4, 128.4, 127.8, 62.6,
46.4, 32.4; ESIHRMS calculated for C17H19N4O2 [M+H]+, 311.1508; found 311.1518.
N,N-Dibenzyl-O-(4-azidobutanoyl)hydroxylamine (62r).
Following the general procedure C, the title compound 62r was isolated (813 mg,
72%) as a colorless oil by stirring 63a (687 mg, 3.22 mmol), 4-azidobutyric acid 69 (624
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mg, 4.83 mmol), and N,N’-dicyclohexylcarbodiimide (996 mg, 4.83 mmol) for 2 h. Eluent:
0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2096, 1756; 1H NMR (400 MHz, CDCl3) δ 7.43
– 7.37 (m, 4H), 7.30 (m, 6H), 4.07 (s, 4H), 2.93 (t, J = 6.8 Hz, 2H), 2.09 (t, J = 7.1 Hz,
2H), 1.57 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.2, 135.9, 129.5, 128.3, 127.7, 62.7,
50.0, 29.5, 24.1; ESIHRMS calculated for C18H21N4O2 [M+H]+, 325.1665; found 325.1673.
N,N-Dibenzyl-O-(1-acetoxy-2-azidoethyl)hydroxylamine (65p).
The title compound 65p (298 mg, 86%) was isolated as a colorless oil from 62p
(300 mg, 1.01 mmol) and DIBAL (1.77 mL, 1 M in hexane, 1.77 mmol) by following the
general procedure D. Eluent: 0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2102, 1751; 1H
NMR (400 MHz, CDCl3) δ 7.44 – 7.22 (m, 10H), 5.89 (ap t, J = 4.9 Hz, 1H), 4.01 (br d, J
= 13.1 Hz, 2H), 3.87 (d, J = 13.1 Hz, 2H), 2.96 (m, 2H), 1.83 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 169.7, 136.8, 129.6, 128.4, 127.6, 97.4, 63.1, 51.2, 21.0; ESIHRMS calculated
for C18H20N4O3Na [M+Na]+, 363.1433; found 363.1434.
N,N-Dibenzyl-O-(1-acetoxy-3-azidopropyl)hydroxylamine (65q).
The title compound 65q (210 mg, 61%) was isolated as a colorless oil from 62q
(300 mg, 0.97 mmol) and DIBAL (1.70 mL, 1 M in hexane, 1.70 mmol) by following the
general procedure D. Eluent: 0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2098, 1743; 1H
NMR (400 MHz, CDCl3) δ 7.44 – 7.12 (m, 10H), 5.87 (ap t, J = 5.4 Hz, 1H), 4.04 (br m,
2H), 3.79 (d, J = 13.0 Hz, 2H), 3.00 (dt, J= 12.5, 7.2 Hz 1H), 2.89 (dt, J = 12.5, 7.2 Hz,
1H), 1.87 (s, 3H), 1.72 – 1.53 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 169.9, 136.9, 129.5,
128.4, 127.5, 98.1, 62.9, 46.1, 32.3, 21.1; ESIHRMS calculated for C 19H22N4O3Na
[M+Na]+, 377.1590; found 377.1603.
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N,N-Dibenzyl-O-(1-acetoxy-4-azidobutyl)hydroxylamine (65r).
The title compound 65r (693 mg, 87%) was isolated as a colorless oil from 62r
(700 mg, 2.16 mmol) and DIBAL (3.78 mL, 1 M in hexane, 3.78 mmol) by following the
general procedure D. Eluent: 0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2097, 1741; 1H
NMR (400 MHz, CDCl3) δ 7.44 – 7.16 (m, 10H), 5.80 (dd, J= 6.0, 5.3 Hz, 1H), 4.05 (br m,
2H), 3.77 (d, J = 13.6 Hz, 2H), 3.00 (t, J = 6.6 Hz, 2H), 1.88 (s, 3H), 1.49 – 1.41 (m, 2H),
1.37 – 1.16 (m, 2H);

13C

NMR (100 MHz, CDCl3) δ 170.2, 137.0, 129.4, 128.3, 127.5,

100.0, 63.0, 50.7, 29.9, 23.2, 21.2; ESIHRMS calculated for C 20H24N4O3Na [M+Na]+,
391.1746; found 391.1748.
N,N-Dibenzyl-O-(2-azidoethyl)hydroxylamine (66p).
To an ice-cold solution of 65p (50 mg, 0.15 mmol) in dry dichloromethane (3 mL)
were added Et3SiH (118 μL, 0.74 mmol) and BF3 . OEt2 (90 μL, 0.74 mmol). The ice-bath
was removed and the reaction mixture was allowed to stir for 4 days. After quenching with
saturated aq. NaHCO3, the resultant mixture was extracted with pentane, and the soobtained organic extract was dried over anhydrous Na2SO4. Concentration followed by
the purification of the residue by flash column chromatography on silica gel afforded 66p
(7 mg, 17%) as a yellow oil (eluent: 0 – 5% EtOAc in hexane). IR (neat, cm-1) √ 2102; 1H
NMR (600 MHz, CDCl3) δ 7.43 – 7.21 (m, 10H), 3.88 (s, 4H), 3.38 (t, J = 5.2 Hz, 2H), 2.96
(t, J = 5.2 Hz, 2H); 13C NMR (150 MHz, CDCl3) δ 137.5, 129.7, 128.2, 127.4, 71.6, 62.8,
49.7; ESIHRMS calculated for C16H19N4O [M+H]+, 283.1559; found 283.1567.
N,N-Dibenzyl-O-(3-azidopropyl)hydroxylamine (66q).
Compound 66q (20 mg, 48%) was prepared according to general procedure F
using 65q (50 mg, 0.14 mmol) with warming to room temperature and stirring for an
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additional 24 h. It was isolated as a yellow oil (eluent: 0 – 5% EtOAc in hexane). IR (neat,
cm-1) √ 2096; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.20 (m, 10H), 3.85 (s, 4H), 3.34 (t, J
= 5.9 Hz, 2H), 2.91 (t, J = 7.0 Hz, 2H), 1.51 – 1.41 (m, 2H);

13C

NMR (100 MHz, CDCl3)

δ 137.7, 129.6, 128.2, 127.3, 69.7, 62.7, 48.4, 28.0; ESIHRMS calculated for C17H21N4O
[M+H]+, 297.1715; found 297.1716.
N,N-Dibenzyl-O-(4-azidobutyl)hydroxylamine (66r).
Compound 66r (45 mg, 54%) was prepared according to general procedure F
using 65r (100 mg, 0.27 mmol) with warming to 0 oC and stirring for an additional 3 h. It
was isolated as a yellow oil (eluent: 0 – 5% EtOAc in hexane). IR (neat,cm-1) √ 2095; 1H
NMR (400 MHz, CDCl3) δ 7.42 – 7.36 (m, 4H), 7.36 – 7.24 (m, 6H), 3.85 (s, 4H), 3.28 (t,
J = 5.7 Hz, 2H), 2.95 (t, J = 6.5 Hz, 2H), 1.30 – 1.25 (m, 4H); 13C NMR (100 MHz, CDCl3)
δ 137.8, 129.6, 128.1, 127.2, 72.0, 62.7, 50.9, 25.6, 25.5; ESIHRMS calculated for
C18H23N4O [M+H]+, 311.1872; found 311.1885.
N,N-Dibenzyl-O-(1-phenyl-3-buten-1-yl)hydroxylamine (70a).
A solution of 62a (51 mg, 0.16 mmol) in dry CH2Cl2 (1 mL) was cooled to –78 oC.
A 1 M solution of DIBAL in hexane (0.32 mL, 0.32 mmol), pyridine (39 μL, 0.48 mmol), a
solution of DMAP (39 mg, 0.32 mmol) in dry CH2Cl2 (0.5 mL), and Ac2O (91 μL, 0.96
mmol) were added sequentially, while maintaining the reaction temperature at –78 oC.
The reaction temperature was maintained for the next 12 h and was warmed to 0 oC in
2.5 h. After quenching reaction by the additions of saturated aq. NH4Cl and saturated aq.
sodium potassium tartrate at 0 oC, the resultant mixture was vigorously stirred vigorously
at room temperature for 1 h. Then the mixture was extracted with dichloromethane, and
the obtained organic layer was washed with brine, dried over anhydrous Na2SO4, and
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concentrated. The crude residue 65a was dissolved in dry dichloromethane (3.2 mL) and
cooled to –78 oC. Allyltributylstannane (124 μL, 0.40 mmol) and BF3.OEt2 (51 μL, 0.40
mmol) were added one after the other, and the reaction mixture was warmed to 0oC in
2.5 h. The reaction was quenched by the addition of saturated aq. NaHCO 3 and was
extracted with pentane. Then the obtained organic extract was dried over anhydrous
Na2SO4, concentrated, and purified in flash column chromatography on silica gel (0 – 5%
of EtOAc in hexane). The desired product 70a (45 mg, 82%) was obtained as a colorless
oil. 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.18 (m, 15H), 5.45 – 5.32 (m, 1H), 4.90 – 4.81
(m, 2H), 4.18 (t, J = 7.1 Hz, 1H), 3.83 (d, J = 13.2 Hz, 2H), 3.71 (d, J = 12.7 Hz, 2H), 2.56
– 2.46 (m, 1H), 2.25 – 2.15 (m, 1H);

13C

NMR (100 MHz, CDCl3) δ 141.7, 137.8, 134.7,

129.7, 128.1, 128.0, 127.7, 127.5, 127.2, 116.5, 84.7, 62.5, 39.5; ESIHRMS calculated
for C24H26NO [M+H]+, 344.2014; found, 344.2012.
N-Benzyl-N-methyl-O-(1-phenylbut-3-en-1-yl)hydroxylamine (70b).
A solution of 62b (100 mg, 0.41 mmol) in dry CH2Cl2 (2.5 mL) was cooled to –78
oC.

A 1 M solution of DIBAL in hexane (0.83 mL, 0.83 mmol), pyridine (101 μL, 1.24

mmol), a solution of DMAP (101 mg, 0.83 mmol) in dry CH2Cl2 (1.2 mL), and Ac2O (234
μL, 2.49 mmol) were added sequentially, while maintaining the reaction temperature at –
78 oC. The reaction temperature was maintained for the next 12 h and was warmed 0 oC
in 2.5 h. After quenching reaction by the additions of saturated aq. NH4Cl and saturated
aq. sodium potassium tartrate at 0 oC, the resultant mixture was vigorously stirred at room
temperature for 1 h. Then the mixture was extracted with CH2Cl2, and the obtained
organic extract was washed with brine, dried over anhydrous Na2SO4, and concentrated.
The so-obtained crude intermediate 65b was dissolved in dry CH2Cl2 (8.3 mL) and cooled
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to –78 oC. Allyltributylstannane (322 μL, 1.04 mmol) and BF3.OEt2 (131 μL, 1.04 mmol)
were added one after the other, and the mixture was warmed to 0 oC in 2.5 h. The reaction
was quenched by the addition of saturated aq. NaHCO3 and was extracted with pentane.
Then the obtained organic layer was dried over anhydrous Na 2SO4, concentrated, and
purified in flash column chromatography on silica gel (0 – 5% of EtOAc in hexane). The
desired product 70b (59 mg, 54%) as obtained as a colorless oil. 1H NMR (500 MHz,
toluene-d8, T = 323 K) δ 7.25 – 6.99 (m, 10H), 5.70 – 5.58 (m, 1H), 4.95 – 4.86 (m, 2H),
4.46 (t, J = 6.9 Hz, 1H), 3.66 (s, 2H), 2.62 – 2.53 (m, 1H), 2.40 – 2.25 (m, 4H);

13C

NMR

(125 MHz, toluene-d8, T = 323 K) δ 143.5, 138.5, 135.7, 130.4, 128.7, 128.6, 127.9, 127.8,
117.0, 84.6, 66.1, 45.9, 41.0; ESIHRMS calculated for C18H22NO [M+H]+, 268.1701;
found, 268.1699.
O-(1-(Adamantan-1-yl)but-3-en-1-yl)-N,N-dibenzylhydroxylamine (70c).
A solution of 65h (100 mg, 0.24 mmol) in dry CH2Cl2 (4.8 mL) was cooled to –78
oC.

Allyltributylstannane (186 μL, 0.60 mmol) and BF3.OEt2 (76 μL, 0.60 mmol) were

added sequentially maintaining the reaction temperature at –78 oC, and the reaction was
warmed to 0 oC in 2.5 h. After quenching reaction by the addition of aq. NaHCO 3, the
resultant mixture was extracted with pentane. The so-obtained organic layer was dried
over anhydrous Na2SO4, concentrated, and passed through a small pad of silica buffered
with 2% triethyl amine in 2:98 mixture of EtOAc and hexane (200 mL). Then the filtrate
was concentrated and purified by column chromatography on silica gel (eluent: same
buffered solution of EtOAc in hexane). The desired product 70c (76 mg, 79%) was
isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.21 (m, 10H), 5.88 – 5.77
(m, 1H), 4.93 – 4.82 (m, 2H), 3.90 (d, J = 10.3 Hz, 2H), 3.73 (d, J = 13.2 Hz, 2H), 3.04
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(dd, J = 4.4, 5.3 Hz, 1H), 2.23 – 2.14 (m, 1H), 2.03 – 1.95 (m, 1H), 1.90 (s, 3H), 1.70 –
1.54 (m, 9H), 1.47 – 1.39 (m, 3H);

13C

NMR (100 MHz, CDCl3) δ 139.2, 137.9, 129.8,

128.0, 127.1, 113.9, 87.6, 61.4, 38.6, 37.3, 37.0, 33.4, 28.4; ESIHRMS calculated for
C28H36NO [M+H]+, 402.2797; found, 402.2809.
1-(Dibenzylaminoxy)-4,4-dimethyl-1-phenylpentan-3-one (70d).
A solution of 62a (100 mg, 0.32 mmol) in dry CH2Cl2 (1.9 mL) was cooled to –78
oC.

A 1 M DIBAL solution in hexane DIBAL (0.64 mL, 0.64 mmol), pyridine (78 μL, 0.96

mmol), a solution of DMAP (78 mg, 0.64 mmol) in dry CH2Cl2 (0.9 mL), and Ac2O (182
μL, 1.92 mmol) were added one after the other, while maintaining the reaction
temperature at –78 oC. The reaction temperature was maintained for 12 h at –78 oC, and
then the mixture was warmed to 0 oC in 2.5 h. After quenching the reaction with saturated
aq. NH4Cl (3.2 mL) and saturated aq. sodium potassium tartrate (2.4 mL), the resultant
suspension was vigorously stirred at room temperature for 1 h followed by extraction with
dichloromethane. Then the obtained organic layer was washed with brine, dried over
anhydrous Na2SO4, and concentrated. The so-obtained crude intermediate 65a was
dissolved in dry CH2Cl2 (6.4 mL) was cooled to –78

oC,

and

3,3-dimethyl-2-

(trimethylsilyloxy)butene (173 μL, 0.80 mmol) and BF3.OEt2 (101 μL, 0.80 mmol) were
added sequentially, dropwise. The reaction was then warmed to 0 oC in 2.5 h before
quenching with saturated aq. NaHCO3. The reaction mixture extracted with pentane, and
the organic layer was dried over anhydrous Na2SO4, concentrated, and purified in flash
column chromatography on neutral alumina (10 – 25% of CH2Cl2 in hexane). The desired
product 70d (85 mg, 66%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
7.32 – 7.19 (m, 13H), 7.17 – 7.13 (m, 2H), 4.82 (dd, J = 8.3, 5.4 Hz, 1H), 3.85 (d, J = 12.7
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Hz, 2H), 3.74 (d, J = 12.7 Hz, 2H), 2.80 (dd, J = 16.6, 5.4 Hz, 1H), 2.38 (dd, J = 16.6, 8.3
Hz, 1H), 0.87 (s, 9H);

13C

NMR (100 MHz, CDCl3) δ 213.2, 141.3, 137.5, 129.9, 128.1,

128.0, 127.6, 127.4, 127.2, 79.6, 61.9, 44.1, 42.2, 25.8; ESIHRMS calculated for
C27H32NO2 [M+H]+, 402.2433; found, 402.2431.
N,N-Dibenzyl-O-((5-methylfuran-2-yl)benzyl)hydroxylamine (70e).
A solution of 62a (100 mg, 0.32 mmol) in dry CH2Cl2 (1.9 mL) was cooled to –78
oC,

and DIBAL (0.64 mL, 1 M in hexane, 0.64 mmol), pyridine (78 μL, 0.96 mmol), a

solution of DMAP (78 mg, 0.64 mmol) in dry CH2Cl2 (0.9 mL), and Ac2O (182 μL, 1.92
mmol) were added one after the other maintaining the reaction temperature at –78 oC.
The reaction was allowed to stir for the next 12 h at –78 oC, and was warmed to 0 oC in
2.5 h. After quenching the reaction by the addition of saturated aq. NH4Cl (3.2 mL) and
saturated aq. sodium potassium tartrate (2.4 mL), the resultant suspension was
vigorously stirred at room temperature for 1 h. The mixture was then extracted with
dichloromethane, and the organic layer was washed with brine, dried over anhydrous
Na2SO4, and concentrated. The so-obtained crude intermediate 65a was dissolved in dry
CH2Cl2 (6.4 mL) and cooled to –78 oC. 2-methylfuran (72 μL, 0.80 mmol) and BF3.OEt2
(101 μL, 0.80 mmol) were added sequentially, and the reaction mixture was quenched by
adding saturated aq. NaHCO3 after stirring for 45 min at –78 oC. The resultant suspension
was extracted with pentane, and the organic layer was dried over anhydrous Na2SO4,
concentrated, and purified in flash column chromatography on neutral alumina (0 – 5% of
EtOAc in hexane). Product 70e (63 mg, 51%) was obtained as a colorless oil. 1H NMR
(400 MHz, CDCl3) δ 7.32 – 7.23 (m, 15H), 5.96 (d, J = 2.9 Hz, 1H), 5.87 (dd, J = 2.9, 1.0
Hz, 1H), 5.16 (s, 1H), 3.86 (d, J = 12.7 Hz, 2H), 3.80 (d, J = 12.7 Hz, 2H), 2.26 (d, J = 0.5
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Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 152.2, 151.9, 139.0, 137.8, 129.7, 128.1, 128.0,

127.9, 127.7, 127.1, 110.5, 106.0, 80.3, 62.4, 13.7; ESIHRMS calculated for C26H26NO2
[M+H]+, 384.1964; found, 384.1965.
N,N-Dibenzyl-O-(1-(5-methylfuran-2-yl)-4-phenylbutyl)hydroxylamine (70f).
A solution of 65g (50 mg, 0.12 mmol) in dry CH2Cl2 (2.5 mL) was cooled to –78 oC.
2-methylfuran (28 μL, 0.31 mmol) and BF3.OEt2 (40 μL, 0.31 mmol) were added one after
the other maintaining the reaction temperature at –78 oC. The reaction was warmed to 0
oC

in 2.5 h and was quenched by adding saturated aq. NaHCO3. The resultant suspension

was extracted with pentane, and the organic layer was dried over anhydrous Na 2SO4, and
concentrated. On purification of the residue by flash column chromatography on neutral
alumina (0 – 5% of EtOAc in hexane), product 70f (11 mg, 20%) was obtained as a
colorless oil along with the recovered starting material 65g (35 mg, 70%). 1H NMR (400
MHz, CDCl3) δ 7.32 – 7.19 (m, 12H), 7.16 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 6.9 Hz, 2H),
6.06 (d, J = 2.9 Hz, 1H), 5.87 – 5.85 (m, 1H), 4.12 (t, J = 7.1 Hz, 1H), 3.78 (d, J = 12.7
Hz, 2H), 3.62 (d, J = 13.2 Hz, 2H), 2.45 – 2.30 (m, 2H), 2.24 (s, 3H), 1.76 – 1.64 (m, 1H),
1.61 – 1.49 (m, 1H), 1.44 – 1.31 (m, 1H), 1.30 – 1.13 (m, 1H); 13C NMR (100 MHz, CDCl3)
δ 153.1, 151.4, 142.3, 137.9, 129.6, 128.4, 128.1, 128.0, 127.1, 125.5, 109.1, 105.9, 77.7,
62.4, 35.4, 31.6, 27.2, 13.6; ESIHRMS calculated for C29H32NO2 [M+H]+, 426.2433;
found, 426.2426.
(R)-N,N-Dibenzyl-O-(2-methyl-3-phenylpropanoyl)hydroxylamine (72).
To an ice-cold solution (<5 oC) of 71 (1 g, 3.09 mmol) in THF-H2O (3:1, 48 mL)
were added LiOH.H2O (0.26 g, 6.18 mmol) and H2O2 (3.50 g, 30 wt% in water, 30.90
mmol). After stirring for 2 h at room temperature, the reaction flask was cooled in ice-bath
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(<5 oC), and the reaction was quenched with Na2SO3 (30 mL 1.5 M in water, 45.00 mmol).
The volatile organic components were evaporated in a rotary evaporator (<25 oC bath
temperature), and the aqueous residue was washed out with CH2Cl2 to discard non-polar
impurities. Then the aqueous layer was cooled in an ice-bath (<5 oC), acidified to pH 1 by
addition of 2 M HCl, saturated with NaCl, and extracted with ether. The ether extract was
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The soobtained crude intermediate acid was dissolved in dry CH2Cl2 (20 mL) together with N,Ndibenzylhydroxylamine 63a (0.99 g, 4.64 mmol) and the resulting solution was cooled in
an ice-bath (<5 oC). To this solution were added HOBt (0.78 g wetted with 20 wt% water,
4.64 mmol), EDCI.HCl (0.89 g, 4.64 mmol), and DIPEA (0.81 mL, 4.64 mmol), and the
reaction was allowed to stir for 4 h at room temperature. The mixture was washed with
water followed by brine, dried over anhydrous Na 2SO4, concentrated under reduced
pressure, and purified by flash column chromatography on silica gel (0 – 5% EtOAc in
hexane) to give 72 (0.96 g, 87%) as a colorless oil. [α]20D –8.7 (c 0.9, CHCl3); 1H NMR
(400 MHz, CDCl3) δ 7.43 – 7.13 (m, 13H), 7.05 (d, J = 7.7 Hz, 2H), 3.99 (ABq, J = 13.4
Hz, 4H), 2.73 (dd, J = 13.1, 6.7 Hz, 1H), 2.54 – 2.44 (m, 1H), 2.40 (dd, J = 13.1, 7.6 Hz,
1H), 0.82 (d, J = 6.8 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 174.1, 139.3, 135.9, 129.4,

129.0, 128.3, 128.2, 127.6, 126.3, 62.1, 40.2, 39.3, 16.6; ESIHRMS calculated for
C24H25NO2Na [M+Na]+, 382.1783; found, 382.1798.
(2R)-N,N-Dibenzyl-O-(1-acetoxy-2-methyl-3-phenylpropyl)hydroxylamine (73).
A solution of 72 (200 mg, 0.56 mmol) in dry CH2Cl2 (3.5 mL) was chilled at –78 oC.
A 1 M DIBAL solution in hexane (0.98 mL, 0.98 mmol), pyridine (135 μL, 1.68 mmol), a
solution of DMAP (137 mg, 1.12 mmol) in dry CH2Cl2 (1.5 mL), and Ac2O (317 μL, 3.36
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mmol) were added one after the other, while maintaining the reaction temperature at –78
oC

. The reaction temperature was maintained for next 12 h at –78 oC, and then it was

warmed to 0 oC in 2.5 h followed by the addition of saturated aq. NH4Cl (5 mL) and
saturated aq. sodium potassium tartrate (4 mL). The resultant suspension was vigorously
stirred for 1 h, and was extracted with CH2Cl2. The organic extract was washed with brine,
dried

over anhydrous Na2SO4,

concentrated, and purified by flash

column

chromatography on silica gel (0 – 5% EtOAc in hexane). The desired product 73 (145 mg,
65%, dr 56:44) was obtained as a colorless oil. [α]20D +7.2 (c 2, CH2Cl2); 1H NMR (400
MHz, CDCl3), both diastereomers, δ 7.48 – 6.96 (m, 15H), 5.91 (d, J = 4.7 Hz, 0.44H),
5.87 (d, J = 4.7 Hz, 0.56H), 4.02 (br s, 1.76H), 3.88 – 3.80 (m, 2.24H), 2.74 (dd, J = 13.5,
4.3 Hz, 0.56H), 2.58 (dd, J = 13.6, 4.1 Hz, 0.44H), 2.11 (dd, J = 13.6, 10.6 Hz, 0.44H),
1.99 (dd, J = 13.5, 10.3 Hz, 0.56H), 1.92 – 1.78 (m, 4H), 0.71 – 0.60 (m, 3H);

13C

NMR

(100 MHz, CDCl3), both diastereomers, δ 170.4, 170.4, 140.4, 140.3, 137.1, 129.5, 129.0,
129.0, 128.3, 128.2, 127.4, 125.8, 125.8, 102.0, 62.6, 38.5, 38.3, 37.3, 37.2, 21.20, 21.17,
13.6, 13.3; ESIHRMS calculated for C26H29NO3Na [M+Na]+, 426.2045; found, 426.2044.
N,N-Dibenzyl-O-((2R)-2-methyl-1-phenylhex-5-en-3-yl)hydroxylamine (74).
To a stirred solution of 73 (100 mg, 0.25 mmol) in dry CH2Cl2 (5 mL) were added
allyltributylstannane (194 μL, 0.63 mmol) and BF3.OEt2 (77 μL, 0.63 mmol) one after the
other at -78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched by
saturated aq. NaHCO3, and extracted with CH2Cl2. The organic extract was dried over
anhydrous Na2SO4, concentrated, and purified by flash column chromatography on silica
gel (0 – 4% EtOAc in hexane). The desired product 74 (83 mg, 87%) was isolated as a
colorless oil and was revealed as a mixture of two diastereomers 74a (minor) and 74b
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(major) in a ratio of 1:1.2 (74a:74b) from the NMR spectra. [α]20D –0.6 (c 3.25, CHCl3);
1H

NMR (600 MHz, CDCl3), both diastereomers, δ 7.63 – 6.84 (m, 15H), 5.67 – 5.53 (m,

1H), 5.01 – 4.87 (m, 2H), 4.00 – 3.71 (m, 4H), 3.43 (td, J = 6.3, 3.6 Hz, 0.55H), 3.37 (dt,
J = 6.8, 4.9 Hz, 0.45H), 2.65 (dd, J = 13.4, 4.4 Hz, 0.55H), 2.60 (dd, J = 13.6, 6.0 Hz,
0.45H), 2.32 (dt, J = 14.0, 6.3 Hz, 0.55H), 2.26 (dd, J = 13.4, 10.5 Hz, 0.55H), 2.16 (dd,
J = 13.6, 9.0 Hz, 0.45H), 2.13 – 2.08 (m, 0.90H), 2.02 – 1.89 (m, 1.55H), 0.69 (d, J = 6.9
Hz, 1.65H), 0.57 (d, J = 6.8 Hz, 1.35H); 13C NMR (150 MHz, CDCl3) both diastereomers,
δ 141.6, 141.5, 137.8, 136.2, 136.0, 129.7, 129.7, 129.6, 129.04, 129.02, 128.10, 128.09,
128.06, 128.04, 127.2, 127.1, 125.6, 125.5, 116.0, 115.9, 83.71, 83.69, 62.2, 62.1, 39.1,
38.9, 36.5, 36.4, 34.6, 33.3, 14.2, 13.6; ESIHRMS calculated for C27H32NO [M+H]+,
386.2484; found, 386.2485.
N,N-Dibenzyl-O-((3R)-3-methyl-4-phenylbutan-2-yl)hydroxylamine (75).
To a stirred solution of 73 (40 mg, 0.10 mmol) in dry CH2Cl2 (2 mL) were added
Me2Zn (250 μL, 1 M in heptane, 0.25 mmol) and BF3.OEt2 (31 μL, 0.25 mmol) one after
the other at -78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched
by slow addition of saturated aq. NaHCO3, and extracted with pentane. The organic
extract was dried over anhydrous Na2SO4, concentrated, and purified by flash column
chromatography on silica gel (0 – 5% EtOAc in hexane). Product 75 (28 mg, 77%) was
isolated as a colorless oil and was revealed as an uncharacterized mixture of two
diastereomers in a ratio of 1:1. [α]20D +2.1 (c 1.25, CHCl3); 1H NMR (600 MHz, CDCl3),
both diastereomers, δ 7.47 – 6.98 (m, 15H), 4.00 – 3.73 (m, 4H), 3.44 (dq, J = 6.3, 3.6
Hz, 0.48H), 3.34 (dq, J = 6.5, 4.1 Hz, 0.52H), 2.73 (dd, J = 13.4, 3.9 Hz, 0.48H), 2.52 (dd,
J = 13.6, 6.0 Hz, 0.52H), 2.16 (dd, J = 13.5, 10.8 Hz, 0.48H), 2.12 (dd, J = 13.7, 9.2 Hz,
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0.52H), 1.98 – 1.89 (m, 0.52H), 1.90 – 1.80 (m, 0.48H), 0.89 (d, J = 6.3 Hz, 1.44H), 0.85
(d, J = 6.4 Hz, 1.56H), 0.66 (d, J = 6.9 Hz, 1.44H), 0.60 (d, J = 6.8 Hz, 1.56H); 13C NMR
(150 MHz, CDCl3), both diasteromers, δ 141.8, 141.4, 137.9, 129.8, 129.7, 129.1, 128.9,
128.10, 128.06, 128.02, 127.2, 127.1, 125.6, 125.5, 80.6, 80.1, 62.7, 62.5, 39.7, 39.0,
38.1, 37.9, 15.4, 14.6, 14.1, 13.7; ESIHRMS calculated for C25H30NO [M+H]+, 360.2327;
found, 360.2325.
1-Boc-1-methyl-2,2-dibenzylhydrazine (77).
A mixture of N-Boc-N-methylhydrazine (1 g, 6.84 mmol), NaHCO3 (1.44 g, 17.10
mmol), BnBr (2.03 mL, 17.10 mmol), DMF (2 mL), and toluene (6 mL) was stirred for 21
h at 85 oC. The reaction was cooled to room temperature, diluted with toluene, washed
with water followed by brine, dried over anhydrous Na 2SO4, and concentrated under
reduced pressure. The residue was purified by flash column chromatography on silica gel
(0 ‒ 8% EtOAc in hexane) to give 77 (1.88 g, 84%) as a colorless oil. 1H NMR (400 MHz,
CDCl3) δ 7.51 – 7.01 (m, 10H), 4.34 (d, J = 11.3 Hz, 1H), 4.01 (d, J = 12.0 Hz, 2H), 3.87
(d, J = 12.5 Hz, 1H), 2.69 (s, 3H, rotamer), 2.45 (s, 3H, rotamer), 1.47 (s, 9H);

13C

NMR

(100 MHz, CDCl3) δ 156.3, 154.9, 138.5, 137.9, 129.4, 129.3, 128.1, 127.3, 79.8, 79.6,
58.1, 57.6, 39.2, 32.3, 28.6; ESIHRMS calculated for C20H26N2O2Na [M+Na]+, 349.1892;
found, 349.1898.
1,1-Dibenzyl-2-methylhydrazine (78).
Trifluoroacetic acid (15 ml) was added dropwise to a solution of 77 (940 mg, 2.88
mmol) in CH2Cl2 (15 mL) at 0 oC. After stirring for 1 h at 0 oC and 1 h at room temperature,
more trifluoroacetic acid (5 mL) was added dropwise. The stirring was continued for the
next 2 h at room temperature, and the mixture was concentrated. The residue was
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dissolved in CH2Cl2 (10 mL), washed with 1 N NaOH followed by brine, dried over
anhydrous Na2SO4, and concentrated to give desired product 78 (652 mg, 100% yield)
as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.23 (m, 10H), 3.79 (s, 4H), 2.66 (br
s, 1H), 2.56 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.4, 128.9, 128.3, 127.1, 59.4, 35.1;
ESIHRMS calculated for C15H19N2 [M+H]+, 227.1548; found, 227.1545.
N',N'-Dibenzyl-N-methyl-4-phenylbutanehydrazide (79).
To a stirred solution of 78 (347 mg, 1.53 mmol), 4-phenylbutyric acid (251 mg,
1.53 mmol), and DMAP (38 mg, 0.31 mmol) in dry dichloromethane (15 mL) was added
DCC (316 mg, 1.53 mmol) at room temperature. The reaction mixture was allowed to stir
for 2 h and filtered through a pad of Celite®. The resulting filtrate was concentrated and
purified by flash column chromatography on silica gel (0 ‒ 10% EtOAc in hexane) to
afford 79 (549 mg, 96% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.06
(m, 15H), 3.81 (ABq, J = 12.8 Hz, 4H), 3.06 (s, 3H), 2.39 (t, J = 7.6 Hz, 2H), 2.16 (t, J =
7.7 Hz, 2H), 1.60 – 1.43 (m, 2H);

13C

NMR (100 MHz, CDCl3) δ 176.0, 142.3, 136.4,

129.5, 129.4, 128.6, 128.2, 127.9, 125.7, 57.8, 35.5, 31.3, 26.2, 24.0; ESIHRMS
calculated for C25H28N2ONa [M+Na]+, 395.2099; found, 395.2105.
1,1-Dibenzyl-2-methyl-2-(4-phenylbutyl)hydrazine

(81)

and

N',N'-dibenzyl-N-

methylacetohydrazide (82).
To a stirred solution of 79 (93 mg, 0.25 mmol) in dry dichloromethane (1.5 mL)
was added DIBAL (0.38 mL 1 M in cyclohexane, 0.38 mmol) dropwise at -78 oC. The
reaction mixture was stirred for 30 min, and pyridine (60 µL, 0.75 mmol), a solution of
DMAP (61 mg, 0.50 mmol) in dry dichloromethane (0.7 mL), and acetic anhydride (142
µL, 1.5 mmol) were sequentially added. The reaction temperature was maintained at -78
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oC

for 12 h and allowed to warm to 0 oC in 2.5 h. After addition of saturated aq. NH4Cl

(2.5 mL) and saturated aq. Rochelle’s salt (2 mL), the resulting suspension was stirred
vigorously at room temperature. The suspension was extracted with dichloromethane and
the obtained organic extract was dried over anhydrous Na2SO4, concentrated, and
purified by flash column chromatography on silica gel (0 ‒ 60% EtOAc in hexane). Two
unknown products were isolated, which were characterized as 81 (30 mg colorless oil,
33% yield) and 82 (20 mg colorless oil, 30% yield) from NMR analysis.
Data for 81; 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.05 (m, 15H), 3.64 (s, 4H), 2.56
(t, J = 6.4 Hz, 2H), 2.51 – 2.45 (m, 2H), 2.42 (s, 3H), 1.49 – 1.34 (m, 4H); 13C NMR (100
MHz, CDCl3) δ 142.9, 140.2, 129.0, 128.5, 128.1, 128.0, 126.6, 125.5, 54.4, 53.1, 35.8,
35.4, 28.9, 27.4; ESIHRMS calculated for C25H31N2O [M+H]+, 359.2487; found, 359.2498.
Data for 82; 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.18 (m, 10H), 3.82 (ABq, J =
12.7 Hz, 4H), 3.03 (s, 3H), 1.72 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 174.0, 136.4, 129.4,
128.6, 127.9, 57.9, 23.9, 20.7; ESIHRMS calculated for C17H20N2ONa [M+Na]+, 291.1473;
found, 291.1471.
Alternative synthesis of 1,1-dibenzyl-2-methyl-2-(4-phenylbutyl)hydrazine (81).
To a stirred solution of 79 (50 mg, 0.13 mmol) in dry dichloromethane (1 mL) was
added DIBAL (0.39 mL 1 M in cyclohexane, 0.39 mmol) dropwise at -78 oC. The reaction
mixture was warmed to 0 oC in 2.5 h and quenched with saturated aq. NH4Cl (2 mL) and
saturated aq. Rochelle’s salt (1.5 mL). The resulting suspension was stirred vigorously at
room temperature and extracted with dichloromethane. The so-obtained organic extract
was dried over anhydrous Na2SO4, concentrated, and purified by flash column
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chromatography on silica gel (0 ‒ 5% EtOAc in hexane) to afford 81 (31 mg, 65% yield)
as a colorless oil. The spectral data were identical with above sample.
1,1-Dibenzyl-2-methyl-2-(7-phenylhept-1-en-4-yl)hydrazine (83).
To an ice-cold (<5 oC) solution of 79 (60 mg, 0.16 mmol) and allyltributylstannane
(150 µL, 0.48 mmol) in dry dichloromethane (1 mL) was added DIBAL (0.20 mL 1M DIBAL
in hexane, 0.20 mmol) dropwise. After stirring for 5 min, BF3.OEt2 (59 µL, 0.48 mmol) was
added dropwise and the ice-bath was removed. The reaction was allowed to stir for 16 h
at room temperature, and then quenched by adding saturated aq. NH 4Cl (2 mL) and
saturated Rochelle’s salt (1.5 mL). The resulting suspension was stirred vigorously for 1
h and was extracted with dichloromethane. The so-obtained organic extract was
concentrated and purified by thin layer chromatography on silica gel (0 ‒ 5% EtOAc in
hexane) to give 83 (20 mg, 31% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
7.37 – 7.02 (m, 15H), 5.49 (ddt, J = 17.1, 10.1, 7.0 Hz, 1H), 4.96 – 4.81 (m, 2H), 3.64
(ABq, J = 13.1 Hz, 4H), 2.65 – 2.56 (m, 1H), 2.52 – 2.33 (m, 6H), 2.08 – 1.96 (m, 1H),
1.58 – 1.42 (m, 1H), 1.38 – 1.19 (m, 3H).

13C

NMR (100 MHz, CDCl3) δ 142.8, 139.8,

137.0, 129.4, 128.4, 128.1, 127.9, 126.7, 125.5, 115.4, 62.7, 55.0, 36.1, 34.8, 30.4, 29.9,
26.8; ESIHRMS calculated for C28H35N2 [M+H]+, 399.2800; found, 399.2804.
N',N'-Dibenzyl-N-methylbenzohydrazide (84).
To a stirred solution of 78 (227 mg, 1.23 mmol), benzoic acid (173 mg, 1.41 mmol),
and DMAP (31 mg, 0.25 mmol) in dry dichloromethane (12 mL) was added DCC (291
mg, 1.41 mmol) at room temperature. The reaction mixture was allowed to stir for 12 h
and filtered through a pad of Celite®. The resulting filtrate was concentrated and purified
by flash column chromatography on silica gel (10 ‒ 40% EtOAc in hexane) to afford 84
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(327 mg, 81% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.12 (m, 9H),
6.99 (d, J = 7.0 Hz, 4H), 6.83 (d, J = 7.6 Hz, 2H), 3.99 – 3.72 (ABq, J = 13.0 Hz, 4H), 3.26
(s, 3H);

13C

NMR (100 MHz, CDCl3) δ 173.7, 137.0, 136.0, 129.3, 128.7, 128.4, 127.8,

127.2, 127.0, 57.4, 25.0; ESIHRMS calculated for C22H22N2ONa [M+Na]+, 353.1630;
found, 363.1622.
1,1,2-Tribenzyl-2-methylhydrazine (85).
To a stirred solution of 84 (50 mg, 0.15 mmol) in dry dichloromethane (1 mL) was
added DIBAL (0.45 mL 1 M in hexane, 0.45 mmol) dropwise at -78 oC. The reaction
mixture was warmed to 0 oC in 2.5 h and quenched with saturated aq. NH4Cl (2 mL) and
saturated aq. Rochelle’s salt (1.5 mL). The resulting suspension was stirred vigorously at
room temperature and extracted with dichloromethane. The so-obtained organic extract
was dried over anhydrous Na2SO4, concentrated, and purified by flash column
chromatography on silica gel (0 ‒ 5% EtOAc in hexane) to afford 85 (29 mg, 61% yield)
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.14 (m, 13H), 7.11 – 6.98 (m, 2H),
3.83 (s, 2H), 3.77 (s, 4H), 2.38 (s, 3H);

13C

NMR (100 MHz, CDCl3) δ 140.0, 139.4,

128.82, 128.82, 128.02, 127.99, 126.7, 126.6, 58.8, 53.7, 35.4; ESIHRMS calculated for
C22H25N2 [M+H]+, 317.2018; found, 317.2029.
N,N'-Dimethyl-4-phenyl-N'-(4-phenylbutanoyl)butanehydrazide (86).
To a stirred solution of sym-dimethylhydrazine dihydrochloride (100 mg, 0.75
mmol) and 4-phenylbutyric acid (309 mg, 1.88 mmol) in dry dichloromethane (8 mL) was
added triethylamine (230 µL, 1.65 mmol) dropwise at room temperature. After stirring for
5 min, DMAP (37 mg, 0.30 mmol) and DCC (389 mg, 1.88 mmol) were added and the
reaction mixture was stirred for next 5 h. The reaction was filtered through a pad of
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Celite®, and the resulting filtrate was washed with saturated aq. NaHCO3 and brine, dried
over anhydrous Na2SO4, and concentrated. After purification via flash column
chromatography on silica gel (20 ‒ 60% EtOAc in hexane), the desired hydrazide 86 (181
mg, 69% yield) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.03
(m, 10H), 3.04 (s, 6H), 2.62 (t, J = 7.6 Hz, 4H), 2.19 (t, J = 7.4 Hz, 4H), 2.00 – 1.86 (m,
4H);

13C

NMR (100 MHz, CDCl3) δ 174.6, 141.2, 128.6, 128.4, 126.1, 35.0, 33.5, 30.6,

25.9; ESIHRMS calculated for C22H28N2O2Na [M+Na]+, 375.2048; found, 375.2052.
1,2-Dimethyl-1,2-bis(4-phenylbutyl)hydrazine (87).
To a stirred solution of 86 (50 mg, 0.14 mmol) in dry dichloromethane (1.7 mL)
was added DIBAL (0.84 mL 1 M in hexane, 0.84 mmol) dropwise at -78 oC. The reaction
mixture was warmed to 0 oC in 2.5 h and quenched with saturated aq. NH4Cl (3 mL) and
saturated aq. Rochelle’s salt (2 mL). The resulting suspension was stirred vigorously at
room temperature and extracted with dichloromethane. The so-obtained organic extract
was dried over anhydrous Na2SO4, concentrated, and purified by flash column
chromatography on silica gel (0 ‒ 20% EtOAc in hexane) to afford 87 (21 mg, 46% yield)
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.06 (m, 10H), 2.62 (t, J = 7.7 Hz,
4H), 2.46 (t, J = 7.1 Hz, 4H), 2.23 (s, 3H), 1.72 – 1.58 (m, 4H), 1.58 – 1.45 (m, 4H);

13C

NMR (100 MHz, CDCl3) δ 142.8, 128.4, 128.2, 125.6, 53.8, 35.9, 34.6, 29.3, 27.7;
ESIHRMS calculated for C22H33N2 [M+H]+, 325.2644; found, 325.2640.
Experimental section for chapter 3
VT-NMR study of nitrogen inversion in N-hydroxy and N-alkoxypiperidines:
Variable temperature (VT) NMR spectroscopy technique was used to determine
inversion barriers for the compounds 91, 92, 94, and 88.

1H

NMR spectra for each
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compound were recorded in 500 MHz instrument over the temperature range of 223 K to
363 K in Toluene-d8 and 233 K to 363 K in DMF-d7 (233 K to 393 K for 93 and 88). Eyring
equation (1) was applied to calculate inversion barriers.
∆GC≠ = 4.575 x 10-3 TC[9.972 + log (TC/∆v)]

(1)

Table 9. Inversion barriers of N-alkoxy and N-hydroxypiperidines.
Entry

Compound

Inversion barrier (∆GC≠) in kcal.mol-1
Tolune-d8 (NMR solvent)

DMF-d8 (NMR solvent)

13.26

12.91

15.88

15.88

No coalescence below

No coalescence below

363 K

393 K

15.34

15.42

16.42

16.42

1

2

3

4

5
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Figure 36. 1H NMR spectra (Toluene-d8) of 94 recorded at variable temperatures
ranging from 223 K to 303 K (2.50 to 3.30 ppm). Tc is coalescence temperature for H-2.

H-2
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293 K
TC =283 K
273 K
263 K
253 K
243 K
233 K
223 K

∆v = 151.46 Hz
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Figure 37. 1H NMR spectra (DMF-d7) of 94 recorded at variable temperatures ranging
from 233 K to 283 K (2.40 to 3.20 ppm). Tc is coalescence temperature for H-2.
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283 K

273 K
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253 K

243 K

233 K
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Figure 38. 1H NMR spectra (Toluene-d8) of 91 recorded at variable temperatures
ranging from 223 K to 363 K (1.90 to 3.50 ppm). Tc is coalescence temperature for H-2.
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Figure 39. 1H NMR spectra (DMF-d7) of 91 recorded at variable temperatures ranging
from 263 K to 283 K (1.90 ppm 3.50 ppm). Tc is coalescence temperature for H-2.
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Figure 40. 1H NMR spectra (Toluene-d8) of 92 recorded at variable temperatures
ranging from 253 K to 343 K (2.80 to 4.00 ppm). Tc is coalescence temperature for H-4.
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Figure 41. 1H NMR spectra (DMF-d7) of 92 recorded at variable temperatures ranging
from 253 K to 343 K (3.80 to 4.90 ppm). Tc is coalescence temperature for H-4.
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Figure 42. 1H NMR spectra (Toluene-d8) of 88 recorded at variable temperatures
ranging from 233 K to 363 K (0.05 to 4.00 ppm). Tc is coalescence temperature for H-2.
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Figure 43. 1H NMR spectra (DMF-d7) of 88 recorded at variable temperatures ranging
from 233 K to 363 K (0.05 to 0.40 ppm). Tc is coalescence temperature for H-2.
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Figure 44. 1H NMR (500 MHz, DMF-d7, T = 393 K) spectrum of (88)

H-3

H-2

H-4

-OH

Experimental section for chapter 4
Synthesis of Kalkitoxin (107):
(R)-4-Benzyl-3-(4-(benzyloxy)butanoyl)oxazolidin-2-one (121).
Triethylamine (4.17 mL, 29.68 mmol) was added dropwise to a solution of acid
119145 in ether (220 mL), and the mixture was stirred for 20 min at room temperature. The
reaction flask was cooled in ice-bath and ethyl chloroformate (2.46 mL, 25.74 mmol) was
added slowly. After stirring for 1 h at room temperature, the resulting suspension was
cooled to −78 oC. In a separate flask n-BuLi (12.5 mL, 2.5 M in hexanes, 31.25 mmol)
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was added dropwise to a solution of (4R)-benzyloxazolidinone (4.56 g, 25.74 mmol) in
THF (40 mL) at −78 °C. The resulting mixture was stirred for 30 min and was transferred
to a reaction flask containing acid 119 via cannula. After stirring for 1 h at −78 oC, the
reaction was allowed to warm to room temperature in 2.5 h and quenched with halfsaturated aq. NH4Cl (200 mL). The organic phase was separated, and the aqueous phase
was extracted with ether. The combined organic phase was washed with brine, dried over
anhydrous Na2SO4, and concentrated. Purification of the residue by flash column
chromatography on silica gel (10 – 20% EtOAc in hexane) afforded 121169 (6.07 g, 67%
yield) as a colorless oil. [α]20D –46.8 (c 1, CHCl3); lit169 [α]20D –42.8 (c 1, CHCl3); 1H NMR
(400 MHz, CDCl3) δ 7.43 – 7.10 (m, 10H), 4.66 – 4.56 (m, 1H), 4.51 (s, 2H), 4.16 – 4.03
(m, 2H), 3.59 (t, J = 6.2 Hz, 2H), 3.26 (dd, J = 13.4, 3.3 Hz, 1H), 3.07 (t, J = 7.2 Hz, 2H),
2.70 (dd, J = 13.4, 9.6 Hz, 1H), 2.10 – 1.98 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 173.1,
153.5, 138.5, 135.4, 129.4, 128.9, 128.4, 127.7, 127.6, 127.3, 72.9, 69.2, 66.1, 55.2, 37.9,
32.5, 24.5.
(R)-4-Benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl)oxazolidin-2-one (122).
To a stirred solution of 121 (12.46 g, 35.26 mmol) in dry THF (50 mL) was added
NaHMDS (50 mL, 1 M in THF, 50.00 mmol) via cannula dropwise at −78 oC. The reaction
mixture was stirred for 1 h at −78 oC and methyl iodide (10.97 mL, 176. 30 mmol) was
added dropwise. After stirring for 3 h at −78 oC, the reaction was quenched with acetic
acid (2.5 mL), and the resulting mixture was warmed to room temperature and extracted
with EtOAc. The so-obtained organic extract was washed with brine, dried over
anhydrous Na2SO4, and concentrated. Purification was performed via flash column
chromatography on silica gel (10 – 15% EtOAc in hexane) to isolated 122169 (10.87 g,
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84% yield, dr 95:5) as a colorless oil. [α]20D –61.6 (c 1, CHCl3); lit169 [α]20D –81.3 (c 1,
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.09 (m, 10H), 4.53 – 4.31 (m, 3H), 4.01 –
3.86 (m, 2H), 3.73 (t, J = 8.4, 1H), 3.61 – 3.46 (m, 2H), 3.19 (dd, J = 13.4, 3.4 Hz, 1H),
2.71 (dd, J = 13.4, 9.6 Hz, 1H), 2.25 – 2.18 (m, 1H), 1.82 – 1.67 (m, 1H), 1.25 (d, J = 6.9
Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 177.1, 153.3, 138.5, 135.4, 129.4, 128.8, 128.3,

127.6, 127.5, 127.2, 72.8, 68.5, 65.8, 55.2, 38.0, 35.1, 33.6, 18.1.
(2R)-4-Benzyloxy-2-methylbutanol (123).
To an ice-cold solution of 122 (10.50 g, 28.58 mmol) in anhydrous diethyl ether
(275 mL) was added dry ethanol (2.5 mL, 42.86 mmol) and lithium borohydride (0.93 g,
42.86 mmol) portion wise. After stirring for 2 h in ice-bath, the reaction was quenched by
slow addition of 1 N NaOH (200 mL). The resulting mixture was stirred for 10 min at room
temperature and was extracted with ether. The ether extract was washed with saturated
aq. NH4Cl, water, and brine and dried over Na2SO4. After concentration, the resulting
residue was purified by flash column chromatography (20 – 30% EtOAc in hexane) to
afford the desired alcohol 12399 (4.99 g, 90% yield) as a colorless oil. [α]20D +10.5 (c 1,
CHCl3); lit99 [α]20D +10.4 (c 7.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.18 (m, 5H),
4.52 (s, 2H), 3.66 – 3.32 (m, 4H), 2.64 (br s, 1H), 1.86 – 1.75 (m, 1H), 1.75 – 1.64 (m,
1H), 1.62 – 1.51 (m, 1H), 0.92 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCL3) δ 138.0,
128.5, 127.8, 127.7, 73.2, 68.7, 68.1, 34.1, 34.0, 17.2.
(2R)-4-Benzyloxy-1-bromo-2-methylbutane (113).
To an ice-cold solution of 123 (5 g, 25.74 mmol) in dry dichloromethane was added
CBr4 (8.95 g, 27.03 mmol) and PPh3 (7.06 g, 27.03 mmol). After stirring for 30 min in icebath and 1 h at room temperature, the reaction mixture was concentrated, and the residue
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was dropped in the stirring hexane (50 mL). The resulting white suspension was filtered,
and the resulting filtrate was concentrated. After purification of the resulting residue by
flash column chromatography on silica gel (0 – 5% EtOAc in hexane), compound 11399
(6.16 g, 93% yield) was isolated as a colorless oil. [α]20D –4.5 (c 1, CHCl3); lit99 [α]20D –4.7
(c 0.32, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.21 (m, 5H), 4.51 (s, 2H), 3.56 –
3.49 (m, 2H), 3.44 (dd, J = 9.9, 4.6 Hz, 1H), 3.37 (dd, J = 9.9, 5.8 Hz, 1H), 2.12 – 1.95
(m, 1H), 1.87 – 1.72 (m, 1H), 1.64 – 1.47 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H); 13C NMR (100
MHz, CDCl3) δ 138.4, 128.4, 127.62, 127.60, 73.0, 67.8, 41.6, 34.6, 32.1, 18.7.
(3’S,4S,5’S)-3-(7’-Benzyloxy-3’,5’-dimethylheptanoyl)-4-phenyloxazolidin-2-one
(126).
To a suspension of magnesium (2.25 g, 61.70 mmol) in dry THF (12 mL) was
added a solution of 113 (2.66 g, 10.34 mmol) in dry THF (3 mL) at room temperature. A
DIBAL solution (1.56 mL, 1 M in THF, 1.56 mmol) was added dropwise and stirred
vigorously for 20 min. This solution was added to a chilled suspension of CuBr.DMS (2.04
g, 10.34 mmol) in dry THF (12 mL) at −78 oC. The resulting suspension was warmed
slowly to −20 oC, stirred for 25 min, and cooled back again to −78 oC. A solution of (S)-N(trans-crotonyl)-4-phenyloxazolidin-2-one 125 in dry THF (9 mL) was added dropwise,
and the stirring was continued for 2.5 h at −78 oC. Then the reaction mixture was warmed
slowly to −30 oC, quenched with saturated aq. NH4Cl, and extracted with ether. This ether
extract was washed with brine, dried over anhydrous Na 2SO4, and concentration.
Purification of the residual oil by flash column chromatography on silica gel (10 – 20%
EtOAc in hexane) gave 12699 (1.19 g, 80% yield, dr 85:15) as a colorless oil. [α]20D +29.5
(c 3, CHCl3); lit99 [α]20D +20.0 (c 2.3, CHCl3) for pure 126; 1H NMR (400 MHz, CDCl3) δ
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7.44 – 7.22 (m, 10H), 5.42 (dd, J = 8.7, 3.6 Hz, 1H), 4.67 (t, J = 8.7 Hz, 1H), 4.48 (s, 2H),
4.26 (dd, J = 9.0, 3.9 Hz, 1H), 3.46 (td, J = 6.7, 1.9 Hz, 2H), 2.92 (dd, J = 15.9, 5.4 Hz,
1H), 2.72 (dd, J = 15.9, 8.1 Hz, 1H), 2.17 – 2.02 (m, 1H), 1.71 – 1.50 (m, 2H), 1.46 – 1.35
(m, 1H), 1.18 (ddd, J = 13.5, 9.6, 4.5 Hz, 1H), 1.05 (ddd, J = 13.8, 9.3, 4.8 Hz, 1H), 0.84
(d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.2, 153.7,
139.2, 138.7, 129.1, 128.7, 128.4, 127.6, 127.5, 126.0, 72.9, 69.8, 68.5, 57.6, 44.3, 43.3,
37.4, 27.11, 27.08, 19.2.
(4S,2’S,3’S,5’S)-3-(7’-Benzyloxy-2’,3’,5’-trimethylheptanoyl)-4-phenyloxazolidin-2one

(127)

and

(4S,2’R,3’S,5’S)-3-(7’-benzyloxy-2’,3’,5’-trimethylheptanoyl)-4-

phenyloxazolidin-2-one (128).
To a solution of 126 (826 mg, 2.02 mmol) in dry THF (8 mL) was added NaHMDS
(2.32 mL, 1 M in THF, 2.32 mmol) dropwise at −78 oC. The reaction mixture was stirred
for 1 h at −78 oC and methyl iodide (0.63 mL, 10.10 mmol) was added dropwise. After
stirring for 3 h at −78 oC, the reaction was quenched with saturated aq. NH4Cl, and the
resulting mixture was warmed to room temperature and extracted with ether. The soobtained organic extract was dried over anhydrous Na2SO4, and concentrated.
Purification was performed via flash column chromatography on silica gel (10 – 15%
EtOAc in hexane) to isolate 12799 (529 mg, 62% yield) and 12899 (172 mg, 20% yield) as
colorless oils.
Data for diastereomer 127; [α]20D +50.2 (c 1.05, CHCl3); lit99 [α]20D +49.7 (c 1.65,
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 10H), 5.40 (dd, J = 8.4, 3.3 Hz, 1H),
4.63 (t, J = 8.7 Hz, 1H), 4.50 (s, 2H), 4.22 (dd, J = 9.0, 3.3 Hz, 1H), 3.71 – 3.64 (m, 1H),
3.53 – 3.47 (m, 2H), 1.96 – 1.82 (m, 1H), 1.72 – 1.43 (m, 3H), 1.22 – 1.06 (m, 2H), 1.03
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(d, J = 6.9 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz,
CDCl3) δ 176.3, 153.5, 139.4, 138.6, 129.2, 128.6, 128.4, 127.7, 127.5, 125.7, 73.0, 69.7,
68.5, 57.8, 43.2, 39.7, 38.0, 32.8, 27.1, 19.0, 17.9, 13.7.
Data for diastereomer 128; [α]20D -18.5 (c 1, CHCl3); lit99 [α]20D -20.6 (c 1.88,
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.23 (m, 10H), 5.45 (dd, J = 9.0, 4.5 Hz, 1H),
4.67 (t, J = 9.0 Hz, 1H), 4.49 (s, 2H), 4.28 (dd, J = 9.0, 4.5 Hz, 1H), 3.70 – 3.62 (m, 1H),
3.45 (t, J = 6.6 Hz, 2H), 1.97 – 1.85 (m, 1H), 1.65 – 1.44 (m, 2H), 1.42 – 1.32 (m, 1H),
1.14 (ddd, J = 13.5, 10.5, 3.6 Hz, 1H), 1.03 (d, J = 6.9 Hz, 3H), 0.89 – 0.79 (m, 1H), 0.71
(d, J = 6.3 Hz, 3H), 0.59 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 176.6, 153.4,
139.2, 138.7, 129.0, 128.7, 128.3, 127.6, 127.5, 126.4, 72.9, 69.5, 68.5, 57.7, 42.9, 42.5,
37.7, 32.9, 27.2, 18.9, 14.3, 11.9.
(4S,2’S,3’S,5’S)-3-(7’-Hydroxy-2’,3’,5’-trimethylheptanoyl)-4-phenyloxazolidin-2one (129).
To a solution of 127 (1.85 g, 4.37 mmol) in EtOAc (30 mL) was added Pd(OH)2 on
carbon (0.37 g). The resultant heterogeneous mixture was stirred under hydrogen
atmosphere at 1 atm pressure for 3 h. Then the reaction mixture was filtered to discard
catalyst, and the filtrate was concentrated to give 12999 (1.46 g, 100% yield) as a colorless
oil. [α]20D +65.2 (c 1, CHCl3); lit99 [α]20D +68.6 (c 2.5, CHCl3); 1H NMR (400 MHz, CDCl3)
δ 7.41 – 7.25 (m, 5H), 5.42 (dd, J = 8.4, 3.3 Hz, 1H), 4.66 (t, J = 8.7 Hz, 1H), 4.24 (dd, J
= 9.0, 3.3 Hz, 1H), 3.74 – 3.61 (m, 3H), 1.93 – 1.81 (m, 1H), 1.70 – 1.57 (m, 1H), 1.56 –
1.33 (m, 3H), 1.27 – 1.05 (m, 2H), 1.03 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.83
(d, J = 6.6 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 176.4, 153.5, 139.3, 129.2, 128.6,

125.7, 69.7, 60.9, 57.8, 43.1, 41.1, 39.8, 32.7, 26.6, 18.8, 17.8, 13.8.
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(4S,2’S,3’S,5’S)-3-(7’-Oxo-2’,3’,5’-trimethylheptanoyl)-4-phenyloxazolidin-2-one
(130).
To a solution of oxalyl chloride (337 µL, 3.93 mmol) in dry dichloromethane (4 mL)
was added a solution of dry DMSO (361 µL, 5.08 mmol) in dry dichloromethane (4 mL)
dropwise at −78 oC, and the resulting mixture was stirred for 15 min. A solution of 129
(770 mg, 2.31 mmol) in dichloromethane (10 mL) was added dropwise followed by stirring
for 15 min while maintaining the reaction temperature at −78

oC.

A solution of

triethylamine (1.45 mL, 10.40 mmol) in dry dichloromethane (5 mL) was added dropwise,
and the reaction was stirred in ice-bath (<5 oC) for 50 min and quenched with saturated
aq. NH4Cl. The resulting mixture was extracted with dichloromethane, and the
dichloromethane extract was washed with brine, dried over anhydrous Na2SO4, and
concentrated. After purification of the residual oil by flash column chromatography on
silica gel (20 – 25% EtOAc in hexane), the desired aldehyde 13099 (686 mg, 90% yield)
was isolated as a colorless oil. [α]20D +70.0 (c 0.45, CHCl3); lit99 [α]20D +69.3 (c 1, CHCl3);
1H

NMR (600 MHz, CDCl3) δ 9.73 (t, J = 2.2 Hz, 1H), 7.40 – 7.22 (m, 5H), 5.41 (dd, J =

8.7, 3.3 Hz, 1H), 4.66 (t, J = 8.8 Hz, 1H), 4.24 (dd, J = 8.8, 3.6, 1.1 Hz, 1H), 3.70 – 3.63
(m, 1H), 2.35 – 2.24 (m, 2H), 2.16 – 2.07 (m, 1H), 1.91 – 1.82 (m, 1H), 1.30 – 1.21 (m,
1H), 1.09 (ddd, J = 13.8, 11.0, 3.6 Hz, 1H), 1.02 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.7 Hz,
3H), 0.88 (dd, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 202.5, 176.1, 153.4, 139.2,
129.2, 128.6, 125.7, 69.7, 57.8, 52.1, 43.0, 39.6, 32.6, 25.3, 18.9, 17.7, 13.8.
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(2R,3’S,5’S,6’S,4”S)-2,N-Dimethyl-N-[3’,5’,6’-trimethyl-7’-oxo-7’-(2”-oxo-4”phenyloxazolidin-3-yl)heptyl]butyramide (133).
To a stirred solution of 130 (686 mg, 2.07 mmol) in dry MeOH (16 mL) were added
methylamine hydrochloride (280 mg, 4.14 mmol), methylamine solution (3.11 mL, 2 M in
THF, 6.21 mmol), and anhydrous Na2SO4 at room temperature. After stirring for 20 min,
NaCNBH3 (195 mg, 3.11 mmol) was added by cooling the reaction mixture in ice-bath.
The resulting mixture was stirred for 1 h at room temperature and concentrated. The
residual oil was dissolved in DMF (20 mL) and cooled in ice-bath. Then, (R)-methylbutyric
acid (408 mg, 4.00 mmol), HOBt (688 mg, 80% in water, 4.00 mmol), EDCI.HCl (756 mg,
4.00 mmol), and Hunig’s base (0.69 mL, 4.00 mmol) were added to this ice-cold solution
one after the other, and the resulting mixture was stirred for 10 h at room temperature.
The reaction was diluted with EtOAc, washed with 1 M HCl and brine, dried over
anhydrous Na2SO4, and concentrated. Purification of the residual oil by flash column
chromatography on silica gel (20 – 40% EtOAc in hexane) afforded a mixture of rotamers
of compound 13399 (50% yield in two steps) as a colorless oil. [α]20D +43.1 (c 0.45, CHCl3);
lit99 [α]20D +40.0 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3), both rotamers, δ 7.39 – 7.25
(m, 5H), 5.42 (dt, J = 8.6, 3.2 Hz, 1H), 4.66 (t, J = 8.8, 1H), 4.24 (td, J = 9.1, 3.5 Hz, 1H),
3.72 – 3.63 (m, 1H), 3.43 – 3.20 (m, 2H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, rotamer),
2.61 – 2.48 (m, 1H), 1.90 – 1.80 (m, 1H), 1.74 – 1.62 (m, 1H), 1.53 – 1.30 (m, 4H), 1.25
– 1.05 (m, 5H), 1.05 – 0.99 (m, 3H), 0.92 – 0.81 (m, 9H);

13C

NMR (150 MHz, CDCl3) ,

both rotamers, δ 176.5, 176.3, 176.2, 176.1, 153.5, 153.4 139.4, 139.2, 129.20, 129.15,
128.7, 128.6, 125.7, 69.72, 69.68, 57.82, 57.79, 48.0, 46.1, 43.1, 39.81, 39.78, 37.43,
37.35, 37.2, 35.5, 35.2, 33.7, 32.8, 32.6, 28.0, 27.4, 27.0, 18.8, 17.8, 17.7, 17.6, 17.1,
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14.0, 13.7, 12.1, 12.0; ESIHRMS calculated for C25H39N2O4 [M+H]+, 431.2910; found,
431.2914.
(2R,3’S,5’S,6’S)-2,N-Dimethyl-N-[7’-hydroxy-3’,5’,6’-tri-methylheptyl]butyramide
(134).
To an ice-cold solution of 133 (442 mg, 1.03 mmol) in dry THF (11 mL) was added
lithium borohydride (67 mg, 3.09 mmol) portion wise. Dry methanol (0.21 mL, 5.15 mmol)
was added dropwise in 5 min, and the stirring was continued for next 40 min in ice-bath
and 10 min at room temperature. The reaction was quenched with water after cooling the
reaction mixture in ice-bath, and the resulting mixture was extracted with EtOAc. The soobtained organic extract was washed with brine, dried over Na2SO4, concentrated, and
purified by flash column chromatography (10 – 50% EtOAc in hexane) to afford a mixture
of rotamers of alcohol 13499 (247 mg, 89% yield) as a colorless oil. [α]20D –40.9 (c 0.55,
CHCl3); lit99 [α]20D –36.2 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) , both rotamers, δ
3.64 – 3.55 (m, 1H), 3.50 – 3.21 (m, 3H), 3.00 (s, 3H, rotamer), 2.92 (s, 3H, rotamer),
2.63 – 2.49 (m, 1H), 1.76 – 1.29 (m, 8H), 1.14 – 1.05 (m, 5H), 0.91 – 0.81 (m, 12H);

13C

NMR (100 MHz, CDCl3) , both rotamers, δ 176.5, 176.2, 66.0, 65.9, 48.1, 46.3, 41.1, 41.0,
40.1, 39.8, 37.4, 37.2, 35.32, 35.26, 33.7, 31.4, 31.2, 28.4, 28.2, 27.4, 27.0, 19.2, 19.0,
17.8, 17.11, 17.06, 16.9, 13.3, 13.2, 12.2, 12.0.
(2R,3’S,5’S,6’S)-2,N-Dimethyl-N-[8’-methoxy-3’,5’,6’-tri-methyloct-7-enyl]butyramide (135).
To a solution of oxalyl chloride (131 µL, 1.50 mmol) in dry dichloromethane (1.5
mL) was added a solution of dry DMSO (142 µL, 2.00 mmol) in dry dichloromethane (1.5
mL) dropwise at −78 oC, and the resulting mixture was stirred for 15 min. A solution of
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134 (272 mg, 1.00 mmol) in dichloromethane (3.5 mL) was added dropwise followed by
stirring for 15 min while maintaining the reaction temperature at −78 oC. A solution of
triethylamine (566 µL, 4.00 mmol) in dry dichloromethane (1.5 mL) was added dropwise,
and the reaction was stirred in ice-bath (<5 oC) for 50 min and quenched with saturated
aq. NH4Cl. The resulting mixture was extracted with dichloromethane, and the
dichloromethane extract was washed with brine, dried over anhydrous Na2SO4, and
concentrated to give a corresponding crude aldehyde intermediate.
(Methoxymethyl)triphenylphosphonium chloride (1.72 g, 5.00 mmol) was dried
under high vacuum at 60 oC for 3 h and cooled in argon atmosphere. Then, it was charged
with dry THF (8 mL) and the resulting suspension was cooled in ice-bath. After adding nBuLi (1.8 mL, 2.5 M in hexane, 4.50 mmol) dropwise to this suspension, the mixture was
stirred for 30 min at room temperature followed by cooling to –2.0 oC. A solution of above
prepared crude aldehyde in dry THF (3.5 mL) was added dropwise, and the resulting
mixture was stirred for 20 min at –2.0 oC and 1 h at room temperature. The reaction was
quenched with MeOH (5 mL), diluted with ether, washed with saturated aq. NH4Cl and
brine, dried over anhydrous Na2SO4, and concentrated. After purification of the residue
by flash chromatography on silica gel (10 – 20% EtOAc in hexane), the desired alkene
13599 (mixture of E and Z isomers, 215 mg, 72% yield in two steps ) was isolated as a
yellow oil. [α]20D –20.88 (c 0.9, CHCl3); lit99 [α]20D –20.04 (c 1.6, CHCl3); 1H NMR (400
MHz, CDCl3) , both E/Z isomers and rotamers, δ 6.17 (dd, J = 12.6, 5.4 Hz, 1H), 5.82 (dd,
J = 9.5, 6.3 Hz, 1H), 4.57 (dd, J = 12.6, 8.9 Hz, 1H), 4.15 (dd, J = 9.9, 6.3 Hz, 1H), 3.51
(d, J = 3.8 Hz, 3H), 3.47 (d, J = 4.0 Hz, 3H), 3.39 – 3.18 (m, 4H), 2.98 (s, 6H, rotamer),
2.89 (s, 6H, rotamer), 2.60 – 2.44 (m, 3H), 1.98 – 1.85 (m, 1H), 1.74 – 1.58 (m, 2H), 1.55
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– 1.20 (m, 10H), 1.16 – 0.98 (m, 10H), 0.97 – 0.80 (m, 18H), 0.79 – 0.70 (m, 6H);

13C

NMR (100 MHz, CDCl3) , both E/Z isomers and rotamers, δ 176.5, 176.1, 146.7, 146.5,
145.5, 145.4, 110.8, 110.3, 106.4, 106.1, 59.4, 55.93, 55.86, 48.1, 48.0, 46.2, 42.04,
41.98, 37.8, 37.7, 37.3, 37.2, 37.1, 36.9, 35.51, 35.45, 35.3, 35.2, 33.64, 33.58, 33.4,
28.1, 28.0, 27.4, 27.0, 19.3, 19.23, 19.19 19.1, 18.8, 18.7, 17.7, 17.1, 15.4, 15.3, 15.2,
12.1, 12.0.
(2’R,3R,4S,6S)-3,4,6-Trimethyl-8-[methyl-2’-(methyl-butyryl)amino]octanoic

acid

(111).
To a stirred solution of 135 (180 mg, 0.61 mmol) in acetonitrile (6 mL) was added
1 N HCl (6 mL) at room temperature, and the mixture was allowed to stir for 1 h . The
reaction was diluted with ether, washed with brine, dried over anhydrous Na 2SO4, and
concentrated to give the crude aldehyde. To a solution of the so-obtained crude aldehyde
in MeOH (20 mL) was added 2-methyl-2-butene (3.19 mL, 30.50 mmol) followed by a
freshly prepared solution of NaClO2 (1.25 M in 20% NaH2PO4 solution, 2.4 mL, 3.05
mmol) at room temperature. The resultant mixture was stirred vigorously for 1 h at room
temperature, diluted with ether, washed with brine, dried over anhydrous Na2SO4,
concentrated under reduced pressure, and purified by flash column chromatography on
silica gel (0 – 5 % MeOH in 1:1 mixture of EtOAc and hexane) to afford 11199 (175 mg,
97% yield) as a yellow oil. [α]20D –37.57 (c 0.7, CHCl3); lit99 [α]20D –35.0 (c 0.4, CHCl3);
1H

NMR (600 MHz, CDCl3) , both rotamers, δ 3.38 (t, J = 7.5 Hz, 1H), 3.34 – 3.22 (m,

1H), 3.00 (s, 3H, rotamer), 2.91 (s, 3H, rotamer), 2.61 – 2.50 (m, 1H), 2.34 (dd, J = 15.1,
5.0 Hz, 1H), 2.08 (dt, J = 14.9, 9.6 Hz, 1H), 2.01 – 1.88 (m, 1H), 1.73 – 1.62 (m, 1H), 1.58
– 1.28 (m, 5H), 1.15 – 1.01 (m, 5H), 0.94 – 0.89 (m, 3H), 0.89 – 0.83 (m, 6H), 0.83 – 0.77
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(m, 3H);

13C

NMR (150 MHz, CDCl3) , both rotamers, δ 178.73, 178.68, 176.7, 176.4,

48.1, 46.2, 40.4, 40.2, 38.0, 37.9, 37.4, 37.2, 37.1, 35.3, 35.2, 35.0, 34.2, 33.8, 28.2, 27.4,
27.0, 19.09, 19.06, 17.7, 17.0, 16.6, 16.5, 16.02, 16.00, 12.1, 12.0; ESIHRMS calculated
for C17H34NO3 [M+H]+, 300.2539; found, 300.2537.
N-((2R)-3-Butenol-2-yl)-[(3R,4S,6S)-trimethyl-8-((2R)-N-methyl-2methylbutyramido)]octanamide (136).
To a mixture of 111 (175 mg, 0.58 mmol) and 112 (143 mg, 1.16 mmol) in dry
CH2Cl2 (5 mL) were added DIPEA (303 μL, 1.74 mmol) and DMAP (35 mg, 0.29 mmol)
at room temperature. After stirring for 10 min, EDCI.HCl (334 mg, 1.74 mmol) was added
and stirring was continued for 14 h. The reaction was then diluted with water (5 mL),
acidified with 1 M HCl (10 mL), and extracted with EtOAc. The so-obtained organic extract
was washed with brine, dried over anhydrous Na 2SO4, and concentrated. Purification of
the residue by flash column chromatography on silica gel (0 – 5 % MeOH in CH2Cl2)
afforded 136101 (210 mg, 98%) as a colorless oil: [α]20D –10.9 (c 1, CHCl3); lit101 [α]20D –
10.8 (c 0.8, CHCl3); 1H NMR (400 MHz, CDCl3) , both rotamers, δ 6.42 (d, J = 7.9 Hz, 1H,
rotamer), 6.27 (d, J = 7.9 Hz, 1H, rotamer), 5.90 – 5.75 (m, 1H), 5.27 – 5.12 (m, 2H), 4.54
(br s, 1H), 3.75 – 3.57 (m, 2H), 3.46 – 3.20 (m, 2H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H,
rotamer), 2.63 – 2.47 (m, 1H), 2.30 – 2.18 (m, 1H), 2.05 – 1.85 (m, 2H), 1.74 – 1.29 (m,
6H), 1.19 – 0.99 (m, 5H), 0.91 – 0.74 (m, 12H);

13C

NMR (100 MHz, CDCl3) , both

rotamers, δ 176.7, 176.6, 173.4, 173.1, 135.5, 135.3, 116.5, 116.4, 65.0, 53.6, 53.5, 48.1,
46.1, 40.6, 40.5, 40.4, 40.0, 37.4, 37.2, 37.1, 35.5, 35.4, 35.3, 35.0, 34.3, 34.1, 33.8, 28.2,
28.1, 27.4, 27.0, 19.3, 19.2, 17.8, 17.1, 16.7, 16.5, 16.2, 15.8, 12.2, 12.0; ESIHRMS
calculated for C21H41N2O3 [M+H]+, 369.3117; found, 369.3118.
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(4R)-4-Ethenyl-2-[(2R,3S,5S)-2,3,5-trimethyl-7-((2R)-N-methyl-2methylbutyramido)-heptyl]oxazoline (137).
To a stirred solution of 136 (210 mg, 0.57 mmol) in dry CH2Cl2 (14 mL) was added
DAST (150 μL, 1.14 mmol) at –78 oC. The reaction was quenched with saturated aq.
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under
reduced pressure, and purified by flash column chromatography on silica gel (50 – 75 %
EtOAc in hexane) to give 137101 (185 mg, 92%) as a colorless oil. [α]20D +18.4 (c 1,
CHCl3); lit101 [α]20D +18.6 (c 0.76, CHCl3); 1H NMR (400 MHz, CDCl3) , both rotamers, δ
5.78 (ddd, J = 17.2, 10.3, 6.9 Hz, 1H), 5.21 (d, J = 17.2 Hz, 1H), 5.11 (dd, J = 10.3, 3.5
Hz, 1H), 4.60 – 4.50 (m, 1H), 4.37 – 4.25 (m, 1H), 3.89 (td, J = 8.1, 4.4 Hz, 1H), 3.41 –
3.18 (m, 2H), 2.98 (s, 3H, rotamer), 2.89 (s, 3H, rotamer), 2.60 – 2.47 (m, 1H), 2.32 –
2.20 (m, 1H), 2.10 – 1.99 (m, 1H), 1.95 – 1.81 (m, 1H), 1.75 – 1.59 (m, 1H), 1.58 – 1.27
(m, 5H), 1.16 – 1.00 (m, 5H), 0.94 – 0.76 (m, 12H);

13C

NMR (100 MHz, CDCl3) , both

rotamers, δ 176.4, 176.1, 168.3, 168.2, 138.2, 138.2, 116.2, 116.1, 71.91, 71.87, 68.2,
48.0, 46.1, 40.1, 37.3, 37.19, 37.16, 36.0, 35.8, 35.4, 35.2, 34.23, 34.15, 33.7, 31.83,
31.77, 28.18, 28.15, 27.4, 27.0, 19.0, 17.8, 17.1, 16.31, 16.25, 16.03, 15.98, 12.2, 12.00;
ESIHRMS calculated for C21H39N2O2 [M+H]+, 351.3012; found, 351.3017.
N-((2R)-3-Butenol-2-yl)-[(3R,4S,6S)-trimethyl-8-((2R)-N-methyl-2methylbutyramido)]octanethioamide (138).
Compound 137 (170 mg, 0.48 mmol) was dissolved in MeOH–Et3N (1:1, 14 mL,
saturated with H2S), and stirred for 16 h at room temperature. The mixture was
concentrated under reduced pressure and purified by flash column chromatography on
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neutral alumina (10 – 35 % acetone in hexane) to afford 138101 (132 mg, 71%) as a
colorless oil. [α]20D +7.6 (c 1, CHCl3); lit101 [α]20D +9.6 (c 0.44, CHCl3); 1H NMR (400 MHz,
CDCl3) , both rotamers, δ 8.20 (d, J = 6.6 Hz, 1H, rotamer ), 7.99 (d, J = 6.6 Hz, 1H,
rotamer), 5.87 (ddd, J = 16.4, 10.5, 5.2 Hz, 1H), 5.41 – 5.20 (m, 3H), 3.93 – 3.73 (m, 2H),
3.53 – 3.23 (m, 2H), 3.01 (s, 3H, rotamer), 2.91 (s, 3H, rotamer), 2.77 – 2.50 (m, 2H),
2.44 – 2.30 (m, 1H), 2.30 – 2.19 (m, 1H), 1.75 – 1.31 (m, 6H), 1.19 – 1.00 (m, 5H), 0.93
– 0.75 (m, 12H).

13C

NMR (100 MHz, CDCl3) , both rotamers, δ 205.6, 205.4, 176.9,

176.8, 133.7, 133.6, 117.5, 117.3, 63.9, 58.6, 58.5, 50.9, 50.7, 48.2, 46.0, 40.6, 39.6,
38.6, 38.5, 37.4, 37.2, 36.9, 35.3, 34.8, 34.3, 33.9, 33.8, 28.2, 28.1, 27.4, 27.0, 19.4, 19.3,
17.8, 17.0, 16.4, 16.2, 15.7, 12.1, 12.0; ESIHRMS calculated for C21H41N2O2S [M+H]+,
385.2889; found, 385.2896.
(+)-Kalkitoxin (107).
To a stirred solution of 138 (128 mg, 0.33 mmol) in dry CH2Cl2 (8 mL) was added
DAST (88 μL, 0.67 mmol) at –78 oC. The reaction was quenched with saturated aq.
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under
reduced pressure, and purified by flash column chromatography on neutral alumina (10
– 30 % EtOAc in hexane) to give kalkitoxin 10795 (94 mg, 77%) as a colorless oil. [α]20D
+9.1 (c 1, CHCl3); lit95 [α]20D +16.0 (c 0.07, CHCl3); 1H NMR (400 MHz, CDCl3) , both
rotamers, δ 5.92 (ddd, J = 17.1, 10.3, 6.7 Hz, 1H), 5.27 (dt, J = 17.1, 1.4 Hz, 1H), 5.20 –
5.06 (m, 1H), 4.99 – 4.82 (m, 1H), 3.47 – 3.33 (m, 2H), 3.32 – 3.21 (m, 1H), 3.09 – 3.01
(m, 1H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 2.62 – 2.46 (m, 2H), 2.37 – 2.24 (m,
1H), 1.92 – 1.80 (m, 1H), 1.75 – 1.61 (m, 1H), 1.61 – 1.28 (m, 5H), 1.17 – 1.04 (m, 5H),
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0.92 – 0.79 (m, 12H); 13C NMR (100 MHz, CDCl3) , both rotamers, δ 176.5, 176.1, 171.6,
171.4, 137.3, 137.2, 116.1, 116.0, 78.57, 78.55, 48.0, 46.1, 40.0, 38.60, 38.57, 38.3, 38.2,
37.41, 37.36, 37.21, 37.18, 35.4, 35.2, 34.2, 34.1, 33.7, 28.24, 28.22, 27.4, 27.0, 19.09,
19.07, 17.7, 17.1, 16.20, 16.16, 16.00, 15.95, 12.1, 12.0; ESIHRMS calculated for
C21H39N2OS [M+H]+, 367.2783; found, 367.2784.
Synthesis of 9-oxa-10-azakalkitoxin (108):
O-Benzoyl-N-methyl-N-(2-(1-methyl-3-phenyltriaz-2-en-1-yl)ethyl)hydroxylamine
(146).
To a stirred solution of N,N’-dimethylethylenediamine (1.32 g, 15 mmol) in water
(100 mL) were sequentially added a solution of benzenediazonium tetrafluoroborate (0.96
g, 5 mmol) in water (30 mL) dropwise in 20 min and a KOH solution (2 M, 5 mL) dropwise
in 10 min at room temperature. The reaction was stirred for 5 min and extracted with
CH2Cl2. The organic extract was dried over Na2SO4 and concentrated under reduced
pressure to afford crude intermediate. This crude intermediate was then dissolved in dry
DMF (2 mL) and was added to a stirred suspension of K2HPO4 (1.31 g, 7.50 mmol) and
benzoyl peroxide (2.66 g 50 % w/w blended with dicyclohexyl phthalate, 5.50 mmol) in
dry DMF (10 mL) at room temperature. After stirring for 1.5 h, the resultant suspension
was diluted with water (50 mL), stirred for 1 h, and extracted with EtOAc. The organic
extract was then washed with saturated aq. NaHCO3, water, and brine, dried over
anhydrous Na2SO4, and concentrated under reduced pressure. Purification of the residue
by flash column chromatography on silica gel (10 – 40 % EtOAc in hexane) afforded 146
(0.82 g, 53% in 2 steps) as a red oil. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.3 Hz,
2H), 7.57 (t, J = 7.4 Hz, 1H), 7.49 – 7.35 (m, 4H), 7.31 (t, J = 7.8 Hz, 2H), 7.14 (t, J = 7.2
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Hz, 1H), 4.00 (t, J = 6.2 Hz, 2H), 3.38 – 3.21 (m, 5H), 2.94 (s, 3H);

13C

NMR (100 MHz,

CDCl3) δ 165.0, 150.7, 133.3, 129.5, 128.9, 128.8, 128.5, 125.5, 120.6, 58.9, 53.2, 47.4,
35.8; ESIHRMS calculated for C17H20N4O2Na [M+Na]+, 335.1484; found, 335.1481.
1-((Methyl(2-(1-methyl-3-phenyltriaz-2-en-1-yl)ethyl)amino)oxy)ethyl acetate (148).
To a stirred solution of 146 (125 mg, 0.40 mmol) in dry CH2Cl2 (2.5 mL) were added
sequentially, dropwise DIBAL (0.60 mL 1 M in hexane, 0.60 mmol), pyridine (97 μL, 1.20
mmol), a solution of DMAP (97 mg, 0.80 mmol) in dry CH2Cl2 (1 mL), and Ac2O (227 μL,
2.40 mmol) at –78 oC. The reaction mixture was stirred for 12 h (overnight) at –78 oC,
warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH 4Cl (4 mL)
and saturated aq. sodium potassium tartrate (3 mL) at 0 oC. The resultant mixture was
warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2. The
organic extract was washed with brine, dried over anhydrous Na 2SO4, and concentrated
under reduced pressure. The so-obtained crude intermediate 147 was then forwarded to
next reaction without further purification.
To a stirred solution of the crude intermediate 147 in dry CH2Cl2 (2.5 mL) were
added sequentially, dropwise DIBAL (0.60 mL 1 M in hexane, 0.60 mmol), pyridine (97
μL, 1.20 mmol), a solution of DMAP (97 mg, 0.80 mmol) in dry CH2Cl2 (1 mL), and Ac2O
(227 μL, 2.40 mmol) at –78 oC. The reaction mixture was stirred for 12 h (overnight) at –
78 oC, warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH4Cl
(4 mL) and saturated aq. sodium potassium tartrate (3 mL) at 0 oC. The resultant mixture
was warmed to room temperature, stirred vigorously for 1 h, and extracted with CH 2Cl2.
The organic extract was washed with brine, dried over anhydrous Na 2SO4, concentrated
under reduced pressure, and purified by flash column chromatography on silica gel (10 –
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20 % EtOAc in hexane) to give 148 (91 mg, 78%, uncharacterized single diastereomer)
as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.4 Hz, 2H), 7.33 (t, J = 7.7 Hz,
2H), 7.14 (t, J = 7.2 Hz, 1H), 6.13 (q, J = 5.4 Hz, 1H), 3.94 (t, J = 6.3 Hz, 2H), 3.28 (br s,
3H), 2.97 (t, J = 6.3 Hz, 2H), 2.68 (s, 3H), 2.06 (s, 3H), 1.36 (d, J = 5.4 Hz, 3H). 13C NMR
(100 MHz, CDCl3) δ 170.1, 150.7, 128.8, 125.5, 120.6, 97.2, 58.9, 52.9, 47.0, 36.1, 21.4,
19.1; ESIHRMS calculated for C14H22N4O3Na [M+Na]+, 317.1590; found, 317.1589.
Benzyl (2-((benzoyloxy)(methyl)amino)ethyl)(methyl)carbamate (150).
To a solution of N,N’-dimethylethylenediamine (4.77 mL, 45 mmol) in dry CH2Cl2
(200 mL) was added a solution of benzyl chloroformate (2.14 mL, 15 mmol) in dry CH 2Cl2
(20 mL) in 1 h at 0 oC. The mixture was stirred for 3 h at 0 oC followed by 2 h at room
temperature. The reaction was quenched by water (200 mL), and the volatile portion was
evaporated under reduced pressure. The aqueous residue was acidified to pH 1 by
adding 2 M HCl, and the nonpolar impurities were washed out with CH 2Cl2. Then the
aqueous phase was basified to pH 9 by adding 10% aq. NaOH and extracted with ether.
The ether extract was dried over anhydrous Na2SO4 and concentrated under reduced
pressure. The so-obtained intermediate was then dissolved in dry DMF (17 mL). To this
solution were added K2HPO4 (1.79 g, 10.32 mmol) and benzoyl peroxide (3.34 g 50 %
w/w blended with dicyclohexyl phthalate, 6.88 mmol) at room temperature. After stirring
for 24 h, the resultant suspension was diluted with water (50 mL), stirred for 1 h, and
extracted with EtOAc. The organic extract was washed with saturated aq. NaHCO3, water,
and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure.
Purification of the residue by flash column chromatography on silica gel (10 – 50 % EtOAc
in hexane) afforded 150 (1.40 g, 59% in 2 steps) as a yellow oil 1H NMR (400 MHz,
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CDCl3), both rotamers, δ 8.18 – 7.89 (m, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.49 – 7.16 (m,
7H), 5.09 (s, 2H), 3.52 (t, J = 6.6 Hz, 2H), 3.20 (t, J = 6.1 Hz, 2H, 1 rotamer), 3.12 (t, J =
6.6 Hz, 2H, 1 rotamer), 2.97 (s, 3H), 2.94 – 2.86 (m, 3H);

13C

NMR (100 MHz, CDCl3),

both rotamers, δ 165.1, 165.0, 156.3, 156.0, 136.7, 133.2, 130.0, 129.4, 128.5, 128.4,
128.3, 127.93, 127.87, 127.79, 67.2, 67.1, 58.8, 58.7, 47.4, 47.2, 46.5, 35.5; ESIHRMS
calculated for C19H22N2O4Na [M+Na]+, 365.1477; found, 365.1478.
Benzyl (2-(hydroxy(methyl)amino)ethyl)(methyl)carbamate (151).
To a stirred solution of 150 (500 mg, 1.46 mmol) in dry CH2Cl2 (9 mL) was added
DIBAL (2.92 mL 1 M in hexane, 2.92 mmol) in 20 min at –78 oC. The reaction was stirred
for 20 min at –78 oC and quenched by addition of saturated aq. NH4Cl (15 mL) and
saturated aq. sodium potassium tartrate (10 mL). The resultant mixture was warmed to
room temperature, stirred vigorously for 1 h, and extracted with ether. The organic extract
was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified
by flash column chromatography on silica gel (50 – 100 % EtOAc in hexane) to give 151
(180 mg, 52%) as a colorless oil: 1H NMR (400 MHz, CDCl3), both rotamers, δ 7.49 –
7.19 (m, 5H), 5.14 (s, 2H), 3.48 (br s, 2H), 2.93 (s, 3H), 2.80 – 2.48 (m, 5H);

13C

NMR

(100 MHz, CDCl3) both rotamers, δ 157.8, 136.7, 128.5, 128.0, 127.7, 67.4, 67.2, 59.4,
58.8, 48.8, 47.9, 46.8, 46.5, 35.1, 34.2; ESIHRMS calculated for C12H19N2O3 [M+H]+,
239.1396; found, 239.1398.
Alternative synthesis by transesterification: A solution of 150 (1.30 g, 3.80 mmol)
in dry MeOH (15 mL) was treated with NaOMe (47 mg, 0.95 mmol) for 2 h at room
temperature. The reaction was quenched by stirring with Amberlyst ® 15 hydrogen form
(0.13 g) until the pH 7 was obtained. The mixture was filtered through a pad of Celite®,
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concentrated under reduced pressure, and purified by flash column chromatography on
silica gel (50 – 100 % EtOAc in hexane) to give 151 (0.83 g, 92%) as a colorless oil. The
spectral data were identical with above sample.
(R)-4-(tert-Butyldimethylsilyloxy)-2-methylbutanoic acid (153).
To an ice-cold solution (<5 oC) of 152148 (300 mg, 0.77 mmol) in THF-H2O (1:1, 4
mL) were added LiOH.H2O (64 mg, 1.54 mmol) and H2O2 (0.34 mL, 30 wt% in water, 3.06
mmol). After stirring for 3 h in ice-bath (<5 oC), the reaction was quenched with Na2SO3
(6 mL 1.5 M in water, 8.58 mmol). The resultant mixture was diluted with water, and
nonpolar impurities were washed out with CH2Cl2. The aqueous layer was acidified to pH
6-7 by addition of 1 M HCl, saturated with NaCl, and extracted with ether. The ether
extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to
give the desired acid 153148 (168 mg, 94%) as a colorless oil: [α]20D –13.21 (c 8.25, EtOH);
lit148 [α]20D +13.51 (c 1.8, EtOH) and –14.06 for (S)-enantiomer of 153; 1H NMR (400 MHz,
CDCl3) δ 3.72 – 3.61 (m, 2H), 2.63 (td, J = 7.5, 6.0 Hz, 1H), 2.03 – 1.85 (m, 1H), 1.68 –
1.53 (m, 1H), 1.20 (d, J = 7.1 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H);

13C

NMR (100 MHz,

CDCl3) δ 183.1, 60.7, 36.2, 36.0, 25.7, 18.3, 16.9, -5.5.
Benzyl

(R)-(3,6,10,10,11,11-hexamethyl-5-oxo-4,9-dioxa-3-aza-10-

siladodecyl)(methyl)carbamate (154).
To an ice-cold solution of hydroxylamine 151 (142 mg, 0.59 mmol) and acid 153
(125 mg, 0.54 mmol) in dry CH2Cl2 (3.5 mL) were added HOBt (136 mg wetted with 20
wt% water, 0.81 mmol), EDCI.HCl (155 mg, 0.81 mmol), and DIPEA (141 μL, 0.81 mmol),
and the resultant mixture was stirred for 4 h at room temperature. The mixture was
washed with water followed by brine, dried over anhydrous Na2SO4, concentrated under
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reduced pressure, and purified by flash column chromatography on silica gel (20 – 30 %
EtOAc in hexane) to give 154 (187 mg, 77%) as a colorless oil: [α]20D –12.4 (c 6.5, CHCl3);
1H

NMR (400 MHz, CDCl3), both rotamers, δ 7.43 – 7.14 (m, 5H), 5.10 (s, 2H), 3.71 –

3.50 (m, 2H), 3.50 – 3.35 (m, 2H), 3.03 (t, J = 6.3 Hz, 1H), 2.99 – 2.91 (m, 4H), 2.79 –
2.70 (m, 3H), 2.67 – 2.52 (m, 1H), 1.99 – 1.80 (m, 1H), 1.65 – 1.50 (m, 1H), 1.26 – 1.06
(m, 3H), 0.87 (s, 9H), 0.02 (s, 6H);

13C

NMR (101 MHz, CDCl3), both rotamers, δ 174.9,

174.8, 156.2, 156.0, 136.7, 128.4, 127.9, 127.8, 67.2, 67.0, 60.5, 58.6, 58.5, 47.1, 46.8,
46.4, 36.2, 35.5, 35.3, 34.8, 25.9, 18.3, 17.2, 17.1, -5.4; ESIHRMS calculated for
C23H41N2O5Si [M+H]+, 453.2785; found, 453.2780.
(10R)-4,7,10,14,14,15,15-Heptamethyl-3-oxo-1-phenyl-2,8,13-trioxa-4,7-diaza-14silahexadecan-9-yl acetate (155).
To a chilled solution of 154 (130 mg, 0.29 mmol) at –78 oC in dry CH2Cl2 (2 mL)
were added sequentially, dropwise DIBAL (0.50 mL1 M in hexane, 0.50 mmol), pyridine
(70 μL, 0.87 mmol), a solution of DMAP (71 mg, 0.58 mmol) in dry CH2Cl2 (0.8 mL), and
Ac2O (164 μL, 1.74 mmol). The reaction mixture was stirred for 12 h (overnight) at –78
oC,

warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH4Cl (3

mL) and saturated aq. sodium potassium tartrate (2.5 mL) at 0 oC. The resultant mixture
was warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2.
The organic extract was washed with brine, dried over anhydrous Na 2SO4, concentrated
under reduced pressure, and purified by flash column chromatography on silica gel (20 –
25 % EtOAc in hexane) to give 155 (86 mg, 60%, uncharacterized single diastereomer)
as a colorless oil. [α]20D +2.7 (c 1.5, CHCl3); 1H NMR (400 MHz, CDCl3), rotamers, δ 7.41
– 7.21 (m, 5H), 5.99 – 5.85 (m, 1H), 5.12 (s, 2H), 3.74 – 3.52 (m, 2H), 3.52 – 3.36 (m,
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2H), 2.95 (s, 3H), 2.91 – 2.72 (m, 2H), 2.66 – 2.53 (m, 3H), 2.11 – 1.99 (m, 3H), 1.91 (br
s, 1H), 1.72 (br s, 1H), 1.37 – 1.21 (m, 1H), 0.97 – 0.85 (m, 12H), 0.04 (s, 6H);

13C

NMR

(100 MHz, CDCl3), rotamers, δ 170.3, 156.2, 156.1, 136.8, 128.4, 127.9, 127.8, 101.1,
67.04, 67.01, 60.9, 60.82, 60.76, 60.70, 58.6, 58.3, 46.8, 46.4, 35.3, 34.8, 34.3, 33.82,
33.77, 33.2, 33.0, 25.92, 25.91, 21.3, 18.29, 18.26, 14.3, 14.2, 13.8, 13.7, -5.3, -5.4;
ESIHRMS calculated for C25H44N2O6SiNa [M+Na]+, 519.2866; found, 519.2852.
Benzyl

((6R)-3,5,6,10,10,11,11-heptamethyl-4,9-dioxa-3-aza-10-

siladodecyl)(methyl)carbamate

(156)

and

benzyl

methyl(2-(methyl(((3R)-3-

methyltetrahydrofuran-2-yl)oxy)amino)ethyl)carbamate (157).
To a stirred solution of 155 (50 mg, 0.10 mmol) in dry CH2Cl2 (2 mL) were added
Me2Zn (0.25 mL 1 M in heptane, 0.25 mmol) and BF3.OEt2 (31 μL, 0.25 mmol) one after
the other at –78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched
by slow addition of saturated aq. NaHCO3, and extracted with ether. The organic extract
was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified
by flash column chromatography on silica gel (10 – 40 % EtOAc in hexane) to give desired
product 156 (12 mg, 27%, dr 63:37) as a colorless oil along with 157 (16 mg, 50%, dr 4:1)
as a colorless oil.
Data for 156: [α]20D +3.3 (c 0.6, CHCl3); 1H NMR (500 MHz, toluene-d8, T = 353 K),
both diastereomers, δ 7.25 (d, J = 7.4 Hz, 2H), 7.13 (t, J = 7.4 Hz, 2H), 7.08 – 7.04 (m,
1H), 5.09 (s, 2H), 3.75 – 3.53 (m, 3H), 3.35 (br s, 2H), 2.82 – 2.69 (m, 5H), 2.41 (s, 3H),
1.87 – 1.79 (m, 1H), 1.40 – 1.26 (m, 2H), 1.09 (d, J = 6.2 Hz, 1.9H), 1.06 (d, J = 6.2 Hz,
1.1H), 0.96 (s, 9H), 0.92 – 0.88 (m, J = 6.8, 3.5 Hz, 3H), 0.08 (s, 6H). 13C NMR (150 MHz,
CDCl3), rotamers and both diastereomers, δ 156.2, 136.9, 128.4, 127.9, 127.8, 80.8, 80.5,
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67.0, 66.9, 61.6, 61.5, 60.0, 58.7, 58.3, 46.9, 46.5, 46.3, 36.24, 36.17, 35.2, 34.7, 34.6,
33.1, 26.0, 25.9, 18.33, 18.29, 15.5, 15.4, 14.8, 14.3, -5.29, -5.32, -5.34; ESIHRMS
calculated for C24H44N2O4SiNa [M+Na]+, 475.2968; found, 475.2975.
Data for 157: [α]20D +60.6 (c 0.8, CHCl3); 1H NMR (500 MHz, toluene-d8, T = 263
K) δ 7.21 (d, J = 7.0 Hz, 2H), 7.13 – 7.00 (m, 3H), 5.13 (d, J = 4.8 Hz, 0.8H), 5.06 (s, 2H),
5.00 (br s, 0.2H), 3.83 (dt, J = 8.7, 3.0 Hz, 0.8H), 3.78 – 3.67 (m, 0.4H), 3.64 – 3.56 (m,
0.8H), 3.49 (br s, 1H), 3.37 – 3.26 (m, 1H), 2.80 (s, 3H), 2.75 – 2.65 (m, 2H), 2.53 – 2.45
(m, 3H), 1.88 – 1.76 (m, 1H), 1.69 – 1.56 (m, 1H), 1.50 – 1.38 (m, 1H), 0.95 (d, J = 6.7
Hz, 2.4H), 0.85 (d, J = 7.0 Hz, 0.6H);

13C

NMR (100 MHz, CDCl3) δ 156.3, 136.9, 128.4,

127.9, 127.8, 106.9, 67.1, 66.9, 66.8, 66.7, 58.8, 58.6, 47.4, 46.7, 46.4, 38.2, 37.9, 37.8,
35.2, 34.7, 32.4, 31.2, 29.7, 12.9, 12.8; ESIHRMS calculated for C17H26N2O4Na [M+Na]+,
345.1790; found, 345.1792.
(S)-4-Benzyl-3-((R,E)-2-methyl-5-phenylpent-4-enoyl)oxazolidin-2-one (159).
To a stirred solution of diisopropylamine (5.09 mL, 36.31 mmol) in dry THF (42 mL)
was added n-BuLi (13.20 mLof 2.5 M solution in hexane, 33.01 mmol) dropwise in 10 min
at –78 oC. The resultant mixture was stirred in ice-bath (<5 oC) for 20 min and chilled back
to –78 oC. A solution of 158 (7.00 g, 30.01 mmol) in dry THF (42 mL) was added dropwise
(40 min) and allowed to stir for additional 30 min at –78 oC. Then a solution of cinnamyl
bromide (8.87 g, 45.01 mmol) in dry THF (10 mL) was added dropwise (15 min). Stirring
was continued for additional 90 min at –78 oC followed by gradually warming to 0 oC in
2.5 h. The reaction was quenched by saturated aq. NH4Cl solution (50 mL), and the
volatile components were evaporated under reduced pressure. The residue was
dissolved in CH2Cl2, washed with water followed by brine, dried over anhydrous Na 2SO4,
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and concentrated under reduced pressure. Purification was performed by flash column
chromatography on silica gel to afford 159170 (7.52 g, 72%, dr 95:5) as a white solid
(eluent: 0 – 25% EtOAc in hexane): Mp. 89-91 oC; [α]20D +10.8 (c 1, CHCl3); 1H NMR (400
MHz, CDCl3) δ 7.46 – 7.13 (m, 10H), 6.47 (d, J = 15.8 Hz, 1H), 6.25 (dt, J = 15.8, 7.0 Hz,
1H), 4.78 – 4.60 (m, 1H), 4.18 (t, J = 9.0 Hz, 1H), 4.12 (dd, J = 9.0, 2.9 Hz, 1H), 4.03 –
3.91 (m, 1H), 3.26 (dd, J = 13.4, 3.1 Hz, 1H), 2.73 – 2.64 (m, 1H), 2.62 (dd, J = 13.4, 9.8
Hz, 1H), 2.46 – 2.35 (m, 1H), 1.24 (d, J = 6.8 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ

176.6, 153.2, 137.3, 135.3, 132.5, 129.3, 128.9, 128.5, 127.3, 127.2, 127.0, 126.1, 66.0,
55.3, 38.0, 37.7, 37.5, 16.6; ESIHRMS calculated for C22H24NO3 [M+H]+, 350.1756;
found, 350.1755.
(R,E)-2-Methyl-5-phenylpent-4-enoic acid (160).
To an ice-cold solution (<5 oC) of 159 (1g, 2.86 mmol) in THF-H2O (4:1, 10 mL)
were added LiOH.H2O (0.48 g, 11.44 mmol) and H2O2 (0.6 mL, 30 wt% in water, 5.72
mmol). After stirring for 1.5 h in ice-bath (<5 oC), the reaction was quenched with Na2SO3
(17 mL 1M in water, 8.58 mmol). The resultant mixture was diluted with water, and
nonpolar impurities were washed out with CH2Cl2. The aqueous layer was acidified to pH
2 by addition of 2 M HCl, saturated with NaCl, and extracted with ether. The ether extract
was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the
desired acid 160149 (0.37 g, 68%) as a colorless oil: [α]20D –18.0 (c 1, EtOH); lit149 [α]20D –
20.3 (c 1.04, EtOH) 1H NMR (400 MHz, CDCl3) δ 11.27 (br s, 1H), 7.53 – 7.11 (m, 5H),
6.47 (d, J = 15.7 Hz, 1H), 6.19 (dt, J = 15.7, 7.0 Hz, 1H), 2.75 – 2.50 (m, 2H), 2.44 – 2.33
(m, 1H), 1.26 (d, J = 6.8 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 182.7, 137.3, 132.4,

128.5, 127.2, 126.8, 126.1, 39.5, 36.7, 16.4.
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Benzyl

(R,E)-methyl(2-(methyl((2-methyl-5-phenylpent-4-

enoyl)oxy)amino)ethyl)carbamate (161).
To an ice-cold solution of hydroxylamine 151 (695 mg, 2.92 mmol) and acid 160
(370 mg, 1.94 mmol) in dry CH2Cl2 (12 mL) were added HOBt (491 mg wetted with 20
wt% water, 2.92 mmol), EDCI.HCl (559 mg, 2.92 mmol), and DIPEA (510 μL, 2.91 mmol),
and the resultant mixture was stirred for 5 h at room temperature. The mixture was
washed with water followed by brine, dried over anhydrous Na2SO4, concentrated under
reduced pressure, and purified by flash column chromatography on silica gel (20 – 50 %
EtOAc in hexane) to give 161 (497 mg, 62%) as a colorless oil. [α]20D –15.0 (c 2.5, CHCl3);
1H

NMR (400 MHz, CDCl3), both rotamers, δ 7.40 – 7.16 (m, 10H), 6.41 (t, J = 14.6 Hz,

1H), 6.22 – 6.03 (m, 1H), 5.10 (s, 2H), 3.43 – 3.31 (m, 2H), 3.01 (t, J = 5.4 Hz, 1H), 2.92
(t, J = 6.9 Hz, 1H), 2.87 (s, 3H), 2.76 – 2.68 (m, 3H), 2.65 – 2.44 (m, 2H), 2.41 – 2.26 (m,
1H), 1.27 – 1.14 (m, 3H);

13C

NMR (100 MHz, CDCl3), both rotamers, δ 174.34, 174.27,

156.2, 155.9, 137.1, 136.8, 132.5, 132.4, 128.50, 128.45, 127.9, 127.8, 127.3, 127.2,
126.7, 126.6, 126.0, 67.1, 67.0, 58.5, 58.4, 47.2, 46.9, 46.4, 38.7, 37.1, 35.4, 35.2, 16.9;
ESIHRMS calculated for C24H31N2O4 [M+H]+, 411.2284; found, 411.2279.
(10R,E)-4,7,10-Trimethyl-3-oxo-1,13-diphenyl-2,8-dioxa-4,7-diazatridec-12-en-9-yl
acetate (162).
To a chilled solution of 161 (300 mg, 0.73 mmol) at –78 oC in dry CH2Cl2 (4.5 mL)
were added sequentially, dropwise DIBAL (1.46 mL1 M in hexane, 0.1.46 mmol), pyridine
(176 μL, 2.19 mmol), a solution of DMAP (178 mg, 1.46 mmol) in dry CH2Cl2 (2 mL), and
Ac2O (414 μL, 4.38 mmol). The reaction mixture was stirred for 12 h (overnight) at –78
oC,

warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH4Cl (7
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mL) and saturated aq. sodium potassium tartrate (5 mL) at 0 oC. The resultant mixture
was warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2.
The organic extract was washed with brine, dried over anhydrous Na2SO4, concentrated
under reduced pressure, and purified by flash column chromatography on silica gel (20 –
30 % EtOAc in hexane) to give 162 (133 mg, 40%) as a colorless oil. [α]20D +5.8 (c 2.5,
CHCl3); 1H NMR (400 MHz, CDCl3), both rotamers δ 7.42 – 7.10 (m, 10H), 6.46 – 6.31
(m, 1H), 6.24 – 6.05 (m, 1H), 6.04 – 5.90 (m, 1H), 5.13 (s, 2H), 3.47 (t, J = 7.0 Hz, 2H),
2.95 (s, 3H), 2.92 – 2.75 (m, 2H), 2.71 – 2.56 (m, 3H), 2.52 – 2.19 (m, 1H), 2.17 – 1.82
(m, 5H), 1.04 – 0.91 (m, 3H); 13C NMR (100 MHz, CDCl3), both rotamers, δ 170.3, 156.2,
156.1, 137.5, 136.8, 131.7, 131.6, 128.49, 128.45, 128.2, 128.1, 127.9, 127.8, 127.0,
126.0, 100.7, 67.1, 67.0, 58.6, 58.3, 46.8, 46.4, 36.8, 36.6, 35.3, 34.8, 34.6, 21.3, 14.2,
13.8; ESIHRMS calculated for C26H34N2O5Na [M+Na]+, 477.2365; found, 477.2363.
Benzyl

methyl(2-(methyl(((3R,E)-3-methyl-6-phenylhex-5-en-2-

yl)oxy)amino)ethyl)carbamate (163).
To a stirred solution of 162 (50 mg, 0.11 mmol) in dry CH2Cl2 (2 mL) were added
Me2Zn (0.23 mL 1.2 M in toluene, 0.28 mmol) and BF3.OEt2 (34 μL, 0.28 mmol) one after
the other at –78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched
by slow addition of saturated aq. NaHCO3, and extracted with CH2Cl2. The organic extract
was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified
by flash column chromatography on silica gel (10 – 20 % EtOAc in hexane) to give desired
product 163 (28 mg, 62%, dr 55:45) as a colorless oil. [α]20D –6.4 (c 1.4, CHCl3); 1H NMR
(500 MHz, toluene-d8, T = 363 K) δ 7.31 – 6.92 (m, 10H), 6.37 (d, J = 11.6 Hz, 0.45H),
6.34 (d, J = 11.1 Hz 0.55H), 6.20 – 6.08 (m, 1H), 5.08 (s, 2H), 3.70 – 3.56 (m, 1H), 3.40
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– 3.29 (m, 2H), 2.83 – 2.68 (m, 5H), 2.47 – 2.36 (m, 3.45H), 2.35 – 2.24 (m, 0.55H), 2.04
– 1.93 (m, 1H), 1.88 – 1.79 (m, 0.45H), 1.79 – 1.67 (m, 0.55H), 1.11 (d, J = 6.3 Hz, 1.65H),
1.09 (d, J = 6.3 Hz, 1.35H), 0.95 – 0.88 (m, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3),
rotamers and diastereomers, δ 156.2, 137.8, 136.9, 131.0, 129.8, 129.6, 129.5, 128.5,
128.4, 127.9, 127.8, 126.9, 125.9, 80.2, 80.0, 67.04, 66.98, 58.7, 58.4, 46.9, 46.5, 46.3,
37.1, 36.9, 36.8, 35.5, 35.2, 34.7, 15.8, 15.3, 15.2, 14.4; ESIHRMS calculated for
C25H34N2O3Na [M+Na]+, 433.2467; found, 433.2460.
O-((2S,3R,4S,5R)-5-(Benzyloxy)-1,2-bis((tert-butyldimethylsilyl)oxy)-4methylhexan-3-yl) 1H-imidazole-1-carbothioate (169).
A mixture of 167151 (1.72 g, 3.56 mmol) and 1,1’-thiocarbonyldiimidazole (3.50 g,
19.66 mmol) was stirred in dry THF (8.5 mL) at 60 oC. After 5 h, additional 1,1’thiocarbonyldiimidazole (1.50 g, 8.43 mmol) was added, and the resultant mixture was
allowed to stir for 15 h. The mixture was then cooled to room temperature, concentrated
under reduced pressure, and purified by flash column chromatography on silica gel (5 –
15 % EtOAc in hexane) to give 169 (1.80 g, 85%) as a colorless oil. [α]20D +2.5 (c 1,
CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.26 (s, 1H), 7.54 (s, 1H), 7.27 – 7.18 (m, 5H), 6.97
(s, 1H), 5.96 (dd, J = 3.9, 3.1 Hz 1H), 4.53 (d, J = 11.6 Hz, 1H), 4.32 (d, J = 11.6 Hz, 1H),
4.14 (td, J = 6.4, 3.9 Hz, 1H), 3.66 (dd, J = 10.5, 6.4 Hz, 1H), 3.60 – 3.52 (m, 2H), 2.35 –
2.27 (m, 1H), 1.19 (d, J = 6.2 Hz, 3H), 1.17 (d, J = 7.0 Hz, 3H), 0.86 (s, 9H), 0.84 (s, 9H),
0.02 (s, 3H), 0.01 (s, 3H), 0.00 (s, 3H), -0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 183.8,
138.6, 136.8, 130.5, 128.1, 127.3, 127.2, 117.8, 85.5, 77.2, 73.4, 70.6, 64.9, 38.3, 25.9,
25.7, 18.3, 17.9, 16.7, 10.6, -4.5, -5.1, -5.5, -5.6; ESIHRMS calculated for C30H53N2O4SSi2
[M+H]+, 593.3265; found, 593.3260.
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(2R,3R,5R)-5,6-Bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-2-ol (170).
A degassed solution of 169 (1.78 g, 3.00 mmol), Bu3SnH (2.42 mL, 9.00 mmol),
and AIBN (49 mg, 0.3 mmol) in dry toluene (75 mL) was stirred for 2.5 h at 85 oC. The
reaction was cooled to room temperature, concentrated under reduced pressure, and
eluted through a short column of silica gel (5% EtOAc in hexane). The so-obtained
intermediate (impure) was stirred with a mixture of 10% Pd/C and Pd(OH)2 (1:1, 1.6 g) in
THF–isopropanol (3:1, 60 mL) under hydrogen gas atmosphere (1 atm) for 18 h. After
filtering through a pad of Celite®, the resulting filtrate was concentrated and purified by
flash column chromatography on silica gel (5 – 10% EtOAc in hexane) to afford 170 (0.57
g, 50% in 2 steps) as a colorless oil. [α]20D +30.9 (c 1, CHCl3); 1H NMR (600 MHz, CDCl3)
δ 3.76 – 3.65 (m, 2H), 3.55 (dd, J = 9.9, 5.2 Hz, 1H), 3.36 (dd, J = 9.9, 6.8 Hz, 1H), 1.77
– 1.68 (m, 1H), 1.55 (d, J = 4.4 Hz, 1H), 1.47 (ddd, J = 13.6, 8.9, 3.8 Hz, 1H), 1.40 – 1.33
(ddd, J = 13.6, 9.4, 3.2 Hz, 1H), 1.12 (d, J = 6.4 Hz, 3H), 0.89 – 0.87 (m, 12H), 0.86 (s,
9H), 0.06 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H);

13C

NMR (150 MHz, CDCl3) δ

71.8, 71.4, 67.9, 37.4, 35.6, 25.9, 25.9, 19.8, 18.3, 18.1, 14.6, -4.0, -4.8, -5.3, -5.4;
ESIHRMS calculated for C19H45O3Si2 [M+H]+, 377.2907; found, 377.2906.
(2S,3R,5R)-5,6-Bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-2-yl

4-

nitrobenzoate (171).
To a stirred solution of 170 (350 mg, 0.93 mmol), p-nitrobenzoic acid (187 mg, 1.12
mmol), and PPh3 (294 mg, 1.12 mmol) in dry THF (4.5 mL) was added a solution of DIAD
(227 mg, 1.12 mmol) in dry THF (0.9 mL) at 0 oC. The resultant mixture was stirred for 3
h at room temperature and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (0 – 5 % EtOAc in hexane) to afford
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171 (450 mg, 92%) as a yellow oil. [α]20D +37.8 (c 1, CHCl3); 1H NMR (400 MHz, CDCl3)
δ 8.27 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 8.8 Hz, 2H), 5.18 – 5.00 (m, 1H), 3.80 – 3.68 (m,
1H), 3.57 (dd, J = 9.9, 5.1 Hz, 1H), 3.37 (dd, J = 9.9, 6.9 Hz, 1H), 2.12 – 1.96 (m, 1H),
1.62 – 1.51 (m, 1H), 1.47 – 1.38 (m, 1H), 1.32 (d, J = 6.4 Hz, 3H), 0.99 (d, J = 6.8 Hz,
3H), 0.89 (s, 9H), 0.88 (s, 9H), 0.09 – 0.06 (m, 6H), 0.05 (s, 3H), 0.04 (s, 3H);

13C

NMR

(100 MHz, CDCl3) δ 164.2, 150.4, 136.3, 130.6, 123.5, 76.9, 70.7, 67.7, 36.8, 33.6, 25.9,
25.9, 18.3, 18.1, 16.7, 15.4, -3.9, -4.8, -5.31, -5.34; ESIHRMS calculated for
C26H47NO6Si2Na [M+Na]+, 548.2840; found, 548.2833.
(2S,3R,5R)-5,6-Bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-2-ol (172).
To a stirred solution of 171 (440 mg, 0.84 mmol) in dry MeOH (3.5 mL) was added
NaOMe (90 mg, 1.67 mmol) in portion wise at room temperature. After stirring for 12 h at
room temperature, the reaction mixture was concentrated, and the residue was purified
by flash column chromatography on silica gel (5 – 50 % EtOAc in CH2Cl2) to give 172
(280 mg, 89%) as a colorless oil. [α]20D +33.0 (c 2.7, CHCl3); 1H NMR (400 MHz, CDCl3)
δ 3.77 – 3.66 (m, 1H), 3.65 – 3.58 (m, 1H), 3.56 (dd, J = 9.9, 5.2 Hz, 1H), 3.37 (dd, J =
9.9, 6.8 Hz, 1H), 1.77 (s, 1H), 1.74 – 1.62 (m, 1H), 1.51 (ddd, J = 13.7, 8.9, 3.3 Hz, 1H),
1.35 (ddd, J = 13.7, 9.2, 3.1 Hz, 1H), 1.12 (d, J = 6.3 Hz, 3H), 0.92 – 0.88 (m, 12H), 0.87
(s, 9H), 0.07 (s, 6H), 0.05 – 0.03 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 72.3, 71.4, 67.8,
37.3, 36.1, 25.94, 25.89, 19.9, 18.3, 18.1, 15.7, -4.1, -4.7, -5.32, -5.34; ESIHRMS
calculated for C19H45O3Si2 [M+H]+, 377.2907; found, 377.2908.
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2-(((2R,3R,5R)-5,6-Bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-2yl)oxy)isoindoline-1,3-dione (173).
To a stirred solution of 172 (340 mg, 0.90 mmol), N-hydroxyphthalimide (177 mg,
1.08 mmol), and PPh3 (286 mg, 1.08 mmol) in dry THF (5 mL) was added a solution of
DIAD (220 mg, 1.08 mmol) in dry THF (1 mL) at 0 oC. After stirring for 30 min at 0 oC and
1.5 h at room temperature, the reaction mixture was concentrated under reduced
pressure. The residue was purified by flash column chromatography on silica gel (0 – 5
% EtOAc in hexane) to afford 173 (419 mg, 89%) as a yellow oil. [α]20D +19.6 (c 1.3,
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H), 7.76 – 7.68 (m, 2H), 4.41 –
4.19 (m, 1H), 3.85 – 3.73 (m, 1H), 3.59 (dd, J = 10.0, 5.4 Hz, 1H), 3.43 (dd, J = 10.0, 6.2
Hz, 1H), 2.16 – 2.00 (m, 1H), 1.72 (ddd, J = 13.7, 9.4, 3.1 Hz, 1H), 1.53 (ddd, J = 13.7,
10.7, 3.0 Hz, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 0.85 (s,
9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.06 – 0.04 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 164.3,
134.3, 129.1, 123.3, 88.1, 71.0, 68.1, 37.0, 33.0, 26.0, 25.9, 18.4, 18.1, 15.8, 14.6, -4.0,
-4.8, -5.31, -5.31; ESIHRMS calculated for C27H51N2O5Si2 [M+NH4]+, 539.3337; found,
539.3335.
(R)-N-Allyl-N,2-dimethylbutanamide (174).
To an ice-cold solution (<5 oC) of an acid (R)-2-methylbutyric acid 132 (0.52 g,
5.00 mmol) in dry CH2Cl2 (20 mL) were added N-allylmethylamine (530 mg, 7.50 mmol),
HOBt (80% in water, 1.35 g, 7.50 mmol), EDCI.HCl (1.44 g, 7.50 mmol), and DIPEA (1.31
mL, 7.50 mmol), and the resulting solution was stirred for 16 h at room temperature. The
mixture was diluted with CH2Cl2, washed with 1 M HCl followed by saturated aq. NaHCO3,
dried over anhydrous Na2SO4, and concentrated under reduced pressure. Purification of

183
the residue by flash column chromatography on silica gel (10 – 30 % EtOAc in hexane)
afforded 174 (0.68 g, 87%) as a colorless oil. [α]20D –38.0 (c 1, CHCl3); 1H NMR (400
MHz, CDCl3), both rotamers, δ 5.82 – 5.63 (m, 1H), 5.25 – 4.97 (m, 2H), 4.10 – 3.80 (m,
2H), 2.94 (s, 3H, 1 rotamer), 2.88 (s, 3H, 1 rotamer), 2.65 – 2.53 (m, 1H, 1 rotamer), 2.53
– 2.41 (m, 1H, 1 rotamer), 1.74 – 1.57 (m, 1H), 1.44 – 1.27 (m, 1H), 1.09 – 1.02 (m, 3H),
0.88 – 0.78 (m, 3H);

13C

NMR (100 MHz, CDCl3), both rotamers, δ 177.1, 176.5, 133.5,

133.2, 117.0, 116.5, 52.1, 50.2, 37.5, 37.3, 34.8, 33.9, 27.5, 27.2, 17.9, 17.3, 12.2, 12.1.
ESIHRMS calculated for C9H18NO [M+H]+, 156.1388; found, 156.1393.
(R)-N,2-Dimethyl-N-(2-oxoethyl)butanamide (166).
Ozone was bubbled in a solution of 174 (189 mg, 1.20 mmol) in MeOH-CH2Cl2
(1:5, 12 mL) until blue color wasn’t observed (20 min) at –78 oC. Argon was bubbled to
decolorize the solution, and dimethyl sulfide (0.44 mL, 6.00 mmol) was added. The
resultant mixture was stirred in an ice-bath (<5 oC) for 1 h and concentrated under
reduced pressure (water bath <25 oC). The so-obtained crude aldehyde 166 was then
used immediately in next reaction without purification.
Formaldehyde

O-((2R,3R,5R)-5,6-bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-

2-yl) oxime (175).
Hydrazine monohydrate (88 μL, 1.76 mmol) was added to a solution of 173 (230
mg, 0.44 mmol) in MeOH-CH2Cl2 (1:1, 7 mL) at room temperature, and the resultant
mixture was stirred for 1 h. The reaction mixture was diluted with CH 2Cl2, washed with
5% aq. NaHCO3 solution and brine, dried over anhydrous Na2SO4, and concentrated
under reduced pressure. The so-obtained O-alkylhydroxylamine intermediate was then
treated with paraformaldehyde (110 μL 37% solution, 1.32 mmol) in MeOH:CH2Cl2 (3:2,
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3.3 mL) at room temperature. After 1 h, the resultant mixture was concentrated and
purified by flash column chromatography on silica gel (0 – 3 % EtOAc in hexane) to give
oxime 175 (161 mg, 90%) as a colorless oil. [α]20D +25.4 (c 1.3, CHCl3); 1H NMR (600
MHz, CDCl3) δ 6.98 (d, J = 8.8 Hz, 1H), 6.35 (d, J = 8.8, 1H), 4.17 – 4.05 (m, 1H), 3.74 –
3.66 (m, 1H), 3.53 (dd, J = 9.9, 5.4 Hz, 1H), 3.36 (dd, J = 9.9, 6.3 Hz, 1H), 2.03 – 1.91
(m, 1H), 1.46 (ddd, J = 13.6, 9.1, 3.3 Hz, 1H), 1.33 (ddd, J = 13.6, 10.5, 3.2 Hz, 1H), 1.15
(d, J = 6.5 Hz, 3H), 0.91 – 0.83 (m, 21H), 0.05 (s, 3H), 0.04 (s, 3H), 0.04 – 0.02 (m, 6H);
13C

NMR (150 MHz, CDCl3) δ 136.1, 83.3, 71.1, 68.1, 36.6, 32.9, 26.0, 25.9, 18.3, 18.1,

15.8, 15.1, -4.0, -4.8, -5.30, -5.34; ESIHRMS calculated for C20H46NO3Si2 [M+H]+,
404.3016; found, 404.3014.
(R)-N-((5R,6R,8R)-8-((tert-Butyldimethylsilyl)oxy)-3,5,6,11,11,12,12-heptamethyl4,10-dioxa-3-aza-11-silatridecyl)-N,2-dimethylbutanamide (176).
NaCNBH3 (75 mg, 1.20 mmol) was added carefully to a stirred solution of 175 (161
mg, 0.40 mmol) in a mixture of 0.1 M HCl and EtOH (1:3, 6 mL, pH = 2-3) at room
temperature. After stirring for 1 h, the reaction was quenched with saturated aq. NaHCO3
and extracted with ether. The organic extract was washed with brine, dried over
anhydrous NaSO4, and concentrated under reduced pressure. The so-obtained crude
N,O-dialkylhydroxylamine was then treated with a aldehyde 166 (189 mg, 1.20 mmol) in
dry MeOH–CH2Cl2 (5:3, 8 mL) at room temperature. After stirring for 2 h, NaCNBH3 (75
mg, 1.20 mmol) and acetic acid (137 μL, 2.40 mmol) were added sequentially, and the
mixture was stirred for next 45 min. The reaction was quenched with saturated aq.
NaHCO3 and extracted with EtOAc. The Organic extract was washed with brine, dried
over anhydrous Na2SO4, and concentrated under reduced pressure. Purification of the
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residue by flash column chromatography on silica gel (10 – 30 % EtOAc in hexane)
afforded 176 (161 mg, 74%) as a colorless oil. [α]20D +10.8 (c 1, CHCl3); 1H NMR (600
MHz, CDCl3), both rotamers, δ 3.73 – 3.31 (m, 6H), 3.05 (s, 3H, 1 rotamer), 2.93 (s, 3H,
1 rotamer), 2.85 – 2.68 (m, 2H), 2.65 – 2.50 (m, 4H), 1.90 (s, 1H), 1.74 – 1.62 (m, 1H),
1.49 – 1.26 (m, 3H), 1.12 – 1.02 (m, 6H), 0.90 – 0.82 (m, 24H), 0.06 – 0.01 (m, 12H); 13C
NMR (150 MHz, CDCl3), both rotamers, δ 176.7, 176.4, 81.3, 71.2, 71.1, 68.2, 68.1, 59.5,
58.2, 47.4, 46.5, 46.2, 45.7, 37.3, 37.1, 36.6, 36.4, 36.1, 34.1, 32.3, 32.1, 27.3, 27.0, 26.0,
25.93, 25.91, 25.89, 18.3, 18.1, 17.8, 17.0, 15.7, 15.6, 15.1, 14.9, 12.1, 12.0, -4.0, -4.7, 5.30, -5.34; ESIHRMS calculated for C28H63N2O4Si2 [M+H]+, 547.4326; found, 547.4328.
(3R,4R)-4-(((2-((R)-N,2-Dimethylbutanamido)ethyl)(methyl)amino)oxy)-3methylpentanoic acid (164).
To an ice-cold solution (< 5 oC) of 176 (161 mg, 0.29 mmol) in dry THF (8 mL) was
added TBAF (1 M THF solution, 1.16 mL, 1.16 mmol), and the resultant solution was
stirred for 1 h at room temperature. The reaction mixture was diluted with EtOAc, washed
with water followed by brine, dried over anhydrous Na 2SO4, and concentrated under
reduced pressure. The so-obtained crude diol intermediate was treated with NaIO4 (94
mg, 0.44 mmol) in CH2Cl2–water (4:1, 5 mL) for 1 h in an ice-bath (<5 oC). The reaction
mixture was diluted with CH2Cl2, washed with water followed by brine, dried over
anhydrous Na2SO4, and concentrated under reduced pressure to give crude aldehyde
intermediate. To a stirred solution of this crude aldehyde in MeOH (11 mL) was added 2methyl-2-butene (1.54 mL. 14.50 mmol) followed by a freshly prepared solution of NaClO2
(1.25 M in 20% NaH2PO4 solution, 1.16 mL, 1.45 mmol) at room temperature. The
resultant mixture was stirred vigorously for 1 h at room temperature, diluted with ether,
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washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure,
and purified by flash column chromatography on silica gel (0 – 5 % MeOH in CH2Cl2) to
afford 164 (71 mg, 80%) as a colorless oil. [α]20D –27.4 (c 0.35, CHCl3); 1H NMR (600
MHz, CDCl3), both rotamers, δ 3.68 – 3.55 (m, 3H, rotamer), 3.55 – 3.40 (m, 3H, rotamer),
3.04 (s, 3H, rotamer), 2.93 (s, 3H, rotamer), 2.87 – 2.69 (m, 2H), 2.62 – 2.45 (m, 5H),
2.28 – 2.18 (m, 1H), 2.15 – 2.04 (m, 1H), 1.72 – 1.59 (m, 1H), 1.44 – 1.31 (m, 1H), 1.10
– 1.01 (m, 6H), 0.95 – 0.88 (m, 3H), 0.88 – 0.81 (m, 3H);

13C

NMR (150 MHz, CDCl3) ,

both rotamers, δ 178.1, 178.0, 177.0, 176.9, 79.3, 79.2, 59.3, 57.8, 47.4, 46.3, 45.8, 45.5,
37.4, 37.2, 36.8, 36.6, 36.0, 34.2, 33.82, 33.76, 27.2, 27.0, 17.6, 16.9, 15.32, 15.25, 12.0,
11.9; ESIHRMS calculated for C15H31N2O4 [M+H]+, 303.2284; found, 303.2292.
(3R,4R)-4-(((2-((R)-N,2-Dimethylbutanamido)ethyl)(methyl)amino)oxy)-N-((R)-1hydroxybut-3-en-2-yl)-3-methylpentanamide (177).
To a mixture of 164 (71 mg, 0.23 mmol), and 112147 (58 mg, 0.47 mmol) in dry
CH2Cl2 (2 mL) were added DIPEA (123 μL, 0.70 mmol) and DMAP (14 mg, 0.12 mmol)
at room temperature. After stirring for 10 min, EDCI.HCl (134 mg, 0.70 mmol) was added.
The mixture was stirred for 14 h and concentrated under reduced pressure. Purification
of the residue by flash column chromatography on silica gel (25 – 50 % EtOAc in hexane)
afforded 177 (86 mg, 99%) as a yellow oil. [α]20D –5.7 (c 0.35, CHCl3); 1H NMR (600 MHz,
CDCl3), both rotamers, δ 6.82 (s, 1H, rotamer), 6.15 (s, 1H, rotamer), 5.87 – 5.79 (m, 1H),
5.37 – 5.05 (m, 2H), 4.61 – 4.49 (m, 1H), 3.89 – 3.26 (m, 6H), 3.05 (s, 3H, rotamer), 2.94
(s, 3H, rotamer), 2.83 – 2.69 (m, 2H), 2.65 – 2.51 (m, 5H, rotamer), 2.41 (dd, J = 14.1,
4.5 Hz, 1H, rotamer), 2.30 – 2.19 (m, 1H), 2.07 (dd, J = 14.1, 7.3 Hz, 1H, rotamer), 1.98
(dd, J = 14.1, 9.6 Hz, 1H, rotamer), 1.73 – 1.59 (m, 1H), 1.46 – 1.34 (m, 1H), 1.11 – 1.02
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(m, 6H), 0.90 (d, J = 7.0 Hz, 3H), 0.88 – 0.84 (m, 3H); 13C NMR (150 MHz, CDCl3), both
rotamers, δ 177.1, 177.0, 173.2, 172.6, 135.4, 135.2, 116.6, 116.4, 79.4, 79.0, 65.2, 65.1,
59.5, 57.8, 53.8, 53.5, 47.4, 46.4, 46.0, 45.5, 39.7, 39.6, 37.4, 37.1, 36.1, 34.6, 34.4, 34.3,
27.3, 27.0, 17.6, 17.0, 16.3, 15.9, 14.8, 14.6, 12.1, 11.9; ESIHRMS calculated for
C19H38N3O4 [M+H]+, 372.2862; found, 372.2861.
(R)-N,2-Dimethyl-N-(2-(methyl(((2R,3R)-3-methyl-4-((R)-4-vinyl-4,5-dihydrooxazol2-yl)butan-2-yl)oxy)amino)ethyl)butanamide (178).
To a stirred solution of 177 (56 mg, 0.15 mmol) in dry CH2Cl2 (5 mL) was added
DAST (40 μL, 0.30 mmol) at –78 oC. The reaction was quenched with saturated aq.
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under
reduced pressure, and purified by flash column chromatography on neutral alumina (25
– 50 % EtOAc in hexane) to give 178 (42 mg, 79%) as a colorless oil. [α]20D +26.7 (c 0.27,
CHCl3); 1H NMR (600 MHz, CDCl3) , both rotamers, δ 5.79 (ddd, J = 17.2, 10.2, 7.1 Hz,
1H), 5.26 – 5.17 (m, 1H), 5.12 (dd, J = 10.2, 4.6 Hz, 1H), 4.57 (dt, J = 14.8, 7.1 Hz, 1H),
4.38 – 4.27 (m, 1H), 3.94 – 3.87 (m, 1H), 3.68 – 3.34 (m, 3H), 3.05 (s, 3H, rotamer), 2.93
(s, 3H, rotamer), 2.87 – 2.70 (m, 2H), 2.60 – 2.51 (m, 4H), 2.49 – 2.41 (m, 1H), 2.21 –
2.14 (m, 1H), 2.14 – 2.04 (m, 1H), 1.72 – 1.60 (m, 1H), 1.45 – 1.31 (m, 1H), 1.11 – 1.04
(m, 6H), 0.94 – 0.89 (m, 3H), 0.88 – 0.83 (m, 3H);

13C

NMR (150 MHz, CDCl3), both

rotamers, δ 176.7, 176.4, 168.1, 167.8, 138.2, 138.1, 116.2, 116.1, 79.4, 72.0, 71.9, 68.2,
59.4, 58.1, 47.4, 46.4, 46.0, 45.6, 37.3, 37.1, 36.0, 34.6, 34.5, 34.1, 30.5, 30.4, 27.3, 27.0,
17.7, 17.0, 15.4, 15.3, 15.1, 15.0, 12.1, 12.0; ESIHRMS calculated for C19H36N3O3
[M+H]+, 354.2757; found, 354.2760.
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(R)-N-(2-((((2R,3R)-5-(((R)-1-Hydroxybut-3-en-2-yl)amino)-3-methyl-5-thioxopentan2-yl)oxy)(methyl)amino)ethyl)-N,2-dimethylbutanamide (179).
Compound 178 (34 mg, 0.01 mmol) was dissolved in MeOH–Et3N (1:1, 3 mL,
saturated with H2S), and stirred for 16 h at room temperature. The mixture was
concentrated under reduced pressure and purified by flash column chromatography on
neutral alumina (25 – 50 % acetone in hexane) to afford 179 (29 mg, 78%) as a colorless
oil. [α]20D +28.8 (c 1, CHCl3); 1H NMR (600 MHz, CDCl3), both rotamers, δ 8.81 (br s, 1H,
rotamer), 8.15 (br s, 1H, rotamer), 5.86 (ddd, J = 17.3, 10.5, 5.4 Hz, 1H), 5.35 – 5.27 (m,
1H), 5.27 (d, J = 17.3 Hz, 1H), 5.24 (d, J = 10.5 Hz, 1H), 3.91 – 3.60 (m, 4H), 3.57 – 3.44
(m, 1H, rotamer), 3.40 – 3.30 (m, 1H, rotamer), 3.05 (s, 3H, rotamer), 2.96 (s, 3H,
rotamer), 2.92 (dd, J = 13.6, 7.4 Hz, 1H), 2.85 – 2.75 (m, 2H), 2.66 – 2.55 (m, 5H), 2.48
– 2.37 (m, 1H), 1.70 – 1.57 (m, 1H), 1.47 – 1.34 (m, 1H), 1.13 – 1.08 (m, 3H), 1.06 (d, J
= 6.8 Hz, 3H), 0.92 (d, J = 7.1 Hz, 3H), 0.88 – 0.83 (m, 3H); 13C NMR (150 MHz, CDCl3),
major rotamer only, δ 205.1, 177.3, 133.7, 117.2, 78.9, 64.0, 58.9, 57.7, 50.1, 46.6, 45.5,
38.2, 37.4, 36.2, 27.0, 17.1, 17.0, 13.8, 11.9; ESIHRMS calculated for C19H38N3O3S
[M+H]+, 388.2634; found, 388.2636.
9-Oxa-10-azakalkitoxin (109).
To a stirred solution of 179 (25 mg, 0.07 mmol) in dry CH2Cl2 (2.2 mL) was added
DAST (17 μL, 0.13 mmol) at –78 oC. The reaction was quenched with saturated aq.
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under
reduced pressure, and purified by flash column chromatography on neutral alumina (25
% EtOAc in hexane) to give 109 (22 mg, 92%) as a colorless oil. [α]20D +10.0 (c 0.35,
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CHCl3); 1H NMR (600 MHz, CDCl3) , both rotamers, δ 5.92 (ddd, J = 17.1, 10.2, 6.8 Hz,
1H), 5.27 (d, J = 17.1, 1H), 5.18 – 5.11 (m, 1H), 4.91 (dt, J = 14.5, 7.5 Hz, 1H), 3.69 –
3.49 (m, 2H), 3.49 – 3.37 (m, 2H), 3.09 – 3.01 (m, 4H, rotamer), 2.93 (s, 3H, rotamer),
2.87 – 2.71 (m, 2H), 2.70 – 2.62 (m, 1H), 2.62 – 2.51 (m, 4H), 2.40 – 2.31 (m, 1H), 2.20
– 2.12 (m, 1H), 1.74 – 1.62 (m, 1H), 1.44 – 1.33 (m, 1H), 1.12 – 1.02 (m, 6H), 0.91 (d, J
= 6.9 Hz, 3H, rotamer), 0.89 (d, J = 6.9 Hz, 3H, rotamer), 0.88 – 0.84 (m, 3H);

13C

NMR

(150 MHz, CDCl3) , both rotamers, δ 176.7, 176.4, 171.2, 170.8, 137.3, 137.2, 116.1,
116.0, 79.4, 78.6, 78.5, 59.4, 58.1, 47.4, 46.4, 46.1, 45.6, 38.62, 38.61, 37.3, 37.1, 36.8,
36.7, 36.0, 35.9, 35.8, 34.1, 27.3, 27.0, 17.8, 17.0, 15.5, 15.4, 14.9, 14.8, 12.1, 12.0;
ESIHRMS calculated for C19H36N3O2S [M+H]+, 370.2528; found, 370.2541.
Synthesis of 7,8-diazakalkitoxin (110):
(R,E)-2-Methyl-5-phenylpent-4-en-1-ol (187).
To a heterogeneous mixture of 159 (7.40 g, 21.18 mmol) and anhydrous diethyl
ether (200 mL) were added EtOH (1.85 mL, 31.77 mmol) and LiBH4 (0.69 g, 31.77 mmol)
at 0 oC. After stirring for 2 h at 0 oC and 2 h at room temperature, the reaction was
quenched by careful slow addition of 1M NaOH (180 mL) at 0 oC followed by stirring for
15 min at room temperature. The resultant mixture was extracted with ether and the ether
extract was washed with saturated aq. NH4Cl, water, and brine, dried over anhydrous
Na2SO4, and concentrated under reduced pressure. Purification was performed by flash
column chromatography on silica gel to afford 187157 (3.33 g, 89%) as a yellow oil (eluent:
dichloromethane). [α]20D +5.4 (c 2.5, CH2Cl2); lit157 [α]D +6.1 (c 1.7, CH2Cl2); 1H NMR (400
MHz, CDCl3) δ 7.42 – 7.16 (m, 5H), 6.42 (d, J = 15.8 Hz, 1H), 6.23 (dt, J = 15.8, 7.3 Hz,
1H), 3.57 (dd, J = 10.6, 6.2 Hz, 1H), 3.51 (dd, J = 10.6, 6.1 Hz, 1H), 2.40 – 2.28 (m, 1H),
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2.17 – 2.05 (m, 1H), 1.89 – 1.76 (m, 1H), 1.58 (s, 1H), 0.98 (d, J = 6.8 Hz, 3H); 13C NMR
(100 MHz, CDCl3) δ 137.6, 131.4, 128.7, 128.5, 127.0, 126.0, 68.0, 36.9, 36.1, 16.5.
(R,E)-2-Methyl-5-phenylpent-4-en-1-al (184).
To an ice-cold solution of 187 (1g, 5.67 mmol) in dry CH2Cl2 (28 mL) was added
Dess-Martin periodinane (4.81 g, 11.35 mmol) portion wise, and the reaction was stirred
for 4 h at room temperature. The reaction was diluted with ether (30 mL), quenched with
a mixture of water, saturated aq. Na2S2O3, and saturated aq. NaHCO3 (1:1:1, 50 mL), and
stirred for 1 h at room temperature. The resultant mixture was extracted with ether, and
the ether extract was washed with brine, dried over anhydrous Na 2SO4, concentrated
under reduced pressure, and purified by flash column chromatography on silica gel to
afford the desired aldehyde 184156 (0.74 g, 75%) as a colorless oil (eluent: 5 – 15% ether
in hexane). This material was immediately forwarded to next reaction. [α]20D –7.12 (c 2.5,
CH2Cl2); lit157 [α]D –6.07 (c 2.39, CCl4) 1H NMR (400 MHz, CDCl3) δ 9.72 (d, J = 1.4 Hz,
1H), 7.40 – 7.18 (m, 5H), 6.46 (d, J = 15.8 Hz, 1H), 6.16 (dt, J = 15.8, 7.2 Hz, 1H), 2.71
– 2.59 (m, 1H), 2.59 – 2.48 (m, 1H), 2.38 – 2.25 (m, 1H), 1.17 (d, J = 7.0 Hz, 3H).

13C

NMR (100 MHz, CDCl3) δ 204.5, 137.1, 132.5, 128.5, 127.3, 126.6, 126.1, 46.3, 34.0,
13.2.
Benzyl N-methyl-N-(methylamino)glycinate (183).
To a stirred suspension of N,N’-dimethylhydrazine dihydrochloride (1 g, 7.5 mmol)
and NaHCO3 (1.89 g, 22.50 mmol) in dry DMF-PhMe (1:3, 10 mL) was added benzyl
bromoacetate158 (1.72 g, 7.5 mmol) dropwise in 1 h at room temperature. The reaction
mixture was stirred for 1 h at 85 oC and cooled to room temperature. Then the mixture
was diluted with toluene, washed with water followed by brine, dried over anhydrous
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Na2SO4, and concentrated under reduced pressure. The residue was purified by flash
column chromatography on silica gel (50 – 100% EtOAc in hexane) to give the desired
product 183 (1.04 g, 67%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m,
5H), 5.15 (s, 2H), 3.52 (s, 2H), 2.95 (s, 1H), 2.61 (s, 3H), 2.53 (s, 3H);

13C

NMR (100

MHz, CDCl3) δ 170.4, 135.6, 128.5, 128.3, 128.3, 66.2, 59.5, 42.3, 35.5; ESIHRMS
calculated for C11H17N2O2 [M+H]+, 209.1290; found, 209.1289.
Benzyl (R,E)-N-methyl-N-(methyl(2-methyl-5-phenylpent-4-en-1-yl)amino)glycinate
(188).
Hydrazine 183 (800 mg, 3.85 mmol) was treated with aldehyde 184 (737 mg, 4.23
mmol) in MeOH-CH2Cl2 (1:1, 21 mL) at room temperature. After stirring for 1 h, NaCNBH3
(724 mg, 11.55 mmol) was added portion wise followed by stirring for 3 h. The reaction
was quenched with 1:1 mixture of saturated aq. NaHCO3 and brine (50 mL) and extracted
with CH2Cl2. The resultant organic extract was dried over anhydrous Na 2SO4,
concentrated under reduced pressure, and purified by flash column chromatography on
silica gel to afford the desired compound 188 (872 mg, 62%) as a colorless oil (eluent: 0
– 25% EtOAc in hexane). [α]20D +3.0 (c 4.5, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.43 –
7.25 (m, 9H), 7.23 – 7.15 (m, 1H), 6.37 (d, J = 15.8 Hz, 1H), 6.21 (dt, J = 15.8, 7.2 Hz,
1H), 5.17 (s, 2H), 3.39 (s, 2H), 2.45 – 2.24 (m, 9H), 2.03 – 1.92 (m, 1H), 1.88 – 1.77 (m,
1H), 0.90 (d, J = 6.6 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 170.6, 137.9, 135.9, 131.0,

129.5, 128.5, 128.5, 128.3, 128.2, 126.7, 125.9, 66.4, 60.0, 57.3, 38.4, 35.8, 34.3, 31.3,
18.0; ESIHRMS calculated for C23H30N2O2Na [M+Na]+, 389.2205; found, 389.2204.
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Benzyl (R)-N-methyl-N-(methyl(2-methyl-4-oxobutyl)amino)glycinate (189).
To an ice-cold solution of 188 (470 mg, 1.28 mmol) in acetone-water (3:2, 10 mL)
was added N-methylmorpholine-N-oxide (451 mg, 3.84 mmol) and OsO4 (12.8 mL, 4 μM
in PhMe, 0.05 mmol). The reaction flask was rapped with aluminum foil and allowed to
stir for 16 h at room temperature. Na2SO3 (807 mg, 6.40 mmol) was added and stirred for
5 min followed by concentration under reduced pressure. The resultant residue was
dissolved in ethyl acetate, washed with water followed by brine, dried over anhydrous
Na2SO4, and concentrated under reduced pressure. The so-obtained diol residue was
treated with NaIO4 (383 mg, 1.80 mmol) in CH2Cl2-water (4:1, 10 mL) at 0 oC for 1.5 h.
The reaction was diluted with CH2Cl2, washed with water followed by brine, dried over
anhydrous Na2SO4, and concentrated under reduced pressure. Purification was
performed by flash column chromatography on silica gel to afford 189 (234 mg, 62%) as
a yellow oil (eluent: 10 – 40% EtOAc in hexane). [α]20D +9.0 (c 1.25, CH2Cl2); 1H NMR
(400 MHz, CDCl3) δ 9.64 (s, 1H), 7.44 – 7.19 (m, 5H), 5.14 (s, 2H), 3.34 (s, 2H), 2.48 –
2.26 (m, 7H), 2.23 (s, 3H), 2.08 (dd, J = 15.7, 4.4 Hz, 1H), 0.90 (d, J = 6.0 Hz, 3H);

13C

NMR (100 MHz, CDCl3) δ 202.9, 170.5, 135.8, 128.5, 128.4, 128.3, 66.4, 60.6, 56.9, 49.4,
35.1, 34.5, 26.9, 18.6; ESIHRMS calculated for C16H25N2O3 [M+H]+, 293.1865; found,
293.1861.
Benzyl

(R)-N-methyl-N-(methyl(2-methyl-4-(methylamino)butyl)amino)glycinate

(190).
MeNH2.HCl (11 mg, 0.16 mmol) and MeNH2 (0.13 ml of 2 M in THF, 0.25 mmol)
were added sequentially to a stirred mixture of 189 (25 mg, 0.08 mmol), anhydrous
Na2SO4 (50 mg), and dry MeOH (0.6 mL) at room temperature. After stirring for 30 min at
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room temperature, the reaction was cooled in an ice-bath and NaCNBH3 (21 mg, 0.33
mmol) was added. The stirring was continued for 45 min at room temperature and the
mixture was concentrated under reduced pressure. Purification was performed by flash
column chromatography on silica gel to afford 190 (18 mg, 72%) as a yellow oil (eluent:
0 ‒ 30 % MeOH in CH2Cl2). [α]20D +17.1 (c 1.4, CHCl3);

1H

NMR (400 MHz, CDCl3) δ

7.43 – 7.27 (m, 5H), 5.16 (s, 2H), 3.43 – 3.30 (m, 2H), 3.11 – 2.99 (m, 1H), 2.90 (dt, J =
12.5, 7.2 Hz, 1H), 2.61 (s, 3H), 2.40 – 2.30 (m, 5H), 2.26 (s, 3H), 1.95 – 1.81 (m, 2H),
1.73 – 1.50 (m, 1H), 0.90 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 135.5,
128.6, 128.4, 128.3, 66.8, 60.8, 56.2, 47.8, 34.8, 34.6, 32.8, 31.4, 29.0, 19.4. ESIHRMS
calculated for C17H30N3O2 [M+H]+, 308.2338; found, 308.2343.
Benzyl

N-(((R)-4-((R)-N,2-dimethylbutanamido)-2-methylbutyl)(methyl)amino)-N-

methylglycinate (191).
To an ice-cold solution (<5 oC) of amine 190 (170 mg, 0.55 mmol) and (R)-2methylbutanoic acid (113 mg, 1.11 mmol) in DMF (3 mL) were added HOBt (187 mg
wetted with 20 wt.% H2O, 1.11 mmol), EDCI.HCl (213 mg, 1.11 mmol), and DIPEA (193
μL, 1.11 mmol), and the reaction mixture was stirred for 12 h at room temperature. Then
the reaction was diluted with EtOAc, washed with water followed by brine, dried over
anhydrous Na2SO4, concentrated under reduced pressure, and purified by flash column
chromatography on silica gel to give 191 (145 mg, 67%) as a yellow oil (eluent: 20 – 80%
ethyl acetate in hexane). [α]20D ‒10.4 (c 6.15, CHCl3); 1H NMR (600 MHz, CDCl3) , both
rotamers, δ 7.44 – 7.27 (m, 5H), 5.13 (s, 2H), 3.47 – 3.08 (m, 4H), 2.95 (s, 3H, rotamer),
2.88 (s, 3H, rotamer), 2.61 – 2.48 (m, 1H), 2.40 – 2.15 (m, 7H), 1.87 – 1.49 (m, 4H), 1.43
– 1.32 (m, 1H), 1.24 – 1.14 (m, 1H), 1.12 – 1.02 (m, 3H), 0.91 – 0.83 (m, 6H);

13C

NMR
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(150 MHz, CDCl3) , both rotamers, δ 176.5, 176.1, 170.5, 170.5, 135.9, 135.8, 128.5,
128.5, 128.22, 128.15, 66.3, 66.2, 61.1, 60.3, 57.0, 56.9, 48.0, 45.9, 37.3, 37.1, 35.9,
35.3, 35.1, 34.5, 34.4, 34.0, 33.6, 32.2, 32.1, 28.9, 28.8, 27.4, 27.0, 18.2, 18.1, 17.8,
17.10, 17.05, 12.1, 12.0; ESIHRMS calculated for C22H38N3O3 [M+H]+, 392.2913; found,
392.2917.
tert-Butyl

(R)-(1-(methoxy(methyl)amino)-1-oxo-3-((2,4,5-

trimethoxybenzyl)thio)propan-2-yl)carbamate (193).
To a stirred solution of 192160 (7.90 g, 19.02 mmol) in dioxane-water (1:1, 38 mL)
were added Et3N (6.63 mL, 47.55 mmol) and Boc2O (5.19 g, 23.78 mmol) in 5 min time
interval at room temperature. After stirring for 30 min at room temperature, volatile
components were evaporated in a rotary evaporator. The residue was diluted with water
(50 mL) and the non-polar impurities were washed out with ether and discarded. The
resultant aqueous phase was cooled in an ice-bath, acidified with half saturated citric acid
to pH 4, and extracted with CH2Cl2. The CH2Cl2 extract was dried over anhydrous Na2SO4
and concentrated under reduced pressure. The so-obtained crude acid intermediate was
Dissolved in dry THF (380 mL) and cooled in an ice-bath. To this ice-cold solution
were added HOBt (4.48 g wet in 14 wt% water, 28.53 mmol) and EDCI.HCl (5.47 g, 28.53
mmol). After stirring for 15 min at room temperature, N,O-dimethylhydroxylamine (2.78 g,
28.53 mmol) and DIPEA (4.97 mL, 28.53 mmol) were added. The stirring was continued
for 20 h and concentrated under reduced pressure. The residue was dissolved in EtOAc,
washed with water, saturated aq. NaHCO3, and brine, dried over Na2SO4, concentrated
under reduced pressure, and purified by flash column chromatography on silica gel (10 –
50 % EtOAc in hexane) to afford desired product 193 (6.23 g, 74%) as a colorless foam:
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[α]20D +63.3 (c 2.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 2H), 5.46 (d, J = 8.1 Hz,
1H), 4.91 (br s, 1H), 3.84 (d, J = 12.8 Hz, 1H), 3.81 (s, 6H), 3.79 (s, 3H), 3.78 (s, 3H),
3.71 (d, J = 12.8 Hz, 1H), 3.20 (s, 3H), 2.84 (dd, J = 13.9, 5.9 Hz, 1H), 2.73 (dd, J = 13.9,
7.4 Hz, 1H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 172.0, 160.3, 158.7, 155.3, 107.7,
90.6, 79.4, 61.6, 55.7, 55.3, 50.8, 33.7, 32.1, 28.3, 24.6; ESIHRMS calculated for
C20H32N2O7SNa [M+Na]+, 467.1828; found, 467.1825.
tert-Butyl (R)-(1-oxo-3-((2,4,5-trimethoxybenzyl)thio)propan-2-yl)carbamate (194).
To a stirred solution of 193 (5.45 g, 12.26 mmol) in an anhydrous diethyl ether (55
mL) was added LiAlH4 (0.70 g, 18.39 mmol) portion wise at 0 oC, and the mixture was
stirred for 40 min. The reaction was diluted with diethyl ether (55 mL) and quenched by
addition of ice-cold 1 M HCl (100 mL). The organic layer was separated, and the aqueous
layer was extracted with diethyl ether. The combined organic extract was washed with 1
M HCl followed by brine, dried over anhydrous Na2SO4, and concentrated under reduced
pressure. Purification by flash column chromatography on silica gel (10 – 50% EtOAc in
hexane) afforded the desired product 194 (4.37 g, 92%) as a white solid. M.p. 90 – 93 oC
[α]20D –16.97 (c 1.65, CHCl3); 1H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 6.12 (s, 2H), 5.48
(br s, 1H), 4.44 – 4.22 (m, 1H), 3.90 – 3.63 (m, 11H), 3.00 – 2.75 (m, 2H), 1.45 (s, 9H);
13C

NMR (100 MHz, CDCl3) δ 199.8, 160.6, 158.8, 155.7, 107.0, 90.6, 80.2, 59.3, 55.7,

55.3, 31.0, 28.3, 24.4; ESIHRMS calculated for C18H27NO6SNa [M+Na]+, 385.1559;
found, 385.1565.
tert-Butyl (R)-(1-((2,4,5-trimethoxybenzyl)thio)but-3-en-2-yl)carbamate (195).
To a stirred suspension of methyltriphenylphosphonium bromide (8.73 g, 24.43
mmol) in dry THF (100 mL) was added KHMDS (44.40 mL 0.5 M in toluene, 22.20 mmol)
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slowly, and the mixture was stirred for 1 h at room temperature. The reaction flask was
cooled to –78 oC, and a solution of 194 (4.28 g, 11.10 mmol) in dry THF (50 mL) was
added drop wise in 30 min. The cooling bath was removed, and the reaction was stirred
for 1 h. Then the reaction mixture was diluted with ether (150 mL), washed with half
saturated aq. sodium potassium tartrate followed by brine, dried over anhydrous Na 2SO4,
and concentrated under reduced pressure. Purification by flash column chromatography
on silica gel (5 – 25% EtOAc in hexane) afforded the desired product 195 (3.15 g, 74%)
as a white solid. M.p. 79 – 81 oC; [α]20D +12.7 (c 2, CHCl3); 1H NMR (400 MHz, CDCl3) δ
6.12 (s, 2H), 5.80 (ddd, J = 17.1, 10.4, 5.3 Hz, 1H), 5.18 (dt, J = 17.1, 1.4 Hz, 1H), 5.10
(dt, J = 10.4, 1.4 Hz, 1H), 5.00 (br s, 1H), 4.38 (br s, 1H), 3.82 (s, 6H), 3.80 – 3.78 (m,
4H), 3.74 (d, J = 12.6 Hz, 1H), 2.70 (dd, J = 13.8, 5.4 Hz, 1H), 2.64 (dd, J = 13.8, 6.4 Hz,
1H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 160.3, 158.8, 155.4, 138.1, 114.9, 107.7,
90.6, 79.3, 55.7, 55.3, 52.3, 36.8, 28.4, 24.6; ESIHRMS calculated for C19H29NO5SNa
[M+Na]+, 406.1664; found, 406.1674.
(R)-1-((2,4,5-Trimethoxybenzyl)thio)but-3-en-2-amine (196).
To a stirred solution of 195 (1g, 2.61 mmol) in dry CH2Cl2 (24 mL) was added
trifluoroacetic acid (24 mL) drop wise at 0 oC. After stirring for 30 min, the reaction mixture
was concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (50 mL)
and stirred with 1 N NaOH (50 mL) for 15 min at room temperature. The organic layer
was separated, and the aqueous layer was washed extracted with CH2Cl2. Combined
organic extracts was washed with brine, dried over anhydrous Na2SO4, and concentrated
under reduced pressure. The residue was purified by flash column chromatography on
silica gel (0 – 10% MeOH in CH2Cl2) to give the desired product 196 (0.59 g, 80%) as a

197
colorless oil. [α]20D –51.5 (c 3.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 2H), 5.83
(ddd, J = 17.1, 10.4, 6.1 Hz, 1H), 5.19 (dt, J = 17.1, 1.3 Hz, 1H), 5.06 (dt, J = 10.4, 1.3
Hz, 1H), 3.84 – 3.74 (m, 10H), 3.71 (d, J = 12.6 Hz, 1H), 3.53 – 3.48 (m, 1H), 2.73 (dd, J
= 13.6, 4.1 Hz, 1H), 2.38 (dd, J = 13.6, 9.0 Hz, 1H), 1.80 (s, 2H);

13C

NMR (100 MHz,

CDCl3) δ 160.3, 158.7, 141.4, 114.3, 107.9, 90.5, 55.7, 55.3, 53.1, 40.1, 23.8; ESIHRMS
calculated for C14H23NO3S [M+H]+, 284.1320; found, 284.1311.
(R)-N-((R)-4-(1,2-Dimethyl-2-(2-oxo-2-(((R)-1-((2,4,5-trimethoxybenzyl)thio)but-3-en2-yl)amino)ethyl)hydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (197).
A heterogeneous mixture of 191 (25 mg, 0.06 mmol), palladium (25 mg 10 wt.%
on carbon) and MeOH (1.5 mL) was stirred under hydrogen environment (1 atm) for 15
min and filtered through a pad of Celite®. The resultant filtrate was concentrated under
reduced pressure to afford crude acid intermediate. To a solution of this crude acid
intermediate and amine 196 (45 mg, 0.16 mmol) in dry CH2Cl2 (0.7 mL) were added HATU
(49 mg, 0.13 mmol) and DIPEA (22 μL, 0.13 mmol) at room temperature. The reaction
was stirred for 5 h and concentrated under reduced pressure. Purification of the residue
by flash column chromatography on silica gel (20 ‒ 70% acetone in CH2Cl2) afforded 197
(29 mg, 81%) as a yellow oil. [α]20D –22.6 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) ,
both rotamers, δ 7.40 – 7.26 (m, 1H), 6.09 (s, 2H), 5.90 – 5.78 (m, 1H), 5.16 (dd, J = 17.2,
6.2 Hz, 1H), 5.10 (dd, J = 10.4, 6.2 Hz, 1H), 4.81 – 4.69 (m, 1H), 3.81 – 3.66 (m, 11H),
3.45 – 3.09 (m, 4H), 2.96 (s, 3H, rotamer), 2.89 (s, 3H, rotamer), 2.79 – 2.70 (m, 1H),
2.70 – 2.63 (m, 1H), 2.59 – 2.50 (m, 1H), 2.35 – 2.19 (m, 8H), 1.73 – 1.49 (m, 3H), 1.42
– 1.27 (m, 2H), 1.09 – 1.03 (m, 3H), 0.94 – 0.89 (m, 3H), 0.88 – 0.82(m, 3H).

13C

NMR

(150 MHz, CDCl3) , both rotamers, δ 176.4, 176.1, 170.1, 169.8, 160.3, 160.3, 158.73,

198
158.72, 137.5, 137.4, 115.04, 115.02, 108.0, 107.9, 90.5, 60.3, 59.7, 58.1, 57.6, 55.7,
55.3, 49.98, 49.89, 47.9, 46.0, 37.4, 37.3, 37.2, 36.9, 36.7, 36.2, 35.5, 35.1, 34.1, 33.6,
32.2, 29.33, 29.28, 29.24, 29.19, 27.4, 27.0, 24.18, 24.15, 18.2, 18.1, 17.8, 17.1, 12.1,
12.0; ESIHRMS calculated for C29H51N4O5S [M+H]+, 567.3580; found, 567.3582.
(R)-N-((R)-4-(2-(2-(((R)-1-Mercaptobut-3-en-2-yl)amino)-2-oxoethyl)-1,2dimethylhydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (198).
To an ice-cold solution (<5 oC) of 197 (25 mg, 0.04 mmol) in dry CH2Cl2 (0.5 mL)
were added trifluoroacetic acid (35 μL, 0.44 mmol) and Et 3SiH (35 μL, 0.22 mmol)
dropwise one after the other. After stirring for 1 h at room temperature, additional
trifluoroacetic acid (35 μL, 0.44 mmol) and Et3SiH (35 μL, 0.22 mmol) were added
dropwise and stirring was

continued for additional 1 h. The reaction mixture was

concentrated under reduced pressure (<25 oC water-bath) and purified by flash column
chromatography on silica gel (0 ‒ 20% MeOH in CH2Cl2) to give 198 (14 mg, 82%) as a
colorless oil. [α]20D –15.2 (c 0.25, CHCl3); 1H NMR (600 MHz, CDCl3) , both rotamers, δ
7.97 (d, J = 8.1 Hz, 1H, rotamer), 7.63 (d, J = 8.4 Hz, 1H, rotamer), 5.99 – 5.59 (m, 1H),
5.33 – 5.08 (m, 2H), 4.76 – 4.54 (m, 1H), 3.63 (d, J = 15.0 Hz, 1H), 3.55 – 3.23 (m, 3H),
3.16 – 3.06 (m, 1H), 3.01 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 2.80 – 2.71 (m, 3H),
2.69 (s, 3H, rotamer), 2.64 (s, 3H, rotamer), 2.61 – 2.56 (m, 1H), 2.47 (s, 3H, rotamer),
2.45 (s, 3H, rotamer), 1.87 – 1.57 (m, 3H), 1.49 – 1.32 (m, 3H), 1.09 – 0.96 (m, 6H), 0.88
– 0.82 (m, 3H);

13C

NMR (150 MHz, CDCl3) major rotamer only; δ 177.1, 167.4, 135.5,

117.2, 59.8, 56.7, 53.1, 45.8, 37.4, 36.2, 35.9, 35.4, 32.0, 28.8, 27.9, 26.9, 18.1, 16.9,
12.0; ESIHRMS calculated for C19H39N4O2S [M+H]+, 387.2794; found, 387.2788.

199
Benzyl N-(dibenzylamino)-N-methylglycinate (199).
A mixture of 1,1-dibenzyl-2-methylhydrazine 78 (470 mg, 2.08 mmol), NaHCO3
(262 mg, 3.12 mmol), benzyl bromoacetate (714 mg, 3.12 mmol), DMF (0.7 mL), and
toluene (2.1 mL) was stirred for 3 h at 85 oC. The reaction was cooled to room
temperature, diluted with toluene, washed with water followed by brine, dried over
anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (0 ‒ 20% EtOAc in hexane) to give 119
(650 mg, 83%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.09 (m, 15H), 5.04
(s, 2H), 3.71 (s, 4H), 3.45 (s, 2H), 2.57 (s, 3H);

13C

NMR (100 MHz, CDCl3) δ 170.4,

139.2, 135.9, 129.1, 128.5, 128.4, 128.2, 128.0, 126.8, 66.3, 58.2, 54.3, 35.8; ESIHRMS
calculated for C24H27N2O2 [M+H]+, 375.2073; found, 375.2074.
N-(Dibenzylamino)-N-methylglycine (200).
To an ice-cold solution of 199 (100 mg, 0.26 mmol) in MeOH (0.4 mL) was added
KOH solution (0.4 mL, 7 M in water, 2.80 mmol) dropwise. After stirring for 22 h at room
temperature, the volatile components of the reaction were evaporated under reduced
pressure. The aqueous residue was diluted with water and non-polar impurities were
washed out with CH2Cl2 and discarded. The leftover aqueous residue was acidified to pH
1 by addition of 2 M HCl and then extracted with CH2Cl2. The so-obtained organic extract
was dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford
the desired acid 200 (75 mg, 99%) as a yellow oil: 1H NMR (400 MHz, CDCl3) δ 7.45 –
7.17 (m, 10H), 3.73 (s, 4H), 3.35 (s, 2H), 2.55 (s, 3H);

13C

NMR (100 MHz, CDCl3) δ

170.6, 136.8, 129.2, 128.7, 127.9, 57.5, 54.1, 34.2; ESIHRMS calculated for C 17H19N2O2
[M‒H]‒, 283.1447; found, 283.1461.

200
(R)-2-(2,2-Dibenzyl-1-methylhydrazineyl)-N-(1-hydroxybut-3-en-2-yl)acetamide
(201).
To a stirred solution of acid 200 (250 mg, 0.88 mmol) and amino alcohol 112147
(280 mg, 2.20 mmol) in dry CH2Cl2 (5 mL) were added DIPEA (470 μL, 2.64 mmol), DMAP
(55 mg, 0.44 mmol), and EDCI.HCl (520 mg, 2.64 mmol) at room temperature. After
stirring for 12 h, the reaction mixture was concentrated under reduced pressure and the
residue was purified by flash column chromatography on silica gel to afford 201 (290 mg,
93%) as a colorless oil (eluent: 50 ‒ 100% EtOAc in hexane). [α]20D +32.8 (c 2.4, CHCl3);
1H

NMR (400 MHz, CDCl3) δ 7.43 – 7.19 (m, 10H), 6.51 (d, J = 6.9 Hz, 1H), 5.45 (ddd, J

= 17.0, 10.5, 5.8 Hz, 1H), 5.05 (d, J = 10.5 Hz, 1H), 4.90 (d, J = 17.0 Hz, 1H), 4.29 – 4.09
(m, 1H), 3.68 (s, 4H), 3.45 (d, J = 16.6 Hz, 1H), 3.41 (dd, J = 11.3, 4.2 Hz, 1H), 3.33 (d,
J = 16.6 Hz, 1H), 3.28 (dd, J = 11.3, 6.8 Hz, 1H), 2.64 (br s, 1H), 2.48 (s, 3H);

13C

NMR

(100 MHz, CDCl3) δ 171.0, 138.9, 134.2, 128.7, 128.4, 127.2, 116.6, 65.2, 59.2, 54.5,
53.8, 35.7; ESIHRMS calculated for C21H27N2O3Na [M+Na]+, 376.2001; found, 376.2007.
(R)-2-((2,2-Dibenzyl-1-methylhydrazineyl)methyl)-4-vinyl-4,5-dihydrooxazole (202).
DAST (9 μL, 0.08 mmol) was added to a chilled solution of 201 (20 mg, 0.06 mmol)
in dry CH2Cl2 (1.2 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and
quenched by saturated aq. NaHCO3. The resultant mixture was warmed to room
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous
Na2SO4, concentrated under reduced pressure, and purified by flash column
chromatography on neutral alumina to afford 202 (6 mg, 32%) as a colorless oil (eluent:
25% EtOAC in hexane): [α]20D +38.0 (c 0.15, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.40
– 7.12 (m, 10H), 5.80 (ddd, J = 17.2, 10.2, 7.1 Hz, 1H), 5.25 (d, J = 17.2 Hz, 1H), 5.16 (d,

201
J = 10.2 Hz, 1H), 4.61 – 4.49 (m, 1H), 4.14 (dd, J = 9.9, 8.4 Hz, 1H), 3.72 (t, J = 8.4 Hz,
1H), 3.66 (ABq, J = 13.2 Hz, 4H), 3.47 (ABq, J = 13.8 Hz, 2H), 2.55 (s, 3H);

13C

NMR

(150 MHz, CDCl3) δ 165.8, 139.5, 138.0, 129.2, 127.9, 126.7, 116.3, 72.1, 68.2, 53.6,
52.5, 35.7; ESIHRMS calculated for C21H26N3O [M+H]+, 336.2076; found, 336.2077.
(R)-2-(2,2-Dibenzyl-1-methylhydrazineyl)-N-(1-hydroxybut-3-en-2yl)ethanethioamide (203).
DAST (55 μL, 0.42 mmol) was added to a chilled solution of 201 (100 mg, 0.28
mmol) in dry CH2Cl2 (5.7 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and
quenched with saturated aq. NaHCO3. The resultant mixture was warmed to room
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous
Na2SO4 and concentrated under reduced pressure. The resultant residue was stirred with
MeOH-Et3N (1:1, 5.7 mL, saturated with H2S gas) for 13 h at room temperature. Then the
reaction was concentrated under reduced pressure and purified by flash column
chromatography on silica gel to give 203 (63 mg, 66%, 2 steps) as a yellow oil (eluent: 0
‒ 50% EtOAc in hexane) along with the starting material 201 (25 mg, 25%) as a colorless
oil (eluent: 50 ‒ 100% EtOAc in hexane). Data for 203: [α]20D +32.1 (c 0.95, CHCl3); 1H
NMR (600 MHz, CDCl3) δ 8.54 (d, J = 7.5 Hz, 1H), 7.46 – 7.15 (m, 10H), 5.39 (ddd, J =
16.9, 10.6, 5.8 Hz, 1H), 5.11 (d, J = 10.6 Hz, 1H), 5.07 – 4.99 (m, 1H), 4.95 (d, J = 16.9
Hz, 1H), 3.95 (d, J = 17.3 Hz, 1H), 3.83 (d, J = 17.3 Hz, 1H), 3.70 (s, 4H), 3.45 (dd, J =
11.2, 4.7 Hz, 1H), 3.36 (dd, J = 11.2, 6.1 Hz, 1H), 2.45 (s, 3H), 1.61 (br s, 1H);

13C

NMR

(150 MHz, CDCl3) δ 199.1, 138.8, 132.6, 128.6, 128.5, 127.2, 117.8, 67.1, 64.2, 57.5,
54.7, 35.6; ESIHRMS calculated for C21H28N3OS [M+H]+, 370.1953; found, 370.1950.

202
(R)-2-((2,2-Dibenzyl-1-methylhydrazineyl)methyl)-4-vinyl-4,5-dihydrothiazole (204).
DAST (5 μL, 0.04 mmol) was added to a chilled solution of 203 (10 mg, 0.03 mmol)
in dry CH2Cl2 (0.5 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and
quenched by addition of saturated aq. NaHCO3. The resultant mixture was warmed to
room temperature and extracted with CH2Cl2. The organic extract was dried over
anhydrous Na2SO4, concentrated under reduced pressure, and purified by flash column
chromatography on neutral alumina to afford 204 (7.3 mg, 77%) as a yellow oil (eluent: 0
‒ 10% EtOAc in hexane): [α]20D +50.0 (c 0.37, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.40
– 7.16 (m, 10H), 5.92 (ddd, J = 17.1, 10.3, 6.8 Hz, 1H), 5.27 (dt, J = 17.1, 1.2 Hz, 1H),
5.16 (dt, J = 10.3, 1.2 Hz, 1H), 4.97 – 4.78 (m, 1H), 3.71 (s, 4H), 3.71 (dd, J = 14.0, 1.2
Hz, 1H), 3.64 (dd, J = 14.0, 1.2 Hz, 1H), 3.25 (dd, J = 11.0, 8.7 Hz, 1H), 2.89 (dd, J =
11.0, 8.4 Hz, 1H), 2.45 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.3, 139.3, 137.3, 129.0,
128.0, 126.8, 116.0, 78.3, 57.7, 54.4, 37.2, 36.3; ESIHRMS calculated for C 21H26N3S
[M+H]+, 352.1847; found, 352.1844.
(R)-N-((R)-4-(2-(2-(((R)-1-Hydroxybut-3-en-2-yl)amino)-2-oxoethyl)-1,2dimethylhydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (206).
A heterogeneous mixture of 191 (65 mg, 0.17 mmol), palladium (65 mg, 10 wt.%
on carbon), and MeOH (4 mL) was stirred under hydrogen environment (1 atm) for 15
min and filtered through a pad of Celite®. The resultant filtrate was concentrated under
reduced pressure to give crude acid intermediate 205. To a stirred solution of this crude
acid 205 and amino alcohol 112147 (51 mg, 0.42 mmol) in dry CH2Cl2 (0.80 mL) were
added DIPEA (89 μL, 0.50 mmol), DMAP (10 mg, 0.08 mmol), and EDCI.HCl (96 mg,
0.50 mmol) at room temperature. After stirring for 12 h, the reaction mixture was

203
concentrated under reduced pressure and the residue was purified by flash column
chromatography on silica gel to afford 206 (43 mg, 70% 2 steps) as a colorless oil (eluent:
25 – 75% acetone in hexane). [α]20D +12.2 (c 0.55, CHCl3); 1H NMR (600 MHz, CDCl3) ,
both rotamers, δ 7.54 (d, J = 6.6 Hz, 1H, rotamer), 7.33 (d, J = 8.1 Hz, 1H, rotamer), 5.95
– 5.77 (m, 1H), 5.30 – 5.10 (m, 2H), 4.53 (br s, 1H), 4.33 (br s, 1H), 3.78 – 3.61 (m, 2H),
3.60 – 3.49 (m, 1H), 3.38 – 3.07 (m, 3H), 3.00 (s, 3H, rotamer), 2.90 (s, 3H, rotamer),
2.64 – 2.50 (m, 1H), 2.43 – 2.12 (m, 7H), 1.88 – 1.73 (m, 2H), 1.73 – 1.52 (m, 2H), 1.45
– 1.30 (m, 1H), 1.30 – 1.15 (m, 1H), 1.13 – 0.99 (m, 3H), 0.99 – 0.65 (m, 6H);

13C

NMR

(150 MHz, CDCl3) , both rotamers, δ 176.6, 170.7, 135.7, 135.1, 116.6, 115.9, 65.1, 64.7,
60.7, 60.20, 57.9, 57.2, 53.2, 53.0, 47.6, 46.9, 37.4, 37.2, 36.9, 36.6, 36.1, 35.6, 35.4,
34.0, 33.7, 32.2, 29.6, 28.7, 27.3, 26.9, 18.3, 18.0, 17.8, 17.0, 12.1, 11.9; ESIHRMS
calculated for C19H39N4O3 [M+H]+, 371.3022; found, 371.3020.
(R)-N-((R)-4-(1,2-Dimethyl-2-(((R)-4-vinyl-4,5-dihydrooxazol-2yl)methyl)hydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (207).
DAST (6 μL, 0.04 mmol) was added to a chilled solution of 206 (11 mg, 0.03 mmol)
in dry CH2Cl2 (0.9 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and
quenched with saturated aq. NaHCO3. The resultant mixture was warmed to room
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous
Na2SO4, concentrated under reduced pressure, and purified by flash column
chromatography on neutral alumina to afford 207 (3 mg, 30%) as a colorless oil (eluent:
50% EtOAC in hexane). [α]20D +33.3 (c 0.15, CH2Cl2); 1H NMR (600 MHz, CDCl3) , both
rotamers, δ 5.79 (ddd, J = 17.2, 10.2, 7.0 Hz, 1H), 5.22 (dd, J = 17.2, 4.5 Hz, 1H), 5.16 –
5.11 (m, 1H), 4.62 – 4.54 (m, 1H), 4.45 – 4.30 (m, 1H), 4.01 – 3.86 (m, 1H), 3.46 – 3.22

204
(m, 4H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 2.63 – 2.51 (m, 1H), 2.41 – 2.20 (m,
8H), 1.78 – 1.52 (m, 3H), 1.44 – 1.32 (m, 1H), 1.32 – 1.18 (m, 1H), 1.10 – 1.04 (m, 3H),
0.92 – 0.90 (m, 3H), 0.88 – 0.84 (m, 3H); 13C NMR (150 MHz, CDCl3) , both rotamers, δ
176.5, 176.1, 166.0, 165.9, 137.9, 137.8, 116.5, 116.4, 72.28, 72.25, 68.1, 61.2, 61.0,
60.0, 51.5, 51.3, 48.0, 46.0, 37.4, 37.1, 35.2, 35.1, 35.0, 34.9, 34.7, 34.0, 33.6, 32.2, 29.0,
28.9, 27.4, 27.0, 18.18, 18.16, 17.8, 17.1, 12.1, 12.00; ESIHRMS calculated for
C19H37N4O2 [M+H]+, 353.2917; found, 353.2915.
(R)-N-((R)-4-(2-(2-(((R)-1-Hydroxybut-3-en-2-yl)amino)-2-thioxoethyl)-1,2dimethylhydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (208).
DAST (22 μL, 0.17 mmol) was added to a chilled solution of 206 (42 mg, 0.11
mmol) in dry CH2Cl2 (2.3 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and
quenched with saturated aq. NaHCO3. The resultant mixture was warmed to room
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous
Na2SO4 and concentrated under reduced pressure. The resultant residue was stirred with
MeOH-Et3N (1:1, 2.3 mL, saturated with H2S gas) for 13 h at room temperature. Then the
reaction was concentrated under reduced pressure and purified by flash column
chromatography on silica gel to give 208 (23 mg, 52%, 2 steps) as a yellow oil (eluent: 25
– 35% acetone in hexane) along with the starting material 206 (17 mg, 40%) as a yellow
oil (eluent: 35 – 75% acetone in hexane). Data for 208: [α]20D +9.5 (c 0.95, CHCl3); 1H
NMR (600 MHz, CDCl3) , both rotamers, δ 9.78 – 9.25 (m, 1H), 5.97 – 5.80 (m, 1H), 5.33
– 5.07 (m, 3H), 4.55 (br s, 1H), 3.91 – 3.75 (m, 2H), 3.76 – 3.51 (m, 3H), 3.40 – 3.25 (m,
1H, rotamer), 3.13 – 3.02 (m, 1H, rotamer), 2.99 (s, 3H, rotamer), 2.89 (s, 3H, rotamer),
2.62 – 2.49 (m, 1H), 2.47 – 2.37 (m, 1H, rotamer), 2.34 – 2.23 (m, 7H), 2.19 – 2.08 (m,

205
1H), 1.87 – 1.51 (m, 3H), 1.45 – 1.13 (m, 2H), 1.10 – 1.00 (m, 3H), 0.96 – 0.81 (m, 6H);
13C

NMR (151 MHz, CDCl3), major rotamer only, δ 199.0, 176.7, 134.0, 116.9, 64.7, 63.4,

61.1, 57.3, 47.0, 37.4, 37.0, 36.4, 35.5, 32.3, 29.8, 26.9, 18.2, 17.0, 11.9; ESIHRMS
calculated for C19H39N4O2S [M+H]+, 387.2794; found, 387.2789.
7,8-Diazakalkitoxin (110).
DAST (5 μL, 0.04 mmol) was added to a chilled solution of 208 (10 mg, 0.03 mmol)
in dry CH2Cl2 (0.5 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and
quenched by addition of saturated aq. NaHCO3. The resultant mixture was warmed to
room temperature and extracted with CH2Cl2. The organic extract was dried over
anhydrous Na2SO4, concentrated under reduced pressure, and purified by flash column
chromatography on neutral alumina to afford 110 (8.5 mg, 89%) as a yellow oil (eluent:
25 – 50% EtOAc in hexane): [α]20D +42.1 (c 0.28, CH2Cl2); 1H NMR (600 MHz, CDCl3) ,
both rotamers, δ 5.97 – 5.86 (m, 1H), 5.26 (dd, J = 17.1, 4.4 Hz, 1H), 5.16 – 5.11 (m, 1H),
4.96 – 4.82 (m, 1H), 3.59 – 3.46 (m, 2H), 3.45 – 3.26 (m, 3H), 3.08 – 2.81 (m, 4H), 2.65
– 2.50(m, 1H), 2.35 – 2.22 (m, 8H), 1.84 – 1.63 (m, 3H), 1.45 – 1.21 (m, 2H), 1.10 – 1.04
(m, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H);

13C

NMR (150 MHz, CDCl3) ,

both rotamers, δ 176.5, 176.1, 173.5, 173.2, 137.3, 137.2, 116.1, 116.0, 78.44, 78.39,
60.9, 60.5, 56.5, 56.4, 48.1, 46.0, 37.4, 37.1, 37.0, 35.9, 35.6, 35.13, 35.09, 34.9, 33.9,
33.6, 32.2, 28.9, 28.8, 27.4, 27.0, 18.18, 18.17, 17.8, 17.1, 12.1, 12.0.; ESIHRMS
calculated for C19H37N4OS [M+H]+, 369.2688; found, 369.2686.

206
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Sun, R.; Lü, M.; Chen, L.; Li, Q.; Song, H.; Bi, F.; Huang, R.; Wang, Q. J. Agric.

Food. Chem. 2008, 56, 11376-11391.
(38)

Yamawaki, K.; Nomura, T.; Yasukata, T.; Uotani, K.; Miwa, H.; Takeda, K.;

Nishitani, Y. Biorg. Med. Chem. 2007, 15, 6716-6732.
(39)

Foot, O. F.; Knight, D. W. Chem. Commun. 2000, 975-976.

(40)

Chen, N.; Xie, J. Org. Biomol. Chem. 2016, 14, 11028-11047.

209
(41)

Melman, A. In The Chemistry of Hydroxylamines, Oximes, and Hydroxyamic

Acids, Part 1; Rappoport, Z., Liebman, J. F., Eds.; Wiley: Chichester, 2009, p 117-161.
(42)

Malik, G.; Guinchard, X.; Crich, D. Org. Lett. 2011, 14, 596-599.

(43)

Sun, L.; Li, P.; Amankulor, N.; Tang, W.; Landry, D. W.; Zhao, K. J. Org. Chem.

1998, 63, 6472-6475.
(44)

Shirokane, K.; Kurosaki, Y.; Sato, T.; Chida, N. Angew. Chem. Int. Ed. 2010, 49,

6369-6372.
(45)

Barnes, K. L.; Chen, K.; Catalano, V. J.; Jeffrey, C. S. Org. Chem. Front. 2015, 2,

497-501.
(46)

Shvo, Y. In The Chemistry of Hydrazo, Azo and Azoxy Groups Patai, S., Ed.;

John Wiley & Sons: New York, 1975, p 1017-1095.
(47)

Penney, W. G.; Sutherland, G. B. B. M. J. Chem. Phys. 1934, 2, 492-498.

(48)

Veillard, A. Theor. Chim. Acta 1966, 5, 413-421.

(49)

Gillespie, R.; Nyholm, R. Q. Rev. Chem. Soc. 1957, 11, 339-380.

(50)

Gillespie, R. Can. J. Chem. 1960, 38, 818-826.

(51)

Gillespie, R. J. Chem. Educ. 1963, 40, 295-301.

(52)

Allen, L. Chem. Phys. Lett. 1968, 2, 597-601.

(53)

Wolfe, S. Acc. Chem. Res. 1972, 5, 102-111.

(54)

Pople, J. A.; Radom, L.; Hehre, W. J. J. Am. Chem. Soc. 1971, 93, 289-300.

(55)

Hamada, Y.; Hirakawa, A. Y.; Tamagake, K.; Tsuboi, M. J. Mol. Spectrosc. 1970,

35, 420-435.
(56)

Waldman, A. J.; Ng, T. L.; Wang, P.; Balskus, E. P. Chem. Rev. 2017, 117,

5784-5863.

210
(57)

Blair, L. M.; Sperry, J. J. Nat. Prod. 2013, 76, 794-812.

(58)

Le Goff, G.; Ouazzani, J. Biorg. Med. Chem. 2014, 22, 6529-6544.

(59)

Qingbo, Z.; Attila, M.; Sumei, L.; Yuchan, C.; Wenjun, Z.; Xinpeng, T.; Haibo, Z.;

Huixian, L.; Weimin, Z.; Si, Z.; Jianhua, J.; Tibor, K.; Changsheng, Z. Eur. J. Org. Chem.
2012, 2012, 5256-5262.
(60)

Zhongli, X.; Martin, B.; Ling, D.; Christian, H. Angew. Chem. Int. Ed. 2012, 51,

10293-10297.
(61)

Gamberini, M.; Cidade, M. R.; Valotta, L. A.; Armelin, M. C.; Leite, L. C.

Carcinogenesis 1998, 19, 147-155.
(62)

Klaus, R.; Tawfig, S. Arch. Pharm. 1998, 331, 308-312.

(63)

Putt, K. S.; Chen, G. W.; Pearson, J. M.; Sandhorst, J. S.; Hoagland, M. S.;

Kwon, J.-T.; Hwang, S.-K.; Jin, H.; Churchwell, M. I.; Cho, M.-H.; Doerge, D. R.;
Helferich, W. G.; Hergenrother, P. J. Nat. Chem. Biol. 2006, 2, 543-550.
(64)

Lopez-Munoz, F.; Alamo, C. Curr. Pharm. Des. 2009, 15, 1563-1586.

(65)

Toth, B. In Vivo 2000, 14, 299-319.

(66)

Gannett, P. M.; Shi, X.; Lawson, T.; Kolar, C.; Toth, B. Chem. Res. Toxicol. 1997,

10, 1372-1377.
(67)

Koepke, S. R.; Kroeger-Koepke, M. B.; Michejda, C. J. Chem. Res. Toxicol.

1990, 3, 17-20.
(68)

Lawson, T.; Gannett, P. M.; Yau, W.-M.; Dalal, N. S.; Toth, B. J. Agric. Food.

Chem. 1995, 43, 2627-2635.
(69)

Gannett, P. M.; Lawson, T.; Miller, M.; Thakkar, D.; Lord, J.; Yau, W.-M.; Toth, B.

Chem. Biol. Interact. 1996, 101, 149-164.

211
(70)

Hung, M. H.; Stock, L. M. J. Org. Chem. 1982, 47, 448-453.

(71)

Kikugawa, K.; Kato, T.; Kojima, K. Mutat. Res. 1992, 268, 65-75.

(72)

Augusto, O. Free Radical Biol. Med. 1993, 15, 329-336.

(73)

Griffiths, J.; Murphy, J. A. J. Chem. Soc., Chem. Commun. 1992, 24-26.

(74)

Bredihhin, A.; Mäeorg, U. Tetrahedron 2008, 64, 6788-6793.

(75)

Huddleston, P. R.; Coutts, I. G. In Comprehensive Organic Functional Group

Transformations; Katritzky, A. R., Meth-Cohn, O., Rees, C. W., Eds.;
Pergamon/Elsevier: Oxford, 1995; Vol. 2, p 371-383.
(76)

Stanley, R. S.; Wolf, K.; Academic Press Inc.: San Diego, California, 1992, p

136-146.
(77)

Ragnarsson, U. Chem. Soc. Rev. 2001, 30, 205-213.

(78)

Hinman, R. L. J. Am. Chem. Soc. 1956, 78, 1645-1649.

(79)

Bredihhin, A.; Groth, U. M.; Mäeorg, U. Org. Lett. 2007, 9, 1097-1099.

(80)

Bredihhin, A.; Mäeorg, U. Org. Lett. 2007, 9, 4975-4977.

(81)

Feuer, H.; Brown Jr, F. J. Org. Chem. 1970, 35, 1468-1471.

(82)

Rosen, B. R.; Werner, E. W.; O’Brien, A. G.; Baran, P. S. J. Am. Chem. Soc.

2014, 136, 5571-5574.
(83)

Audrieth, L. F.; Diamond, L. H. J. Am. Chem. Soc. 1954, 76, 4869-4871.

(84)

Omietanski, G. M.; Melmers, A. D.; Shellman, R. W.; Sisler, H. H. J. Am. Chem.

Soc. 1956, 78, 3874-3877.
(85)

Diamond, L. H.; Audrieth, L. F. J. Am. Chem. Soc. 1955, 77, 3131-3131.

(86)

Wallace, R. G. Aldrichimica Acta 1980, 13, 3-11.

(87)

Keller, R.; Smith, P. A. J. Am. Chem. Soc. 1944, 66, 1122-1124.

212
(88)

Armstrong, A.; Jones, L. H.; Knight, J. D.; Kelsey, R. D. Org. Lett. 2005, 7, 713-

716.
(89)

Greck, C.; Genêt, J. P. Synlett 1997, 741-748.

(90)
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ABSTRACT
HYDROXYLAMINES AND HYDRAZINES AS SURROGATES OF SP3 CARBONS IN
MEDICINAL CHEMISTRY
by
SANDEEP DHANJU
May 2019
Advisor: Dr. David Crich
Major: Chemistry (Organic)
Degree: Doctor of Philosophy
Current compound libraries that are used in high-throughput screening (HTS) are
populated by low molecular weight and relatively planar compounds with high sp2
character and little stereochemical complexity. Unfortunately, such planar compounds
cover only a very small corner of chemical space. In order to increase the diversity,
structurally complex molecules with high fractions of sp3-hybridized atoms should be
included in compound libraries. However, generating a large number of architecturally
complex molecules using the current organic synthesis toolbox is considered tedious due
to the requirement of multi-step synthesis. Recognizing this need, several creative
strategies, like diversity-oriented synthesis, have been developed with the aim to access
structurally complex drug-like scaffolds in a minimum number of steps. However, the
efficiency of these strategies is impeded by the time-consuming process of addressing
stereogenic complexity. The research presented in this thesis is aimed at providing an
alternative strategy that not only enriches the Fsp3 in compound collections but also
reduces the stereogenic complexity.
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Chapter one introduces hydroxylamines and hydrazines as interesting functional
moieties that are capable of enriching current compound collections by increasing the
fraction of sp3-hybridized atoms without additional stereochemical complexity. As the
basis of the research presented in this thesis is the rapid conformational changes of
hydroxylamine and hydrazine-related molecules at ambient temperature due to their low
barrier to inversion at nitrogen centers, their conformational properties are highlighted in
this chapter. Moreover, the present position of hydroxylamines and hydrazines in
medicinal chemistry, and the synthetic accessibility of hydroxylamine and hydrazinerelated compounds are also discussed. The chapter ends by proposing kalkitoxin, a
natural anti-cancer agent, as a substrate to test the concept of hydroxylamines and
hydrazines as convertible mimics of the stereogenic centers.
Chapter two presents the discovery of an efficient synthetic method for trisubstituted hydroxylamine synthesis. This method was developed on the basis of
acylation of N,N-disubstituted hydroxylamines followed by two-step reduction of the
resulting O-acylhydroxylamines. The first reduction was conducted with DIBAL and was
followed

by

treatment

with

acetic

anhydride

to

give

the

O-(α-

acetoxyalkyl)hydroxylamines; the second reduction was executed with triethylsilane and
a Lewis acid. Manipulating the second reduction step, by replacing triethylsilane with a
carbon nucleophile afforded a new C-C bond formation, and further expanded the scope
of this method. The efficiency of the method is exemplified by synthesis of several novel
tri-substituted hydroxylamines.
Chapter three describes the VT-NMR studies that were conducted to understand
the contribution of three processes (N-inversion, N-O bond rotation, and ring flip) to the
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complex stereomutation of N-alkoxypiperidine systems. Since the VT-NMR phenomena
were found to be dependent on substituents at the 4-position of the piperidine ring system,
the ring inversion process is concluded to be the main component of the barrier to
stereomutation of such systems.
Chapter four concerns the design and development of hydrazine and
hydroxylamine analogs of kalkitoxin, with the aim of testing the hypothesis of hydrazines
and hydroxylamine as convertible mimics of stereogenic centers. The syntheses of
kalkitoxin and its convertible hydrazine and hydroxylamine mimetics, 9-oxa-10azakalkitoxin and 7,8-diazakalkitoxin, are described. Currently, their cytotoxicity studies
against several human and murine tumor cell lines are under progress. The hydroxalog
9-oxa-10-azakalkitoxin (IC50 = 2.4 nm) was found to be as potent as kalktoxin (IC50 = 3.2
nm) against a human liver cell line, so supporting the hydroxylamine analog concept.
The thesis ends with a conclusion and the complete experimental details for the
work presented.
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